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Just like a phantom, the topic of »gene doping« keeps haunting the debates regarding the 
future of competitive sports for years. Very often, corresponding fantasies and visions 
culminate in the imagination of super athletes who are permanently manipulated with 
regard to their genetic disposition. However, the application scenarios to be expected will 
be far more unspectacular, but more probable and more obvious at the same time. Very 
soon, we will have to expect the use of new substances as well as of methods in gene and 
cell therapy for targeted manipulation of gene activity. Their use promises a highly effici-
ent performance enhancement and will be difficult to prove, if at all. This book provides 
comprehensive answers to the key questions of the further development: Which scientific 
results could cater to the needs of potential gene doping? Where are the future gateways 
in top-level and popular sports? And how can prohibitions and monitoring be used in 
responding to this?  Another question will be which individual behavioural patterns of 
athletes and which social contexts will play a role with regard to the potential »career« of 
gene doping.
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The Office of Technology Assessment at the German Bundestag is an independ-
ent scientific institution created with the objective of advising the German 
Bundestag and its Committees on matters relating to research and technology. 
TAB is operated by the Institute for Technology Assessment and Systems Analy-
sis (ITAS) at the Karlsruhe Research Centre. In executing its working pro-
gramme the Karlsruhe Research Centre cooperates with the Fraunhofer-Institut 
für System- und Innovationsforschung (ISI), Karlsruhe. 
TAB's task is to design and implement technology assessment (TA) projects and 
to monitor and analyse important scientific and technological trends and the 
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THE COMMITTEE'S PREFACE 
The promotion of recreational, competitive, and elite sport is an important so-
cial and political responsibility. Widespread abuse of performance-enhancing 
substances with intent to deceive, i.e. doping, seriously compromises compari-
sons of athletic performance and threatens competition by jeopardizing both 
equality of opportunity and the health of doping athletes. In addition, doping 
undermines the basic principles of fairness and playing by the rules – important 
elements that contribute to the social context of sport. For some time now, 
based on a growing body of knowledge from the field of human genome re-
search, fears have been expressed that this threat will be further aggravated by 
novel methods of manipulation at the genetic level, an approach known as gene 
doping.  
The potential explosiveness of the issue means that the legislature must address 
this problem at an early stage. In view of the paucity of currently available in-
formation, the Committee on Education, Research and Technology Assessment, 
at the suggestion of the Sports Committee, commissioned the Office for Tech-
nology Assessment of the German Bundestag (TAB) to carry out an investigation 
into gene doping. This report concludes that project. 
The aim was to analyze the scientific and sociopolitical dimensions of gene dop-
ing by reviewing the status of doping-relevant findings from genome research 
with special attention to individual and social risks. This was accomplished by 
exploring detection and control possibilities, including the resulting need to re-
fine relevant statutory instruments, and by discussing possible preventive strate-
gies in the fields of information dissemination, education, and public debate. 
This report provides what is probably the most comprehensive examination to 
date of foreseeable developments in the field of gene doping and its potential 
impact. It reveals that a broad range of new medical and pharmaceutical tech-
niques and procedures – most still under development – could be misused to 
illegally enhance athletic performance. Possible points of entry include elite 
sport, the highly competitive bodybuilding scene, and in the long term anti-aging 
medicine as part of a general social trend towards manipulating performance in 
everyday life.  
Besides the unpredictable risks to the health of users, this TAB report reveals the 
growing challenge of detecting potential gene doping methods and highlights the 
need for a comprehensive refinement of control and analysis methods. Other 
areas requiring action are the adaptation of statutory instruments and the devel-
opment of educational measures targeted at specific groups. 
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This report provides the German Bundestag with valuable up-to-date infor-
mation as a basis for parliamentary discussion of gene doping – a topic that is of 
relevance to sports, research, and social policymaking alike. 
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In all likelihood a new form of doping will emerge in the coming years, posing 
new challenges in the fight against doping, namely the widespread use of a num-
ber of cutting-edge substances and procedures aimed specifically at modulating 
gene activity. These may be methods derived from gene and cell therapy or 
methods for manipulating gene expression based on the use of highly specific 
agents (collectively termed gene doping in the broad sense). By contrast, strate-
gies aimed at inducing permanent changes in the genetic makeup of athletes (so 
far only theoretical in nature) are unlikely in the foreseeable future. 
The following key questions form the keystones of the TAB report. What scien-
tific findings might potential gene doping utilize? Where are the future points of 
entry in top-level and recreational sport? And how can bans and monitoring be 
applied in response these developments? To complement these thematic perspec-
tives, gene doping will also be viewed in the context of social trends and struc-
tures. We will ask what behavioral patterns and attitudes play a role at the level 
of the individual athlete and how gene doping as a form of deviant behavior is 
influenced by various social contexts and actors.  
This final report concludes the TAB Gene Doping Project. It was commissioned 
by the Select Committee for Education, Research, and Technology Assessment 
on the recommendation of the Sports Committee of the German Bundestag. 
THE TERM GENE DOPING – IN THE NARROW AND BROAD SENSES  
The term gene doping is often construed very narrowly, namely as the misuse of 
gene and cell therapy methods, by means of which genetic material in the form 
of DNA or RNA is inserted into a cell, an organ, or an organism. The TAB 
analysis is based on the broader perspective adopted by the World Anti-Doping 
Agency (WADA), which –in line with its Prohibited List – explicitly understands 
gene doping to also include the use of other methods aimed at modulating gene 
activity: »the nontherapeutic use of cells, genes, genetic elements, or the modula-
tion of gene expression having the capacity to improve athletic performance«.  
Only by adopting this broader interpretation is it possible to include as many 
relevant methods, procedures, and agents as possible in the impact assessment. 
The scientific basis for new methods of (gene) doping is formed by the ever-
advancing techniques of molecular biology and growing knowledge of the mo-
lecular mechanisms of cell function. The social and political explosiveness of the 
topic arises from the fact that these advances will increase the possibilities for 
manipulating gene activity in specific and subtle ways that are likely to be in-
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creasingly difficult to detect. Whether this process of manipulation occurs by 
transmission of actual genetic material, i.e. DNA or RNA, or by some other 
pharmacologic mechanism is not a reasonable exclusion criterion for the pur-
poses of an impact analysis, especially in respect of future antidoping measures. 
NO »GENETICALLY OPTIMIZED« ATHLETES IN 
THE FORESEEABLE FUTURE 
According to a widely held notion, gene doping is aimed at »improving« the 
genetic makeup of athletes based on knowledge of which gene variants can bring 
about a particularly high level of performance, either by specifically manipulat-
ing the whole organism or by prenatal selection. However, a detailed analysis of 
genome research findings shows that molecular genetic knowledge of »high-
performance gene variants« is still extremely limited, imprecise, and contradicto-
ry, with the result that »promising« techniques for inducing specific alterations 
in an individual's genetic constitution are h unlikely to be developed in the fore-
seeable future. Accordingly, the TAB project has uncovered no evidence that any 
strategies based on human selection or breeding for enhanced athletic ability are 
likely to become technically feasible within the foreseeable future. At present, 
therefore, notions about the possibility of gene doping in this narrow sense have 
no scientific basis.  
THE AIM OF GENE DOPING: GENE REGULATION 
The objective of gene doping is therefore to specifically influence (modify) the 
activities of the body's genes by activating them or by strengthening, weakening, 
or blocking their expression. The underlying biochemical and physiological pro-
cesses are highly complex, both at the cellular level and at the level of overall 
regulation in the body (and therefore will only be outlined in this report). The 
network of regulatory mechanisms controlling attributes relevant to physiologi-
cal performance presents a broad array of targets for pharmacological and mo-
lecular biological modulation – for new therapeutic treatment strategies as well 
as for doping purposes. The potential consequences of such interventions are 
extremely hard to predict. This continues to be seen in medical trials of treat-
ments for patients (in the form of side effects or lack of drug efficacy). Where 
such methods and procedures are misused in healthy or highly trained individu-
als – who are also highly susceptible to interference despite their high level of 
physiological performance – the consequences are again likely to be highly un-
predictable. 
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GENE THERAPY AND OTHER METHODS OF MODIFYING GENE ACTIVITY 
Gene doping in the narrow sense misuses the techniques of gene and cell therapy 
for the purpose of enhancing physical performance. The term »gene therapy« is 
used to denote strategies in which genes or genetic elements are introduced into 
cells from outside to remedy inherited or acquired genetic disorders. Genes are 
introduced into the cells (a process known as gene transfer) by means of vectors 
(or gene carriers, usually specially modified viruses). Gene therapies already test-
ed on humans have been directed mainly at cancers, monogenic inherited diseas-
es, infectious diseases (especially HIV), and cardiovascular disorders. In contrast 
to what is commonly reported, the objective here is often not to effect a perma-
nent change. Instead, the procedures are transient measures that may have to be 
repeated. 
An assessment of the current results of gene therapy is important for evaluating 
its potential relevance to doping. Overall, gene therapy is not yet an established 
medical practice. It is essentially still at the experimental stage, and the evalua-
tion of current therapeutic results is a matter of considerable controversy. 
Treatments are still frequently associated with serious side effects, including 
death. The vectors used are believed to be responsible for some of the side effects 
observed. The proportion of clinical experiments that forgo the use viral vectors, 
which are more efficient but also particularly risky, in favor of the use of so-
called »naked« DNA has increased steadily in recent years. This is significant for 
potential gene doping, since nonviral DNA is probably much simpler and also 
less risky to use. 
In addition to the methods that are unambiguously described as constituting 
gene therapy, there exist many other modern pharmacologic strategies that are 
intended to induce a specific modification of the body's gene activity in order to 
achieve a desired therapeutic outcome. The pharmacologic agents concerned 
include a broad range of, in some cases very complex, biomolecules such as pro-
teins and RNA, but also some easily synthesized simple compounds. 
PHYSIOLOGICAL APPROACHES AND MOLECULAR TARGETS – 
RESEARCH STRATEGIES AND DEVELOPMENT PROJECTS  
The most likely methods by which gene doping might be attempted relate to 
three areas of physiology and their molecular regulation, namely formation of 
skeletal muscle, oxygen supply, and energy supply.  
Among the research strategies and development projects identified in the TAB 
project and described in detail in the report which have already reached the stage 
of clinical testing, there is only one that pursues an explicit gene therapy ap-
proach. The other techniques at an advanced stage of development are all phar-
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macological strategies for modifying gene activity. Success in the preclinical 
phase, i.e. in animal experiments, has been achieved with a large number of 
techniques that constitute gene doping both in the narrow sense (e.g. the well-
known case of Repoxygen) and in the broad sense.  
PHYSIOLOGICAL TARGETS FOR GENE DOPING STRATEGIES 
> Skeletal muscles: Growth, structure, strength, endurance, regeneration 
(molecular targets: myostatin, HGH/IGF/MGF, Pax7, PPAR-delta) 
> Oxygen supply: Hemoglobin concentration, blood vessel supply (molecu-
lar targets: EPO, HIF, VEGF) 
> Energy supply: Fatty acid and glucose metabolism in the liver and muscles 
(molecular targets: FATPs, GLUTs, PTP-1B) 
SPECIFIC HEALTH RISKS: AN EFFECTIVE OBSTACLE? 
Common to all doping practice is the fact that the relevant techniques and 
agents were developed for the treatment of diseases and accordingly have not 
been studied in relation to their use for performance enhancement in healthy 
persons. Hence, the health risks associated with their misuse for doping purpos-
es cannot be assessed. This is evidenced by the severe to catastrophic doping-
induced ill effects on health, in some cases leading to death, that some athletes 
have suffered in the past. 
From this point of view gene doping techniques could scarcely be riskier. At the 
same time, the principles that underlie the techniques used to bring about specif-
ic modifications of gene activity entail specific risks which, in the absence of em-
pirical evidence, must be regarded merely as scientifically plausible assumptions. 
In this respect a distinction can be made between risks that arise as a result of 
insertion of genetic material into the organism (lack of tissue specificity of vec-
tors leading to uncontrolled spread of the foreign gene in the organism; muta-
tions and immune reactions) and risks that result from overexpression (i.e. ex-
cessive production in the body) of performance-relevant biomolecules (e.g. pro-
motion of uncontrolled cell growth). Given the complexity of the mechanisms 
that regulate gene activity, it is highly likely that manipulation of these mecha-
nisms can result in a broad variety of side effects and potentially in severe dam-
age to health. 
Nevertheless, experience gained with conventional doping practices casts consid-
erable doubt on the notion that these imponderable health risks constitute an 
effective disincentive to the use of these methods, even if those that are scientifi-
cally unproven. Besides their availability, of course, the crucial factors governing 
the use and spread of gene doping techniques will probably be their presumed 
 SUMMARY 13 
achievable effect – i.e. a potential improvement in performance – and their de-
tectability or lack thereof (see below). 
ROUTES OF ACCESS 
Therapeutic techniques and drugs that are either already licensed or at least at 
the clinical trial stage would appear to be the most likely initial candidates for 
misuse for doping purposes. In order to predict which gene doping strategies 
could become relevant within what period of time, it is essential to monitor pro-
gress in research and development, especially in pharmaceutical companies, on a 
continuous basis. Nevertheless, it must be assumed that by no means all projects 
that could be relevant in terms of gene doping become known to the public (at 
least in their early stages). 
Along with misuse of licensed therapeutic agents or those in the process of being 
licensed, another, and potentially even more worrying, possibility is emerging – 
namely a form of »individual« gene doping in which all the testing procedures 
that form part of the drug regulatory process are circumvented. As in the case of 
the designer steroids that were explicitly manufactured by the Balco company 
for doping purposes, genetic-pharmaceutical gene doping agents could also be 
produced that are specifically tailored to individuals or a small group of athletes. 
In some cases, the time and expenditure involved would probably be no greater 
than for non-designer agents. Relatively simple methods include construction of 
virus-based gene vectors, production and administration of naked DNA, and the 
construction of gene vaccines to induce the production of antibodies. These are 
all routine tasks for molecular biologists, and many of the individual steps can 
be performed using standard procedures and apparatus and commercially avail-
able kits. 
A common objection to gene doping is that the relevant methods are not vali-
dated and in particular that enhanced performance has not been demonstrated 
either in normal subjects or in highly trained athletes. Nevertheless, results ob-
tained in preventive research oriented towards doping practice show that even 
when the effectiveness of a particular doping strategy has been repeatedly denied 
(as in the case of growth hormone), athletes will nevertheless continue to use it. 
POINTS OF ENTRY: ELITE SPORT, BODYBUILDING, 
AND ANTI-AGING APPLICATIONS? 
Overall we can assume that gene therapy-based methods (i.e. gene doping in the 
narrow sense) probably pose far greater obstacles to misuse than the many dif-
ferent techniques and pharmaceutical developments used for the specific manip-
ulation of gene activity. Given the present state of advancement of a number of 
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projects being pursued by the biotechnology and pharmaceutical industries, it 
must be assumed that such methods can already be misused for doping purpos-
es, since – as is apparent from experience gained with peptide hormones (EPO, 
growth hormone) – abusers can gain access to them in clinical studies. 
In this respect it should be noted that misuse of myostatin inhibitors, for exam-
ple, is far less likely to occur in competitive sport than in recreational sport, 
most notably in the world of bodybuilding, and these new drugs have long been 
discussed and sought after in internet forums that cater to bodybuilders. 
In the longer term, a potentially far more significant route of access than illegal 
appropriation of gene-modulating substances and techniques from clinical trials 
(or the sort of »designer« gene doping referred to above) could arise at the fring-
es of the treatment of age-related disabilities, e.g. the treatment of excessive 
muscle loss with (by then) licensed drugs. This area of medicine borders on and 
blends imperceptibly into what has become known as »enhancement«, i.e. the 
nontherapeutic use of lifestyle drugs to improve everyday performance, an in-
creasingly discussed topic that is of considerable social and political relevance. 
DETECTABILITY AND TEST DEVELOPMENT 
When strategies for preventing and combating doping are being devised, a key 
question is whether, and if so how, gene doping can be detected. Past experience 
suggests that reactive development of detection methods is quite inadequate as a 
means of combating doping effectively. The WADA responded to this problem 
some years ago by establishing an international program to promote research 
into methods of detecting gene doping. 
Techniques of gene therapy or gene modulation are aimed either at inserting a 
gene or genetic element into specific somatic (body) cells and activating it, or else 
at activating or inhibiting an existing gene or genetic element. Where the insert-
ed genetic or gene-regulating element is chemically different from the body's 
natural substances, direct detection should be both possible and qualitatively 
sufficient. However, due to the rapid pace of development in this field and the 
variety and complexity of gene modulation, most experts believe that techniques 
for direct detection are likely to become less important, since it would be far too 
expensive to test for all possible forms of genetic manipulation. 
Though theoretically plausible, approaches based on vector detection (in gene 
therapy procedures) pose a number of problems, e.g. the difficulty of distin-
guishing them from naturally occurring viruses. Detection of nonviral vectors 
(naked DNA, siRNA) is likely to be far more difficult because of the short bio-
logical half-life of nucleic acids. At present it is entirely unclear whether and how 
detection might be possible in the case of gene doping techniques where cells are 
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removed from the body, genetically altered outside of the body, and then re-
turned to the body (ex vivo techniques). 
The vast majority of the 20 research projects currently being supported by the 
WADA are therefore aimed at identifying deviations from normal physiological 
conditions as indirect evidence of gene doping. This involves the determination 
of highly differentiated profiles of all sorts of molecules (DNA, RNA, proteins) 
in blood and tissue samples, so-called biomarkers or »molecular fingerprints«. 
The aim or strategy here is to develop an intelligent form of biomonitoring 
which provides unambiguous evidence of manipulated gene activity. This in it-
self might suffice as proof of tampering. This method might, however, also only 
allow an initial suspicion to be substantiated, requiring additional specific evi-
dence in order to prove with reasonable analytic certainty that anti-doping regu-
lations have been violated. The question as to whether the biomonitoring strate-
gy will be successful in the long run cannot be answered at this time, since the 
relevant projects are in an early stage of development (for instance, the devel-
opment of a specific practical test to determine overall myostatin activity is men-
tioned as an aim in just one project). There is, however, currently no alternative 
in sight. 
TESTING AND SANCTIONS 
Five years ago, as a precautionary measure, the WADA placed gene doping on 
the list of banned substances and methods (Prohibited List), which together with 
the World Anti-Doping Code (WADC) forms an important basis for measures 
employed by sports associations and national governments in their common 
fight against doping. All the defined violations of the WADC anti-doping regula-
tions are applicable to gene doping. Self-administration, refusal to undergo test-
ing, possession, trafficking, administration to others, and participation in vari-
ous other activities are prohibited. Sports associations that have incorporated 
the WADC or NADA code for Germany into their statutes have thereby formal-
ly prohibited their members from engaging in gene doping. This is true of large 
sections of competitive sport, but not of individual sports activities such as those 
practiced at fitness clubs and the like. 
The Prohibited List has also been incorporated into German law. The German 
Drug Law (Arzneimittelgesetz, AMG) forbids trafficking in substances on the 
Prohibited List, prescribing them, or administering them to others for doping 
purposes in sport (including any attempt at such actions). The same applies to 
substances required for use in the methods listed [including gene doping; § 6, 
no. 2, AMG]. However, there is no reference to § 4, no. 9, AMG which, defines 
gene transfer agents as medicinal products. 
16 SUMMARY 
 
In the particular case of gene doping, the principal problem will lie not so much 
in prohibiting actions as in monitoring compliance with the prohibition and ob-
taining proof of violations that will stand up in a court of law (problem of en-
forcement). The main tool available to sports associations for monitoring com-
pliance with these prohibitions is that of doping tests. The most reliable evidence 
that can be obtained by sports organizations is to be found in samples of body 
tissues and fluids on the basis of which a prohibited act can be demonstrated 
using detection methods that provide a sufficient degree of certainty. The state 
enjoys broader investigative authority. Since doping tests violate the individual 
rights of the athlete, the nature of the prohibited act must be formulated in a 
sufficiently precise manner (principle of clarity and definiteness). From the legal 
perspective it is doubtful whether the present definition of gene doping satisfies 
this requirement. 
Detection of gene doping is likely to prove far more demanding than in the case 
of current doping practices. If gene doping is to be detected, the present system 
of in-competition and out-of-competition testing will need to be expanded. If it 
is necessary to take more blood samples or indeed tissue samples, the sampling 
requirements increase considerably. Since this bears on the personal rights of the 
athlete, the legality of the procedure must be well-founded as a matter of princi-
ple. This is probably possible only if a violation can be detected with sufficient 
certainty – i.e. if there is a test able to stand up in a court of law. All in all, as a 
result of gene doping the entire process of detecting gene doping will place even 
greater demands on sport jurisdiction than is the case with current doping prac-
tices. 
The state has the capacity to assist organized sport in the pursuit of cases of gene 
doping. The setting up and training of special police units and specialized public 
prosecutor's offices for effective criminal prosecution of offenders, clearly de-
fined contact routes and contact persons, and closer cooperation between prose-
cuting authorities and other relevant entities and individuals (science, sport, 
pharmaceutical manufacturers) are already important means for combating con-
ventional doping and will be indispensable in the fight against gene doping. 
Since these repressive measures in the fight against gene doping will be very ex-
pensive and are still beset by a number of unresolved legal issues, they are by 
themselves unlikely to act as an effective deterrent against gene doping and will 
need to be supplemented by strategies to prevent gene doping from occurring in 
the first place. 
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TABLE 1 DOPING VIOLATIONS AND THE REGIMEN OF SANCTIONS IN GERMANY 
 
Source: WADA/NADA code, German Drug Law (Arzneimittelgesetz), Prohibited List  
(German Federal Law Gazette 2007, Part II, No. 18) 
SOCIAL ASPECTS OF DOPING 
Doping is an act of an individual in a social context. Like other rule-breaking 
behavior, it is the outcome of individual developmental processes and conscious 
decisions. In view of the magnitude that doping has assumed in sport, however, 
it is not sufficient to point the finger at the deviant behavior of individual ath-
letes. Rather, to gain a comprehensive understanding of doping activity it is im-
portant to consider its social contexts. These include, for instance, the global 
commercialization of competitive and top-level sport. Sport itself has become a 
business and for many athletes a professional career. This has been promoted by 
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the media and the expectations of a global audience, which also intensify the 
process of commodization of athletic performance. This makes winning »at any 
price« all the more important. The dominance of the performance imperative, 
together with the prospect of profits, gives rise to structures that are receptive to 
any means of improving performance. 
In the system of sport, sports associations are the entities that seek to mediate 
between the demands for performance and success surrounding the athlete – 
politics, the media, sponsors, the public – on the one hand and the athlete 
him/herself on the other. They promote their athletes' willingness and capacity 
to perform, and they organize competitions to test performance. Their position 
and their influence on the overall course of events depend on the success of their 
athletes. Hence, like the athletes, they too are caught in a kind of »doping trap«. 
They must satisfy demands for clean, rule-abiding competitive sport by taking 
an active role in the fight against doping. But by testing and sanctioning, they 
tend to jeopardize their athletes' success. Much of what the sports associations 
do or fail to do with regard to doping can be better understood by considering 
their involvement in the »system logic« of competitive sport. 
However, the diagnosis of structural involvement in doping activity is true not 
only of athletes, sports physicians, and organizations, but also of governmental 
entities. They promote sport because they are interested in success, but they also 
support structures for detecting and punishing doping and establish prohibitions 
and statutory offences in legal codes. Yet the success of anti-doping activities 
could mean a lack of success on the part of national athletes – possibly also be-
cause doping practices of foreign competitors are not countered with equal vig-
or. 
Overall, doping must be understood as a product of specific social structures. By 
acting or failing to act, many actors have contributed to a system of organized 
irresponsibility. As a collectively engendered problem, the widespread practice of 
doping can only be solved through common action at multiple levels. Given the 
structures that have evolved over many years, optimism is out of place here. 
However, the considerable problems of credibility in competitive sport could 
certainly usher in effective curbing of doping practices. Gene doping could thus 
act as a warning sign, promote insights into the potential danger of doping for 
sport, and aid in the process of reorientation. 
NEED FOR INFORMATION AND ACTION 
Gene doping means entering a political sphere characterized by incomplete and 
uncertain knowledge coupled with an urgent need for action. The following ac-
tions could form the elements of a specific anti-gene-doping strategy. 
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SCREENING OF BIOMEDICAL AND PHARMACEUTICAL DEVELOPMENT 
PROJECTS FOCUSING ON THEIR RELEVANCE TO GENE DOPING  
Gene doping misuses knowledge from basic and/or applied research in the life 
sciences that was intended to lead to new therapeutic strategies. Continuous 
predictive monitoring of biomedical and pharmaceutical development projects 
and of the potential demand side could provide strategically important infor-
mation. This could become a kind of early warning system, providing guidance 
for those involved in the fight against doping and preventive doping research. A 
willingness on the part of the industry to cooperate in this area would be help-
ful. 
INVESTIGATING DETECTABILITY, DEVELOPING TESTS, DESIGNING 
INTELLIGENT MONITORING SYSTEMS 
There is a great need for research and development work in the detection of gene 
doping as a key element in the monitoring and sanctions system. A two-step ap-
proach currently appears to be the most promising. It covers intelligent monitor-
ing and, where there are grounds for suspicion, specific tests for verification. 
This kind of monitoring requires both specialized (what parameters measured at 
what intervals provide evidence of doping-induced physiologic abnormalities?) 
and legal clarification with regard not only to sanctioning but also data protec-
tion and personal protection.  
CONCEPTS AND ACTIVITIES FOR PUBLIC INFORMATION CAMPAIGNS  
SPECIFIC TO GENE DOPING 
In parallel with the further development of testing and sanctioning structures, 
independent public information campaigns focusing on gene doping must be 
devised. For these to have a preventive effect, a broad concept is needed which 
covers the whole process of individual sports development during which mental-
ities and attitudes favorable to doping can gradually arise. Such an approach 
should take into consideration both the athlete's immediate milieu (trainers, 
managers, physicians) and the role of sponsors and the media. 
ADAPTING FUNDING POLICIES 
In the context of the public funding of sport, those receiving financial support 
are now required to adhere to the rules set down by the WADA and NADA. To 
this extent, gene doping is covered. Repayment of financial support in the event 
of violations, however, requires proof that will stand up in court. Here again 
detection proves to be the Achilles heel. Nevertheless, the demand for compli-
ance with anti-doping rules should be upheld in any case and, indeed, applied 
even more stringently to gene doping. To this extent, the state could serve as a 
role model for private-sector sponsorship in its funding activities. 
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GERMAN DRUG LAW: CHECKING ITS APPLICABILITY AND FURTHER 
STATUTORY OFFENCES  
The German Gesetz zur Verbesserung der Bekämpfung des Dopings im Sport 
(Law to Improve the Fight against Doping in Sport) has created better condi-
tions for the prosecution of doping, particularly in the athlete's own milieu. 
However, the legislature must investigate whether and, if so, how these and oth-
er legal norms will be adapted to the dynamics of scientific and technical pro-
gress and doping practice. For example, gene doping could be more clearly de-
fined as a prohibited act in order to satisfy the principle of clarity and definite-
ness. Given the recent extension of the definition of doping to include any sub-
stance intended for use in conjunction with prohibited methods, it should be 
possible to include substances relevant to gene doping. To satisfy the principle of 
clarity and definiteness, for instance, reference could be made in § 6a, nos. 2 and 
2a AMG to § 4, no. 9a, AMG. In this way, the use of gene transfer agents for 
the purpose of gene doping could be prohibited. Furthermore, it should be con-
sidered whether the constituent element »nicht geringe Menge« (= more than a 
small amount) is even valid for gene doping or whether instead any medically 
unindicated use of gene transfer agents in humans should be made a punishable 
offence. 
PARLIAMENTARY TECHNOLOGY IMPACT ASSESSMENT 
The relevance of gene doping stems not only from its significance as a factor that 
will probably intensify the problem of doping in sport. Rather, it reflects a gen-
eral social trend towards the use of pharmaceutical agents to manipulate physi-
cal and psychological performance. »Routine doping« or »enhancement« is a 
topical subject that will continue to be relevant to technology impact evaluation 




BACKGROUND AND AIM OF THE TAB GENE DOPING PROJECT 
Will gene doping be the next stage in the banned manipulation of performance 
in sport? This fear gained increasing immediacy as the Human Genome Project 
neared completion in the late 1990s. Although precise information on the scien-
tific basis of such manipulation did not yet exist, the far-reaching aims and vi-
sions of human genome research and its potential application to gene diagnostics 
and therapy were projected – usually in vague terms – onto the competitive and 
even recreational sports arenas. Notions about human selection and human 
breeding were mooted. Often the term »gene doping« was and is used in the 
media as the superlative of »doping« in general. 
Given a growing number of gene therapy studies, scientific committees and pub-
lications in recent years have also addressed the question as to whether, how, 
and when gene doping can or will pose a real threat to sport (Andersen et al. 
2000; Schulz et al. 1998). In particular, some researchers investigating gene 
therapy methods for muscle diseases have drawn attention to the potential mis-
use of these techniques to boost performance in sport (Sweeney 2004). Given the 
long, uninterrupted tradition of doping, it appears plausible that, despite bans 
and threats of far-reaching sanctions, there is a strong tendency both in sport 
and in its illegal and fraudulent milieu to experiment with and use agents and 
techniques, including those that are highly risky and largely untested by medical 
science. 
In 2001 – after gene doping had long been officially dismissed as an alarmist 
horror scenario – the Medical Commission of the International Olympic Com-
mittee (IOC) met for the first time to discuss the potential impact of gene thera-
py on sport. 2002 marked the first meeting of the World Anti-Doping Agency 
(WADA) on the subject of gene doping. In the same year the ethical problems, 
gene techniques, and manipulation of physical performance were the subject of 
two meetings of the United States President's Council on Bioethics, the results of 
which were included in the highly respected report »Beyond Therapy: Biotech-
nology and the Pursuit of Happiness« (The President's Council on Bioethics 
2003). Shortly thereafter the IOC and WADA decided to prohibit gene doping. 
Since January 1, 2003 gene doping has been included as a prohibited method in 
the WADA's Anti-Doping Code. In Germany the Federal Institute of Sport Sci-
ence, following up on the WADA's activities, held a »small conference« on gene 
doping in 2002 (BISp 2003). 
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Detailed investigations into and reports on gene doping remain patchy. In 2004 
the Dutch Anti-Doping Agency published a brief report (NECEDO 2004); in 
2005 the Rathenau Institute, the Dutch technology impact assessment body – 
published a study on the interfaces between (high-level) sport and gene technol-
ogy in general (van Hilvoorde/Pasveer 2005). A bioethical discussion paper on 
»genetically modified athletes« was published by A. Miah in 2004. However, its 
reflections on the possible approval of (gene) doping (in the context of the ques-
tion of the ethical acceptability of genetic modification in humans in general 
above and beyond its use in sport) is in stark opposition to the central principles 
underpinning the fight against doping (Miah 2004). More recent but condensed 
reports have come from WADA (WADA 2005) and the chair of the WADA 
Gene Doping Committee, T. Friedmann (Schneider/Friedmann 2006). 
In view of the potential explosiveness of the subject coupled with the insufficient 
body of information available, the TAB, at the suggestion of the German Bun-
destag, was commissioned by the Committee for Education, Research, and 
Technology Impact Assessment to carry out a project on the subject of gene dop-
ing. Its aim was to investigate the scientific and sociopolitical dimensions of gene 
doping based on an analysis of the following main points: 
> The status and perspectives of doping-relevant findings in genome research 
and relevant gene therapy techniques, taking into account individual and so-
cial risks;  
> Methods for detecting gene doping and their implications for procedures and 
systems of doping control; 
> The necessary further development of relevant (international) legal instruments; 
> The necessary geopolitical conditions (education, prevention, prosecution, 
public debate, codes of conduct) and new internationally coordinated strate-
gies. 
PROCEDURE 
The TAB carried out the project in two phases. Throughout the process, it en-
gaged in intensive cooperation with a network of outside experts. 
In the first phase of the project the relevant current status of genome and prote-
ome research was characterized, an overview of the approaches of detection 
methods was given, and an attempt was undertaken to summarize the available 
empirical findings on the current doping situation. To this end three expert re-
ports were commissioned: 
> Gene doping: Techniques, potential biological aims, and possibilities of detec-
tion (Dr. Patrick Diel, Dr. Ulrike Friedel; German Sports University, Cologne) 
 INTRODUCTION 23 
> Doping structures in sport with special consideration of the possibilities and 
limitations of doping detection (Dr. Heiko Striegel; Bietigheim-Bissingen) 
> Status and perspectives of doping-relevant findings of genome research and 
relevant gene therapy techniques (Dr. Bernd Wolfarth, Dr. Johannes Scherr, 
Anja Pertl; Munich Technical University/Klinikum rechts der Isar, Munich) 
The aim of the second project phase was to carry out a review of the literature 
regarding the actors and structures of conventional doping and to predict the 
effects of gene doping on them. To this end several brief reports were commis-
sioned, and their main theses were discussed at an expert workshop in Septem-
ber 2007. 
> Doping – a non-accidental dilemma: (traditional) responsibility of athletes in 
the (global) system world of sport (Prof. Elk Franke; Berlin) 
> Nature and enhancement: The ethical evaluation of gene doping (Dr. Michael 
Fuchs, Dr. Dirk Lanzerath, Prof. Dieter Sturma; Institute for Science and Eth-
ics [IWE], Bonn) 
> Gene doping – potential suppliers and possible means of control (Prof. Ale-
xander S. Kekulé, Institut für Biologische Sicherheitsforschung GmbH, Halle) 
> The perpetrator-victim relationship in its ethical dimension and related limita-
tions and possibilities of antidoping strategies (Prof. Nikolaus Knoepffler in 
collaboration with Dr. Reyk Albrecht; Freising) 
> Legal aspects of gene doping in sport  
(Prof. Jürgen Simon, Jürgen Robienski, Dr. Rainer Paslack; Lüneburg) 
> Doping in democratic social systems  
(Andreas Singler, Prof. Gerhard Treutlein; Mainz/Heidelberg) 
The aforementioned reports form a cornerstone of the present report. We wish 
to thank all the reviewing experts for their willing cooperation and several of 
them for commenting on the draft versions of individual sections. The authors of 
the TAB report are solely responsible for the selection and interpretation of the 
information presented in the reports. A special thanks goes out to our colleague 
Ulrike Goelsdorf for handling the illustrations and setting up the layout. 
STRUCTURE OF THE REPORT 
An important point of reference in the following report is formed by the relevant 
activities of the World Anti-Doping Agency (WADA). When the Prohibited List 
was adopted in 2003, gene doping was defined in terms analogous to the use of 
gene and cell-therapy strategies in medicine: »Gene or cell doping is defined as 
the non-therapeutic use of genes, genetic elements, and/or cells that have the ca-
pacity to enhance athletic performance.« However, the following year, in 2004, 
the WADA shifted its focus. Since then it has defined and prohibited doping in 
terms that include the modulation of gene expression without limiting the meth-
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ods and techniques used: »The non-therapeutic use of cells, genes, genetic ele-
ments, or of the modulation of gene expression, having the capacity to enhance 
athletic performance, is prohibited.« (WADA 2008; italics added by the author). 
In the Gene Doping Project the TAB adopted this expanded perspective of the 
WADA, which some experts criticize as being too vague. Why – despite the ter-
minological vagueness – this is not only scientifically sound but necessary, espe-
cially with regard to future doping problems, is explained and justified in detail 
in Section II, »Scientific Basis and Perspectives of Use«. 
The aim of that chapter is to present the scientific underpinnings and strategies 
of various forms of gene doping to derive plausible theses about the potential 
diffusion of gene doping in sport. First we give a brief overview of the levels of 
gene regulation and targets for manipulation in general (Section II.1), after 
which we present the principles, approaches, and current limitations of gene 
therapy in particular. We then summarize the findings presented in the reports 
by Wolfarth, Scherr und Pertl, which review and discuss the current status of 
genome research into »high-performance variants«, as it has been found that 
there is little in the way of concrete facts to report. The core of the chapter 
therefore presents – on the basis of the Diel and Friedel reports – a detailed but 
concise view of the most important potential biological targets of gene doping 
and the currently relevant research avenues and development projects (Sec-
tion II.2). After presenting foreseeable health risks (Section II.3), we then dis-
cuss – with reference to the report by Kekulé – the plausibility of several sce-
narios of gene doping diffusion – routes of access, points of entry, and time 
horizons (Section II.4). 
The chances of success in the fight against future gene doping depend largely on 
whether its use can be unambiguously detected. Section III is therefore devoted 
to the questions of detectability and test development, again on the basis of the 
Diel and Friedel reports. Again, the point of reference is formed by the activities 
of WADA, which has been strategically sponsoring research projects on the de-
tection of gene doping since 2003. The questions those projects have raised 
about the foreseeable significance of indirect detection methods and of a bio-
monitoring or screening systems for athletes will be a crucial factor in determin-
ing if action needs to be taken. 
Specific methods for detecting gene doping are an essential tool for monitoring 
compliance with regulations. Section IV looks at whether gene doping is already 
covered by existing legal norms, monitoring systems, and sanction structures 
and whether they are able to counter the potential future use of gene doping. 
The reports by Franke, von Simon, Robienski, Paslack, and Striegel serve as im-
portant sources of information. The chapter's central point of reference is the 
World Anti-Doping Code (WADC) with the Prohibited List, which has formed 
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the framework for action – increasingly based on a division of responsibilities – 
by sport organizations and politicians in many countries since 2003. Section IV.1 
gives an overview of prohibited activities relevant to gene doping and their deci-
sion basis. Through a process of definition and adoption to the German legal 
landscape, the WADC and the Prohibition List are gradually being implemented 
in German law. Section IV.2 discusses the NADA Code as a basis for antidoping 
rules of German sport organizations that apply at the federation or club level. To 
counter increasingly subtle doping practices, the majority of sports organizations 
in Germany are broadening their doping monitoring and sanction systems in line 
with the NADA Code. Focusing on unanswered questions and foreseeable modifi-
cations and with the aim of ensuring compliance with the (gene) doping ban, an 
overview is given of the established doping monitoring methods and their limita-
tions. Lawmakers must support the efforts of sport in the antidoping battle by 
ratifying international treaties (Section IV.3.1) and enacting national legislation 
(Section IV.3.2). We show how gene doping is already covered by the German 
Drug Law and other offenses and where regulation problems exist. 
Despite bans and far-reaching sanctions, gene doping – like doping and other 
rule-breaking behavior before it – could gain a foothold across swathes of socie-
ty. To understand and evaluate (gene) doping, the subject must be analyzed and 
discussed not only as a biological, chemical, and physiologic process but also as 
an individual action within social contexts. This is done in a cursory manner in 
Section V, which draws on the reports by Knoepffler, Albrecht, Singler and 
Treutlein, Fuchs, Lanzerath, and Sturma. Gene doping can be the result of indi-
vidual developmental processes, in the course of which attitudes, mentalities, 
and behavioral patterns disposed toward doping are acquired. 
Section V.1.1 explains this first in the context of high-level sport, addressing the 
specific role of medical managers, who are key players in determining whether a 
doping mentality develops and the practice of doping becomes entrenched 
among athletes. Section V.1.2 discusses other »peripheral players« who influence 
athletes. For example, it should be made clear to sport organizations and promot-
ers that although athletes act and decide independently, they are influenced by 
their social milieu. Taking bodybuilding and sports pursued by older people as 
examples, Section V.2 examines the question of how doping behavior typically 
arises within individual sports. Both sections (V.1 and V.2) deal specifically with 
those factors that athletes are thought likely to consider when deciding for or 
against gene doping. 
From an analysis and discussion of the scientific, legal, and social situation, it is 
possible to infer what information and action will be needed in the foreseeable 





GENE DOPING: SCIENTIFIC BASIS AND 
PERSPECTIVES OF USE II. 
As explained in the introduction, this report is not restricted to the commonly 
encountered view of gene doping as the transfer of gene and cell therapy strate-
gies in the narrow sense. Rather, it adopts the broadened perspective of the 
World Anti-Doping Code, which explicitly defines gene doping to include the 
modulation of gene activity by other methods as well, i.e. »the nontherapeutic 
use of cells, genes, genetic elements, or the modulation of gene expression having 
the capacity to improve athletic performance« (NADA 2006b). 
In this report the term gene doping denotes gene doping in the broad sense as 
the targeted modification of gene activity. This includes the use of gene and cell-
therapy strategies for the general purpose of enhancing physical performance, 
which is referred to as gene doping in the narrow sense, as well as other modern 
substances aimed specifically at influencing gene activity directly or indirectly 
insofar as they are based on an understanding of molecular processes and are 
potentially relevant to doping. 
After giving a brief overview of genome research results, gene-regulation levels, 
and the principle and approach of gene therapy, Section II.1 explains why it is 
not just scientifically sound but necessary to adopt such a broadened perspective 
with regard to future doping problems. This is then justified in detail in Section 
II.2. 
Section II.2 presents the three areas which according to a broad consensus are 
likely biological targets for gene doping: muscle formation, oxygen supply, and 
energy supply in the body. The basic molecular knowledge required for under-
standing the targets of molecular and gene-regulating manipulations is presented 
for each of these three fields based on the Diel/Friedel (2007) report. 
Section II.3 examines the specific health risks of several gene doping methods. 
Section II.4 broadly discusses the perspectives of use and the plausibility of the 
broader use of gene doping, while giving due consideration to routes of access, 
time horizons, and points of entry.  
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CURRENT SITUATION: LIMITS AND TARGETS 1. 
A commonly held view is that gene doping methods aim to »improve« the genet-
ic makeup of athletes. It assumes that in recent decades human genome research 
has produced an extensive body of knowledge about gene variants that have a 
specific effect on performance. Using techniques of gene and/or stem-cell thera-
py, these »high-performance gene variants«, it is believed, may some day be 
transferred to individuals – whether in the embryonic stage, in childhood, or in 
adulthood – to replace less performance-enhancing variants. Other conceivable 
options arising from such a scenario are prenatal and preimplantation diagnostic 
tests where the »selected parameters« are genetic factors for specific physical 
and/or mental characteristics. 
The TAB project uncovered no evidence whatsoever that such scenarios of hu-
man selection or breeding for athletic prowess will be technically feasible in the 
foreseeable future. Such gene doping scenarios are scientifically unfounded and 
misleading in that they divert attention from far more urgent and practicable 
developments demanding consideration and action. 
As a preliminary comment to the results presented in this report, it should be 
stressed that a whole series of new pharmaceutical methods and techniques exist 
or are under development which could potentially be misused for illegally boost-
ing performance and as such could be seen as and referred to as gene doping in 
the narrow or broad sense. Among these are several which would probably be 
no more complicated to use or more expensive than current doping methods but 
would be at least as difficult to detect (see Section III for a full discussion of this 
point). 
Before the aspects of gene regulation and gene therapy relevant to the future prac-
tice of gene doping are explained below, we should justify why visions of human 
selection or breeding for athletic performance in the foreseeable future have no 
scientific basis. 
RELEVANT KNOWLDEGE ABOUT 
HIGH-PERFORMANCE VARIANTS 1.1 
Does a relevant body of molecular genetic knowledge exist about »high-
performance variants« that could potentially be used to enhance athletic per-
formance? A detailed examination of findings from the fields of genome analysis 
and genetic diagnostics gives the following picture regarding genes that could be 
used to redress individual »genetic disadvantages« through targeted gene ma-
nipulation (Wolfarth et al. 2007): Molecular genetic knowledge of »high-
performance gene variants« (or performance-relevant polymorphisms) is still 
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extremely limited, imprecise, and contradictory, with the result that »promising« 
techniques for inducing specific alterations in an individual's genetic disposition 
are extremely unlikely to be developed in the foreseeable future. This consensus 
of the reviewing experts is summarized below. (The experts are [founding] 
members of an international research group which has been reviewing interna-
tional research findings from molecular genetic studies on phenotypes relevant 
to physical performance and fitness since 2001) (Wolfarth et al. 2007, pp. 4 ff.). 
Genome research has been examining the phenomenon of physical performance 
for the past 40 years or so. In the 1970s and 1980s the main research tool was 
the study of twins. However, in the past 15 years researchers have increasingly 
also been investigating individual genetic variants with the help modern molecu-
lar biological methods. As has happened in many other fields of medical science 
(e.g. research into the causes of prevalent diseases such as hypertension, diabetes, 
obesity, and coronary heart disease), the initial euphoria about the genetic basis 
of physical performance as a complex quality has since given way to a more so-
bering view. Although the number of publications in this research field has risen 
steeply in the past 20 years, a breakthrough in the form of robust data is still 
nowhere in sight. Even extensively studied physiologic subsystems that are rele-
vant to performance (e.g. the hormonal renin-angiotensin system and adrenergic 
receptors) have so far yielded highly contradictory results regarding the effects of 
gene variants. As in other fields of medical science, large population studies have 
failed to identify or confirm any links between genetic variations and physical 
performance.1 
It is expected that technical progress will bring about further changes in the re-
search field of genome analysis and that the increasing efficiency of high-volume 
methods will open up ever new quantitative and qualitative dimensions of ge-
nome analysis. Whether these technical developments will simplify or resolve the 
problem of characterizing and explaining complex genetic traits remains unan-
swered. It is possible that, owing to their complexity, the genetic basis of many 
physiologic traits and parameters cannot be definitively explained – or at least 
not in such a way that they could be used for selection or as »blueprints« for 
athletes. 
The question of whether it is possible to specifically manipulate the genome to 
enhance physical performance based on scientifically sound findings from poly-
morphism research must be answered with a categorical »no« at present. Nor is 
it possible to predict reliably whether and when such a potential could arise in 
the future. The discovery of just one truly performance-enhancing gene could 
change the situation suddenly, at least insofar as it could be used to select off-
                                            
1 To be fair it should be noted that in comparison to medically and therefore economical-
ly more relevant parameters, less research is devoted to questions regarding the non-
pathogenic impairment of performance. 
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spring by means of preimplantation diagnostics (Kekulé 2007). Judging from 
genome research findings from the past 15 years, a »breakthrough« is highly 
unlikely, at least not within the next five to ten years. 
GENE REGULATION – TARGET FOR GENE DOPING 1.2 
The human body consists of around 100 trillion cells, each of which (with few 
exceptions, e.g. red blood cells) contains the complete genome (Diel/Friedel 
2007, pp. 8 ff.). The genetic substance itself is DNA (deoxyribonucleic acid), 
which occurs in the cell nucleus in the form of 46 chromosomes (one set of 23 
homologous chromosomes from each parent). Each chromosome is made up of 
a long strand of DNA, which is compressed by supercoiling so that it fits inside 
the tiny cell nucleus. The highly specific sequence of the four »building blocks« 
of DNA (adenosine, cytosine, guanine, and thymine), which is essentially identi-
cal within a given species, contains the biological information for many thou-
sands of functional DNA segments or genes. 
Classical or coding genes are active when they are expressed, i.e. when the in-
formation they contain is read, causing the cell to produce a functionally active 
protein (Fig. 1).2 In the first step of this process the segment of the nuclear DNA 
that codes for the protein concerned is copied, not in the form of DNA, but in a 
slightly altered chemical form as RNA. The product of this process of transcrip-
tion is known as messenger RNA (mRNA). In a complex process known as 
translation, mRNA serves as a template for the production of a highly specific 
protein. The primary structure of the protein is determined by the sequence of 
the gene that was read. However, in the course of the protein biosynthesis pro-
cess, modifications may occur at various sites, depending on the physiologic 
state of the cell. This is one reason why proteins with very different effects can 
be traced back to individual genes and one of the reasons why the »gene« is such 
a fuzzy, hard-to-define concept. 
The body's mechanisms for controlling and influencing this gene expression are 
collectively known as gene regulation. Gene regulation forms the basis of cellu-
lar differentiation and morphogenesis (organ and form development) and for the 
variety and adaptability of all organisms. For these highly complex processes to 
take place, the right gene must be expressed in the right cells, in the right 
amount, and at the right time (Diel/Friedel 2007). Although the relevant body of 
knowledge is enormous, it is also severely limited. New knowledge is continu-
                                            
2 »Classic« because in the early days of gene research it was thought that this is the main 
function of the DNA in human chromosomes (one gene, one protein model). It is now 
known that the bulk of DNA exerts its functions through other mechanisms. These 
mechanisms are often regulatory in nature but research into them is still very limited. 
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ously being gained from genome research and proteome research (research into 
the entire complement of proteins), with every finding throwing up new ques-
tions, so that the real complexity of these biological processes is now becoming 
clear. 
FIG. 1 METHODS OF MODIFYING THE BODY'S GENE ACTIVITY 
 
Source: P. Diel, using an illustration from Roche 
Since each and every step in gene expression is subject to highly complex physio-
logical regulatory mechanisms, there are many points at which pharmacologic or 
molecular biological modulation is potentially possible – either for therapeutic 
intervention or for doping purposes (Fig. 1). 
Over moderate and long physiologic periods gene expression in the body is con-
trolled, e.g. via chemical modification of DNA and altered spatial arrangement 
(condensation) of DNA segments. In particular, methylation (the attachment of 
methyl groups to specific parts of the DNA molecule) leads to gene silencing, as 
it prevents the genes from being read. Such inactivation can be very long-lasting 
and can even be inherited. Mechanisms that modify gene expression without 
altering the DNA sequence are subsumed under the term epigenetics. Methods 
to specifically influence methylation, for example, are still in the early stages of 
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Short-term physiologic gene regulation, by contrast, is achieved via the interac-
tion of DNA with specific proteins known as transcription factors, which influ-
ence the production of messenger RNA (mRNA). A scientifically satisfactory 
description of the highly complex regulatory mechanisms of transcription and 
translation goes well beyond the scope of this report. Relevant facts are there-
fore given only in relation to the examples of developments pertinent to (gene) 
doping in Section II.2. 
GENE THERAPY: PRINCIPLE AND APPROACH 1.3 
When a gene fails to fulfill its normal function in a cell, tissue, or organ and this 
circumstance gives rise to a disease, a genetic defect is said to exist. A genetic 
defect can be inherited or can arise in the course of a person's life (so-called so-
matic mutations, which are implicated, for example, in cancer development). 
Such defects may be due to changes in individual DNA building blocks (base or 
point mutations) or to the rearrangement or loss of longer DNA segments. More 
generally, any disorder of gene regulation can be regarded as a genetic defect 
(Diel/Friedel 2007, p. 14). 
Gene therapy is a term used to denote strategies that aim to eliminate genetic 
defects by inserting genes or genetic elements into tissue or cells for the purpose 
of obtaining therapeutic or preventive benefits associated with the expression 
and function of those genes (DFG 2006, p. 6).  
The process of introducing genes into cells is known as gene transfer. In most 
cases this is achieved with the help of a vector which carries the therapeutic ge-
netic element (corrective gene, foreign gene, transgene) (Fig. 2). Gene therapy is 
intended to enable the body to, as it were, produce its own medicine 
(Diel/Friedel 2007, p. 15). Notwithstanding commonly held notions to the con-
trary, in many cases the change thus induced is impermanent, being a transitory 
modification that might have to be repeated. 
In principle it a therapeutic gene could be inserted either into somatic cells (nor-
mal body cells) or into germ cells (reproductive cells, i.e. ovum or sperm cells). In 
Germany only somatic gene therapy is allowed. There is a broad international 
consensus that germ-line therapy is scientifically and ethically unacceptable at pre-
sent, due to the incalculable risk of transmission and diffusion of the transferred 
gene in the human population. 
Depending on the gene-transfer method used, somatic gene therapy is divided into 
in vivo and ex vivo techniques (Fig. 2). In ex vivo therapy, cells are removed from 
the body. The corrective gene is then inserted into those cells in a laboratory, after 
which the cells are put back into the body. Ideally, the cells migrate to their site of 
action, where they multiply, differentiate, and start producing the missing protein. 
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However, only a few types of somatic cells can be cultivated outside the body (e.g. 
blood cells), and few of these can be successfully reintroduced into the body. 
FIG. 2 PRINCIPLE OF EX VIVO GENE THERAPY 
 
Source: Bibliographisches Institut & F.A. Brockhaus 
In in vivo therapy, the therapeutic gene is inserted directly into cells inside the 
body. This gene-transfer approach would be desirable for reasons of efficiency, 
but it is beset by a number of practical problems. The vectors injected into the 
blood are rapidly diluted. En route through the body they encounter many cell 
types that are unaffected by the disorder concerned. In these circumstances 
stringent requirements for vectorial specificity, effectiveness, and safety and for 
therapeutic efficacy must be met – requirements that the today's usual vectors 
cannot satisfy (see below). 
A general distinction can be made between the following methods of gene 
therapy (Kekulé 2007, pp. 9 ff.): 
> Gene correction: A strategy to correct mutation, gene correction is still purely 
theoretical. 
> Gene replacement: It would be more realistic to replace a gene as a whole. To 
do so the original gene must be removed from the genome and the replace-
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only in a few animal experiments and is therefore a long way from being used 
for medical purposes in humans.  
> Gene addition: A new gene is inserted into the cell without removing the orig-
inal (defective or suboptimal) gene. In this way the total amount of gene 
product is increased or, in the case of a regulative gene, the new gene takes 
over function of the original (assuming that it is not affected by the presence 
of the original gene). The additional gene does not necessarily have to be inte-
grated into the genome (i.e. into a chromosome). The extrachromosomal in-
sertion of a gene into a plasmid, which can move around freely within the cell 
or cell nucleus, is also conceivable. By inactivating the plasmid it is theoreti-
cally possible to reverse the gene addition more easily. 
> Gene inactivation: This can be achieved in several ways – by destroying the 
gene itself (i.e. the corresponding DNA sequence on the chromosome), by 
modifying the regulator sequence, or by inactivating mRNA (e.g. by blocking 
it with complementary antisense RNA or by modifying its base sequence to 
accelerate its breakdown). RNA blockade methods in particular could be 
used reversibly. 
> Gene activation: It is also theoretically possible to activate genes by modifying 
the regulator sequences or mRNA (e.g. by modifying its base sequence to 
slow its breakdown). 
In principle, these methods could be combined. For example, one could insert a 
foreign gene (gene addition) and then control its expression with the help of anti-
mRNA. 
To date, successful attempts at gene therapy in human beings have been limited 
to techniques based on gene addition (so far only undirected, i.e. by random 
chromosomal or extrachromosomal integration) and gene inactivation (see Sec-
tion II.3.1 for details).  
The »therapeutic« or »corrective« gene itself must be: 
> therapeutically effective 
> easily regulated (control of the time and intensity of its expression), and 
> safe (without adverse effects). 
Theoretically many diseases could be treated with gene therapy. The gene thera-
pies that have been tested in humans to date have been directed mostly at can-
cers, monogenic hereditary diseases, infectious diseases (especially HIV infec-
tion), and cardiovascular disorders, with over 60% of studies focusing on can-
cers (Diel/Friedel 2007, p. 17). However, the assessment of gene therapy results 
achieved to date remains a matter of great contention. 
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VECTORS 
The success and risk of gene therapy depend largely on vectors used to transport 
the corrective gene into the cells. The vector must (Diel/Friedel 2007, pp. 16 ff.) 
> be able to penetrate into specific cells (tissue specificity and efficiency of cell 
entry), 
> ensure sufficiently strong, lasting gene expression (expression rate and persis-
tence), and  
> have as few side effects as possible (safety). 
The type of vector used not only determines the efficiency of the gene transfer 
but also influences the intensity and duration of gene expression and may con-
tribute to regulatory functions. In the case of undirected gene transfer without a 
vector, the probability of a therapeutic gene being successfully integrated is be-
tween 1:1000 and 1:100,000. In a targeted transfer using a vector, success rates 
are much higher, and the case of hemopoietic cells, success rates of 1:2 can be 
achieved (Diel/Friedel 2007, p. 16). 
So far mostly viral vectors have been used in gene therapy (see box). Viral vec-
tors are viruses that are unable to replicate. They have been genetically modified 
so that they are harmless and so that they are able to transport normal DNA 
into cell nuclei. Recently a growing use of nonviral vectors has been observed 
(Diel/Friedel 2007, p. 17). There is no such thing as the ideal vector; each must 
be adapted specifically to the nature of the genetic defect being treated (form of 
administration, tissue specificity, expression characteristics, etc.). The challenge 
of gene therapy lies in designing the best vector for treating the disease con-
cerned (Diel/Friedel 2007, p. 44). 
VECTORS FOR GENE THERAPY (FROM DIEL/FRIEDEL 2007, PP. 49 FF.) 
Retroviruses and lentviruses: The genetic information of these viruses (which 
include HIV) is inserted into the chromosomes of the recipient cells and is 
passed on when the cells divide. In principle this allows the efficient produc-
tion of gene therapy proteins but can also cause severe side effects (including 
cancer) due to integration in nuclear DNA. 
Adenoviruses: The DNA of these viruses (which include the common cold vi-
ruses) remain outside the chromosomes rather than being integrated within 
them. This limits the possible duration of action but also prevents the afore-
mentioned adverse effects of integration. However, severe immune reactions 
remain a problem. 
Adeno-associated viruses: These particularly small, harmless viruses usually 
integrate at a specific site within nuclear DNA without severe consequences 
and with a very high expression rate of the transferred genes. Their major 
disadvantage is their limited capacity to transport genes. 
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Naked DNA: The integration of naked DNA in somatic cells (without the 
biological insertion mechanisms of viruses) is greatly limited but can be en-
hanced by lipofection (coupling to suitable molecules) or electroporation (use 
of electrical pulses). The greatly limited intracellular efficacy of naked DNA 
is offset by the major advantages of simple production and few adverse ef-
fects. 
ADVERSE EFFECTS 
Gene therapy, elegant as it may seem in theory, has proved extraordinarily diffi-
cult and risky in reality (Diel/Friedel 2007, p. 24). The causes of the (in some 
cases very serious) complications observed, e.g. severe immune reactions, leuke-
mia-like symptoms, and even death, lie at the cellular and subcellular levels (see 
Section II.3.2 for details). 
A comparatively mild complication is the functional loss of the cells treated by 
gene therapy. In the simplest case this could be due to dilution of the corrective 
gene: Once a therapeutic gene has been inserted into the target cells, for example 
by an adenovirus, it remains outside the nuclear (chromosomal) DNA. When the 
target cell divides, the corrective gene is passed on to only one of the daughter 
cells. Thus its concentration in the tissue decreases steadily, as does its therapeu-
tic effect (Diel/Friedel 2007, p. 24). 
The long-term efficacy of gene therapy is also determined by the stability and life 
span of the target cells. If the life of the host cells is only a few months, gene 
therapy must be repeated at regular intervals. This increases the risk of immune 
reactions and – if inserting vector systems are used – the likelihood that foreign 
DNA will be integrated at an unsuitable site in the genome, thus causing severe 
untoward effects, e.g. the promotion of cancer (Section II.3.2). The latter can 
also be caused by the corrective genes themselves, in particular by cytokines (tis-
sue hormones), which play an important role in cancer therapy but are also can-
didates for doping misuse. 
GENE DOPING – IN THE NARROW AND BROAD SENSES 1.4 
Certainly not all the experts have adopted the concept of gene doping inherent 
in the broadened WADA definition (»the nontherapeutic use of cells, genes, ge-
netic elements, or the modulation of gene expression having the capacity to im-
prove athletic performance«). Kekulé (2007, pp. 6 ff.), for example, points out 
that both in the vernacular of the major cultural languages and in scientific par-
lance gene doping is understood as the use of gene and cell-therapy methods for 
the purpose of doping. He emphasizes that in its official publications even the 
WADA uses the term »gene doping« to refer exclusively to gene and cell-therapy 
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methods. For this reason, the broader formulation derived from the WADA's 
Prohibited List should not be construed as being the WADA definition. Owing 
to the special characteristics of genetic methods, gene doping in the narrow sense 
must be defined and analyzed separately in terms of its effects on performance 
enhancement and health and its detectability. Kekulé is therefore against sub-
suming conventional methods for the (indirect) modulation of gene activity un-
der the term gene doping (Kekulé 2007, p. 6). On the other hand, he points out 
that conventional hormones, for example, would otherwise fall under the term 
gene doping, since they indirectly influence gene activity. According to Kekulé 
(2007), modern nongenetic molecular biological methods harbor their own per-
ils of misuse for doping purposes which are even more acute in the short term 
than those associated with gene doping (in the narrow sense). Precisely because 
of this danger, he believes, novel nongenetic doping methods should be distin-
guished from gene doping and investigated separately. Diel/Friedel (2007, pp. 6 
ff.) also confirm that a strict understanding of gene doping implies the transfer 
of genetic material, but they stress that in many cases it is very difficult and 
therefore unhelpful to draw a sharp distinction between gene doping and »con-
ventional« methods. 
These terminological imprecisions are not easily resolved. It is undisputed that 
the shared scientific basis of new and foreseeable doping possibilities lies in our 
burgeoning knowledge about the molecular mechanisms of cellular function and 
the increasingly sophisticated molecular biological techniques and possibilities 
facilitated by the targeted, subtle manipulation of gene activity, which, moreo-
ver, will presumably become increasing difficult to detect (Diel/Friedel 2007, 
p. 7). In many senses whether a manipulation process involves the transfer of 
genetic material in the strict sense, i.e. DNA or RNA, or is otherwise accom-
plished pharmacologically is not a sensible exclusion criterion in the fields of 
impact assessment and prevention research. 
The following detailed presentation of potential molecular target structures for 
gene doping and the related relevant therapeutic and pharmaceutical develop-
ments (Section II.2) confirms the need for a broad perspective. As will be made 
clear, most gene therapy techniques aim to modulate gene activity through en-
hancement, activation or blockade. In principle, it can therefore be said that the 
modulation of gene activity is the aim or purpose, while gene and cell therapy as 
well as other pharmacologic techniques are the means or methods. 
For the purposes of this report »gene doping« will be understood in the broad 
sense to denote both gene and cell therapy methods and modern »conventional« 
substances used for the direct and indirect modulation of gene activity where the 
latter are based specifically on knowledge of molecular processes and have a 
potential for doping. The misuse of gene and cell therapy strategies in itself is 
not considered gene doping in the narrow sense. 
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Strictly speaking, some of the new manipulation methods presented below fall 
outside the broad definition of gene doping because, for example, they only in-
fluence the effect of a protein (as a gene product) but not genetic activity or gene 
expression (e.g. blockade of a hormone or receptor with specific antibodies). 
Because these are not covered by the gene doping prohibition of WADA, it 
would be sensible to broaden or redefine the term in the future (Section IV.1). 
FIG. 3 POSSIBLE FOUNDATIONS FOR GENE DOPING: GENE THERAPY AND 
 MODULATION OF GENE EXPRESSION  
 
Own illustration 
POTENTIAL BIOLOGICAL TARGETS FOR GENE DOPING 2. 
In recent years debate and speculation have been ripe at international symposia 
and conferences as well as among the public regarding which biological targets 
might be relevant to gene doping. In principle, all molecular factors that pro-
mote or inhibit human performance come into question. The consensus among 
all the experts consulted in the TAB project and in the scientific literature is that 
the most likely targets for gene doping lie in three physiologic areas and their 
molecular regulation: the formation of skeletal muscle, oxygen supply, and ener-
gy supply (specific references to the modulation of pain sensitivity by gene dop-
ing, as is sometimes mooted, could not be found. 
PHYSIOLOGICAL TARGETS FOR GENE DOPING STRATEGIES 
> Oxygen supply: Hemoglobin concentration, blood vessel supply (molecu-
lar targets: EPO, HIF, VEGF) 
> Skeletal muscles: Growth, structure, strength, endurance, regeneration 
(molecular targets: myostatin, HGH/IGF/MGF, Pax7, PPAR-delta) 
> Energy supply: Fatty acid and glucose metabolism in the liver and muscles 
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The following discussion of these areas and potential molecular targets for gene 
doping is based on the Diel/Friedel report (2007, pp. 58 ff.) but does not cite the 
report in detail. At the same time the status of relevant therapeutic developments 
is reviewed. When dealing with scientific technical developments in the early 
stage, as is the case with (potential) gene doping methods, it is useful to identify 
the phase of research and development that has been reached, because this de-
termines the time horizons for possible utilization. In the case of medical and 
pharmacologic developments, it is helpful to use a classification system corre-
sponding to the phases of clinical testing and drug development (see box). A 
noteworthy difference, however, is that because of the assumed unpredictability 
of complications (Section II.3.2), only patients with life-threatening disease and no 
alternative treatment options are entered in clinical phase I gene therapy trials. 
PHASES OF CLINICAL TESTING AND DRUG DEVELOPMENT 
Preclinical research: Search for drug candidates, including testing in animal 
models and experiments. 
Phase I: Tested for the first time in (up to 50) healthy volunteers to investi-
gate tolerance and initial adverse effects and to determine the minimum and 
maximum doses; duration: several weeks. 
Phase II: First proof of concept in a limited number of patients (50 to 200) 
having the disease concerned; investigation of various doses; duration: several 
months. 
Phase III: Randomized and preferably double-blind studies in 100 to 10,000 
patients; investigation of efficacy compared to established drugs and/or pla-
cebo, risk-benefit analysis; duration: up to 2½ years; aim/completion: drug 
licensing. 
Phase IV: Postmarketing surveillance, i.e. long-term observation and record-
ing of adverse effects of the treatment in several tens of thousands of patients; 
possibly also identification of new indications. 
Source: Kollek et al. 2004, p. 93; www.wikipedia.org 
SKELETAL MUSCLE 2.1 
Skeletal muscle is one of the most highly developed and largest organs in the 
human body. In common with bones and nerves, skeletal muscle in essential for 
physical activity and forms the basis of locomotion in humans and other ani-
mals. Its development at the molecular, cellular, and organ level has been exten-
sively researched (Wassarman 2002). Skeletal muscle is characterized by its plas-
ticity, i.e. its ability to respond to external stimuli (such as physical work or ath-
letic exertion) by adapting in shape and performance over time. 
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SKELETAL MUSCLE DEVELOPMENT AND COMPOSITION –  
MOLECULAR BASIS 
Knowledge of the molecular mechanisms regulating skeletal muscle is being ap-
plied to the development of therapeutic methods, e.g. for degenerative muscle 
diseases. The same information is also being used to identify targets for pharma-
cologic and genetic manipulation aimed at enhancing performance. 
Embryonic myogenesis (muscle development) proceeds from muscle precursor 
cells, which form skeletal muscle after undergoing differentiation and fusion. In 
the process, muscle-specific genes are expressed to produce the muscle-specific 
proteins actin and myosin, which make up the contractile units (dynamic molec-
ular structures that are responsible for muscle contraction and strength) (Jones 
et al. 2004). The skeletal muscle continues to mature into adolescence but re-
tains its ability to adapt to outside stimuli even after the growth process has 
ceased. 
Whereas most muscle cells fuse to form multinucleated muscle fibers (which in 
turn are arranged in bundles to form of individual muscle groups; Fig. 4), 
around 5% to 10% remain in the form individual cells with a potential to divide 
and differentiate. These cells, known as satellite cells, act as stem cells for the 
formation of skeletal muscle. 
FIG. 4 STRUCTURE OF SKELETAL MUSCLE CONSISTING OF INDIVIDUAL BUNDLES 
 COMPOSED, IN TURN, OF INDIVIDUAL MUSCLE FIBERS 
 
Source: http://en.wikipedia.org/wiki/Muscle_fascicle 
Research into molecular, embryonic developmental processes has identified two 
main types of specific transcription factors: muscle regulatory factors (MRFs) 
and myocyte enhancer factor 2 (MEF2). These are key sites of myogenesis regu-
lation, influencing the development of all skeletal muscle. In addition, there are 
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skeletal muscle regeneration, and the development and maintenance of satellite 
cells (e.g. Pax7; see below). 
Besides muscle-specific factors, higher-level growth factors also have an im-
portant influence on the reproduction and differentiation of satellite cells, espe-
cially during regeneration of skeletal muscle. These include insulin-like growth 
factors I and II (IGF-I and IGF-II), hepatocyte growth factor (HGF), fibroblast 
growth factors (FGFs), and interleukin 6 and leukemia inhibitory factor (LIF). 
The particularly relevant factor myostatin, a member of the TGF-ß family 
(transforming growth factors), inhibits, for example, the muscle regulation fac-
tor MyoD. 
MOLECULAR REGULATION OF MUSCLE-FIBER COMPOSITION 
Human skeletal muscle consists mainly of red type 1 (slow-twitch) fibers and 
white types Iia and Iix (fast-twitch) fibers. The latter are distinguished by their 
metabolic and regulatory properties. The distribution of these muscle-fiber types 
has a major influence on an individual's performance. Locomotor muscles have 
a larger share of fast (and fast tiring) fibers; supportive muscle, by contrast, has 
significantly more slow fibers (for greater endurance). In most people muscle 
composition is rather uniform, differing within an individual by only about 
20%. However, through intensive training – probably genetically »enhanced« in 
most cases – much greater deviations from the norm can be achieved with ex-
treme distributions of 90:10 or 10:90 in some muscles. The sprinter Carl Lewis, 
for example, had an over 90% proportion of fast-twitch fibers in his leg mus-
cles. The different roles played by heredity and training remain unclear (Sec-
tion II.1.1). Recently, however, it has been found that muscle-fiber composition 
can be specifically influenced by pharmacologic and genetic manipulation (e.g. 
via PPAR-delta). 
POTENTIAL TARGETS FOR MUSCLE GENE DOPING 
MYOSTATIN 
Myostatin, a (negative) growth factor (i.e. actually a growth inhibitor), is one of 
the most commonly mentioned potential targets for a range of quite different 
molecular doping manipulations. Blockade of its action can lead to an increase 
in skeletal muscle mass. Myostatin is an extracellular chemical messenger. It is 
formed in the body by skeletal muscle cells and – as the product of a complex 
signal chain – is secreted when the physiologically desired length of a muscle has 
been reached in response to its physical developmental state or external stimuli, 
e.g. physical training (Ma et al. 2003). 
Mutations or variants of the gene that codes for myostatin have been described 
in some people, including some athletes, although no specific correlation with 
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performance has been established. In some cattle breeds, by contrast, the ef-
fects of naturally occurring mutations of the myostatin gene are quite obvious. 
For over 200 years so-called double-muscled lines such as the Belgian Blue, 
Piedmontese, and Asturiana de los Valles have been bred which have 20% to 
30% more muscle mass than normal cattle. This effect was created experimen-
tally in the late 1990s by deactivating the myostatin gene in what are known as 
knock-out mice. This involves a permanent change in the genome that is also 
passed on to offspring. According to a broad international consensus, such 
manipulation of the germ line in humans would be absolutely prohibited, as it 
could have biologically and medically unpredictable risks and its use would be 
ethically unacceptable. 
Muscle mass gain as a consequence of myostatin blockade is due to hypertrophy 
(increase in muscle fiber thickness) as well as hyperplasia (increase in the number 
of fibers) (Huet et al. 2001; Lee/McPherron 2001; McPherron et al. 1997). Tar-
geted inhibition of the myostatin signal pathway could be utilized for breeding 
transgenic animals for agriculture and has been experimentally achieved in 
chickens and sheep with corresponding effects on body structure. 
Apart from inhibition of the myostatin gene itself (e.g. by means of inhibitory 
RNA), the myostatin signal pathway can be blocked at the next level by inhibit-
ing the synthesis of the myostatin protein or preventing its maturation (or pro-
cessing; Section II.1.2) into a functional form. This maturation process depends 
on, among other things, metalloproteases (enzymes that are able to specifically 
cut or shorten proteins), whose inhibition also appears to suppress tumor 
growth. Metalloprotease inhibitors have been developed mainly with the latter 
indication in mind, and clinical trials in humans are under preparation 
(Coussens et al. 2002). 
FOUR POSSIBLE LEVELS OF MYOSTATIN BLOCKADE 
(Prohibited as a germ-line manipulation: permanent, inheritable inactivation 
of the gene in nuclear DNA [knock-out]). 
1. Gene doping in the narrow sense: Inhibition of gene reading or myostatin 
production by means of inhibitory RNA. 
2. Gene doping in the broad sense: Prevention of maturation of the myostatin 
protein (by means of enzyme blockade). 
Same effect, but no gene doping: 
3. Blockade of the myostatin receptor, e.g. by competitive proteins. 
4. Blockade of myostatin itself by specific antibodies. 
A third level is blockade of the myostatin receptor on target cells, so that alt-
hough myostatin is produced, the signal to end muscle growth is no longer re-
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layed to the muscle cells. Such a blockade can be achieved, for example, with the 
help of competitive proteins or specific blocking antibodies, which can be pro-
duced in the laboratory for almost any protein. Both methods have been success-
fully tried in mice (Bogdanovich et al. 2002; Lee/McPherron 2001), and corre-
sponding drugs for use in humans are being developed and prepared for clinical 
testing (see box on ACE-031). 
ACE-031 – A MYOSTATIN-INHIBITING PROTEIN (ACELERON PHARMA, USA) 
ACE-031 is a protein which, according to Aceleron Pharma (www.acce 
leronpharma.com/content/products/ace-03x.jsp), blocks the type IIB activin re-
ceptor IIB (ActRIIB), thus inhibiting the action of myostatin. ACE-031 is the 
first of various myostatin inhibitors to be clinically tested by the company. 
All the others are still in the preclinical research stage. The specified clinical 
indications are sarcopenia, dystrophy, and other diseases associated with loss 
of muscle mass. 
The fourth level would then involve the specific inhibition of myostatin itself, 
which probably has the greatest importance for potential doping misuse. Here 
too antibodies (see box on Stamulumab), which have been shown to lead to a 
dramatic gain in muscle mass in wild-type mice (Whittemore et al. 2003), could 
be used. 
STAMULUMAB (MYO-029) – A BLOCKING ANTIBODY AGAINST THE GROWTH FAC-
TOR MYOSTATIN (WYETH, USA) 
According to Wyeth, the aim of the company's development work is to treat 
muscular degenerative diseases, e.g. Duchenne muscular dystrophy. The web-
site of Metamorphix, which holds the rights for the growth factor (Myo-
statinTM), states that Wyeth has also set its sights on conditions such as ca-
chexia (pathological weight loss), ALS (amyotrophic lateral sclerosis), sarco-
penia, and metabolic diseases such as type 2 diabetes (www.metamor phix-
inc.com/MMIcorpoverviewpres.pdf). The myostatin-blocking antibody MYO-
029 (proprietary name Stamulumab) has been undergoing phase I and II clini-
cal testing since the spring of 2005 (www. wyeth.com/research_hcp/ pipe-
line_hcp). The initial results of these studies were announced for the spring of 
2007 but were not yet available as of January 2008. 
In the last two methods mentioned, it is not the production of myostatin that is 
inhibited but its action. These methods therefore do not constitute gene doping 
per se. The examples were included purposely to highlight the fact that even the 
broad definition of gene doping as the modulation of gene expression has its 
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limitations and that it will be necessary to keep an eye on all these developments 
in the interest of fighting doping efficiently (Section IV.1).  
GROWTH HORMONE AND IGF-1 
Growth hormone is often called somatotropin (somatotropic hormone, STH) or 
HGH (human growth hormone). It is one of the peptide hormones that has long 
been misused for doping purposes and is included in the list of prohibited sub-
stances (Section II.1.2.2). It is produced in and secreted by the pituitary mainly 
during growth phases, with a peak occurring during puberty. When height 
growth ceases, the production of the hormone falls sharply but continues to be 
stimulated by energy-consuming processes (physical activity, mental stress, hun-
ger). 
If the production of growth hormone or the response of cells to growth hormone 
is impaired, the result is short status; that of excess production gigantism or en-
largement of some parts or organs of the body. The chief target organs in which 
growth hormone exerts anabolic (building) effects are the bones, skeletal muscle, 
and liver. Growth hormone increases amino acid uptake and utilization, raises 
blood glucose levels, and reduces fat. It is therefore praised by some as an anti-
aging wonder drug, despite the fact that there is no reliable scientific basis for 
such an effect. 
The »conventional« misuse of growth hormone in sport is already the subject of 
intensive reporting and speculation. Growth hormone is produced by recombi-
nant techniques by a large number of pharmaceutical companies. Although the 
manufacturers claim that they take rigorous steps to prevent illegal sale of the 
drug, numerous anonymous pharmaceutical vendors are hawking somatotropin 
products on the internet. It is therefore assumed that appreciable amounts of 
growth hormone will find their way to athletes. 
The production of growth hormone in skeletal muscle itself has been achieved 
via gene transfer in a number of experiments on mice. Effective expression of the 
transferred gene has been accomplished with the help of both viruses and plas-
mids (Peroni et al. 2005), which brought about functional improvements of 
skeletal muscle (strength increase) and systemic effects (e.g. a reduction of the 
body's fat index). Human gene therapy with growth hormone is usually dis-
cussed in the context of therapies for muscular dystrophies. WADA expects that 
growth hormone could be one of the first candidates for gene doping strategies 
(WADA 2005). 
On the subject of growth hormone, the effects of the somatomedins IGF-1 and 
IGF-2 (insulin-like growth factors) must also be considered. These are produced 
in the liver and, as secondary hormones mediate (along with a number of other 
substances) the differentiated effects of growth hormone on specific organs and 
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cells, e.g. most of the growth-promoting effects observed in skeletal muscle. In 
addition to its direct anabolic effect on skeletal muscle, e.g. in the form of in-
creased protein synthesis, IGF-1 also promotes the proliferation and differentia-
tion of muscle stem cells (satellite cells). However, the cell-proliferation-
promoting effect of IGF-1 is associated with health risks, particularly with re-
gard to cancer development (Baserga 1999). Elevated serum IGF-1 levels have 
been found in prostate cancer, colorectal carcinoma, and lung cancer (Grim-
berg/Cohen 2000). 
As in the case of growth hormone, a number of research groups have succeeded 
in producing therapeutic effects through gene transfer and the expression of 
IGF-1 in the skeletal muscle of animal models (mice), e.g. improved regeneration 
capacity after injury and a slowing of disease progression in muscular dystrophy 
models (Schakman et al. 2005; Schertzer/Lynch 2006; Takahashi et al. 2003). 
Reports in recent years of a variant of IGF-1 specific to skeletal muscle, MGF 
(mechano growth factor) have attracted attention (also in the internet forums of 
the bodybuilding scene: if you enter »MGF« into Google, these are the first hits). 
The functional significance of MGF is still highly controversial, but the sub-
stance appears to play an important role in skeletal muscle regeneration follow-
ing injuries (Goldspink/Yang 2004). 
TRANSCRIPTION FACTORS OF THE PAX TYPE  
An interesting molecular target – though one that his hitherto received little at-
tention in connection with doping – is transcription factor Pax7, a specific 
marker for resting and activated satellite cells (Seale et al. 2004), whose func-
tion, however, has yet to be definitively elucidated. The interplay between Pax 
proteins and MRF genes (muscle regulation factors) probably determines the 
self-renewal of satellite cells (Olguin/Olwin 2004). Progressive loss of satellite 
cells and a severe defect in muscle regeneration have been observed in Pax7 
knockout mice (i.e. mice in which the Pax7 gene has been blocked) (Ustanina 
2005; Seale et al. 2004). 
High hopes have been pinned on satellite cells as therapeutic stem cells, e.g. for 
the treatment of muscular diseases such as Duchenne muscular dystrophy. In 
this context Pax7 could be a prime target for the manipulation of satellite cells 
(Relaix et al. 2005; Seale/Rudnicki 2000; Seale et al. 2004). Pax7 is also dis-
cussed in connection with the possible treatment of age-related muscle loss, in 
which a decline in the satellite cell population appears to play a key role (Char-
gé/Rudnicki 2004; Chi/Epstein 2002; Relaix 2006). 
PPAR-DELTA 
Several years ago molecular mechanisms were described, by means of which the 
fiber composition of muscles can apparently be altered (Wang et al. 2004). In 
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transgenic mice the overproduction of PPAR-delta (peroxisome proliferator-
activated receptor delta) results in the conversion of fast to slow muscle fibers. 
This protein controls an entire series of genes involved in energy metabolism in 
muscle and increases the fat burning rate. The use of PPAR-delta agonists (sub-
stances that bind to the receptor and activate it) is therefore being discussed in 
connection with the treatment of metabolic syndrome (a condition marked by 
the interdependent factors of obesity, diabetes, dyslipidemia, and hypertension). 
In genetically modified mice it transformed fast fibers (type II) into slow fibers 
(type I), which obtain their energy supply to a far greater extent from the burning 
of fat. The endurance of muscle is largely determined by its ability to metabo-
lize fat. In fact, the genetically modified mice were able to run twice as long 
on a treadmill as their untreated counterparts. At the same time the mice 
were protected from the usual adverse consequences of a high-fat diet: they 
neither gained significant weight nor developed insulin resistance or type 2 dia-
betes. These animals, dubbed »marathon mice«, have since gained media fame. 
Investigations in humans also appear to have confirmed a relationship between 
PPAR-delta and endurance (Kramer et al. 2006). Professional cyclists have a 
significantly greater proportion of type I muscle and PPAR-delta receptors than 
untrained individuals – and they, in turn, a greater proportion than paraplegics. 
This change is accompanied by growing insulin sensitivity (i.e. more glucose 
transported to the now better-performing muscle). However, as far as the mag-
nitude of the training effect is concerned, marked differences – possibly genetic 
in nature – have been observed between individuals. Overall, these findings indi-
cate that it could be possible to influence endurance by way of genetic manipula-
tions at the level of skeletal muscle. Medical pharmaceutical strategies to modu-
late the activity of PPAR delta could therefore be potentially misused for doping 
purposes, irrespective of whether the techniques used are genetic or pharmaco-
logic in nature. 
PPAR-DELTA DRUG DISCOVERY PROGRAM (GALPAGOS NV/HILLCREST 
THERAPEUTICS, USA) 
In a communiqué to the market issued in late 2006, the two US companies 
Galpagos NV and Hillcrest Therapeutics announced a joint drug discovery 
program for PPAR-delta agonists (www.bionity.com/news/e/61454/). Para-
mount BioSciences, a subsidiary of Hillcrest Therapeutics, will be responsible 
for clinical testing and commercialization. The strategies that will ultimately 
be pursued are left open. The communiqué states that drug candidates have 
already been identified. 
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MODULATION OF OXYGEN SUPPLY 2.2 
In addition to modifying muscle-fiber composition and the supply of energy to 
muscles, the supply of oxygen to muscles is an important factor, particularly for 
endurance. The main parameters governing the availability of oxygen to muscle 
tissue are: 
> Gas exchange in the lungs (the efficiency of oxygen uptake) 
> The performance of the heart as a pump 
> The oxygen transport function of the blood 
> The degree of capillarization (i.e. the network of fine blood vessels) in the 
target tissue (muscle), which determines oxygen-exchange capacity. 
These parameters can be differentially modified by various training methods but 
also by pharmacologic and possibly genetic intervention. Gas exchange in the 
lungs and cardiac performance have hitherto been amenable to pharmacologic 
manipulation only to a limited extent (e.g. modification of pulmonary capacity 
by amphetamines). By contrast, the oxygen-transport capacity of the blood can 
readily be modified by pharmacologic means. 
The (relative) concentration of oxygen-transporting red blood cells (erythro-
cytes) and thus the oxygen transport protein it contains (hemoglobin, meas-
ured by the hematocrit concentration) can be improved only to a limited de-
gree by normal physical training. This makes physiologic sense, because an 
increase in the hematocrit concentration – especially during hard, prolonged 
exercise – would greatly reduce cardiac output due to greater viscosity (thick-
ness) of the blood. This would slow blood flow, thus impairing other vital 
functions of the blood (nutrient transport, heat regulation). Differences in oxy-
gen-transport-related physical performance between athletes and nonathletes 
or between children and adults are due mainly to the blood volume and hence 
the total amount of hemoglobin in the body. 
Unlike normal training, high-altitude training leads to a marked increase in 
erythrocyte concentration. This adaptation process is controlled mainly by the 
hormone erythropoietin, which is therefore an obvious target for pharmacolog-
ic and genetic manipulation of the blood's oxygen-transport capacity. 
The actual supply of oxygen to muscle cells depends largely on the vasculariza-
tion of the muscle, i.e. the density of the fine blood vessels, the capillaries, which 
transport oxygen to and metabolic breakdown products from the tissue. When 
muscles are working, selective vascular dilation results in a redistribution of the 
blood, so that during exercise around 80% of total blood flow goes to the mus-
cles, compared to around 20% at rest. Local blood flow thus increases by a fac-
tor of 15 to 20. Training can improve both blood flow and capillary density (by 
up to 45%). 
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Some time ago factors were identified at the molecular level that influence the 
capillarization of tissues, e.g. VEGF (vascular endothelial growth factor). The 
inhibition or activation of such factors has long been the subject of medical re-
search as a strategy for fighting cancer but has also opened up avenues for the 
pharmacologic or genetic manipulation of performance. 
ERYTHROPOIETIN 
Erythropoietin (EPO) is a glycoprotein hormone that is synthesized primarily in 
the kidneys. It plays a key role in hemopoiesis (the formation of blood cells) as a 
growth factor which promotes the formation of erythrocytes (red blood cells). As 
a therapeutic agent, recombinant erythropoietin is used mainly for the treatment 
of anemia in dialysis patients, in whom blood formation is impaired due to the 
underlying kidney disease. In addition, EPO is currently one of the best-known 
doping agents, especially in endurance sports (Donati 2007). 
However, the physiologic function of erythropoietin is not limited to erythrocyte 
formation. Erythropoietin receptors occur in a range of cell types, notably in 
brain cells but also in heart muscle cells. It has been shown to influence cell divi-
sion processes, vascularization, and apoptosis (programmed cell death). 
After the human EPO gene was isolated in 1983, it was successfully produced by 
recombinant techniques in Escherichia coli cells in 1984 and in mammalian cells 
in 1985. EPO was one of the first genetically engineered drugs produced on a 
large scale, and since its market launch by the Amgen company in 1989 it has 
been far and away the biggest selling biopharmaceutical (i.e. recombinant drug). 
Today EPO is produced by a number of pharmaceutical companies and is sold 
in slightly modified forms for various indications. The enormous success of the 
first EPO products (unlike other recombinant growth factors) gave rise to nu-
merous strategies to enhance the activity of the EPO molecule, facilitate its ad-
ministration, or improve its tolerance. Among the latest developments in this 
field are EPO analogs, also known as mimetics, gene-therapeutic strategies for 
improving EPO availability in vivo, and combination products with neuropro-
tective substances for use in the treatment of neurodegenerative diseases (Ehren-
reich et al. 2004). Two development projects are especially relevant to gene dop-
ing: Repoxygen™ and FG-2216 (see box). 
REPOXYGEN™ – PRODUCTION OF ERYTHROPOIETIN BY GENE THERAPY METHODS 
(OXFORD BIOMEDICA, UK) 
Repoxygen™ is the proprietary name of a gene therapy method for the con-
trolled intracorporeal production of erythropoietin (EPO). Repoxygen sur-
faced in the media in connection with investigations against the light athletics 
trainer Springstein, who mentioned the substance in the context of doping in 
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emails. Repoxygen was developed by Oxford BioMedica for the treatment of 
anemia (www.oxfordbio medica.co.uk/news/2002-ob-05.htm). It is a viral 
gene-delivery vector containing the human EPO gene. The gene is activated 
by a hypoxia (oxygen deficiency) control element, so that erythropoietin is 
formed only in the presence of reduced oxygen concentrations. It is adminis-
tered intramuscularly and contains adenoviral vectors for transporting the 
EPO gene into muscle cells. Despite media reports, Oxford BioMedica says 
that Repoxygen has only been tested in preclinical studies, i.e. in animal ex-
periments. Its efficacy (or inefficacy) in humans is therefore unknown. Ac-
cording to the company, development of the product has been suspended un-
til further notice while a commercial partner is sought. Nevertheless, the sys-
tem appears to be technically mature and therefore could theoretically be 
misused for doping purposes.  
 
FG-2216 AND FG-4592 – INHIBITION OF THE ENZYME PROLYLHYDROXYLASE 
FOR STABILIZING HYPOXIA-INDUCED FACTORS (HIF) (FIBROGEN, USA) 
The drug candidates that go by the names FG-2216 and FG-4592 are 
thought to influence the stability of a transcription factor, thereby increasing 
EPO synthesis. A special property of 2216 and FG-4592 is that they are oral-
ly administered, chemically synthesized, low-molecular-weight compounds 
(and not, like the other examples, complex recombinant protein molecules 
that have to be injected). The two substances inhibit the function of the en-
zyme prolylhydroxylase, which is responsible for breaking down hypoxia-
induced factor (HIF). As a result of HIF stabilization, the EPO gene is over-
expressed. FG-4592 is intended for use in the treatment of ACD (anemia of 
chronic disease) syndrome. In April 2006 the Japanese pharmaceutical com-
pany Astellas acquired the commercial rights for FG-4592 and FG-2216 out-
side the USA (www.astellas.com/global/about/news/2006/060428_eg.html). In 
May 2007 a death was reported in a phase II clinical trial (www.astellas. 
com/global/about/news/2007/pdf/070507_eg.pdf), the cause of which re-
mains unknown. As a result, the clinical trials were suspended (in Poland, 
Finland, and Germany, among other countries). 
ANGIOGENESIS AND VEGF 
The term angiogenesis denotes the growth of small blood vessels and capillaries. It 
is distinguished from the new formation of blood vessels, known as vasculogene-
sis. VEGF (vascular endothelial growth factor) is an important growth factor in 
the control of angiogenesis. Its chief function is to activate the cell types respon-
sible for the formation of vessel walls (endothelial cells, pericytes, smooth muscle 
cells). Angiogenesis is of considerable biological and medical importance. For 
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example, solid tumors depend on a growing capillary network to supply them 
with oxygen and nutrients. Many pharmaceutical companies are therefore de-
veloping angiogenesis inhibitors for the treatment of cancer. So far around 60 
angiogenesis inhibitors with various mechanisms of action have been tested in 
clinical studies (including antibodies to VEGF, VEGF receptor tyrosine kinase 
inhibitors, direct inhibitors of endothelial cell activation, and substances that 
attack newly formed blood vessels). 
Conversely, the stimulation of angiogenesis could be a therapeutic strategy, 
namely for the treatment of ischemia – the deficient supply of oxygen to a tissue 
or organ due to poor blood flow. If protracted, it can lead to cell necrosis 
(death) (e.g. as occurs in a heart attack). Ischemia is usually caused by blood 
vessel changes in the form of a constriction or occlusion. A number of research 
groups are working on stimulating the capillarization of tissues by transferring a 
gene for VEGF or other potentially effective growth factors (endostatin, T-
cadherin and HIF1alpha), and they have already chalked up successes in animal 
models (Arsic et al 2004; Barandon et al. 2004; Idris et al. 2004). An ongoing 
development project is focusing on the use of naked DNA (see box). 
GENASIS – INDUCTION OF THE EXPRESSION OF VEGF-2 IN CARDIAC MUSCLE 
USING NAKED DNA (CORAUTUS GENETICS INC., USA) 
In this form of gene therapy the gene for VEGF-2 is inserted directly into car-
diac muscle – not by means of a viral vector (Section II.1.3) but in the form 
of a naked DNA plasmid. The object is to stimulate blood-vessel formation, 
e.g. in order to repair damage in patients with coronary heart disease (angi-
na). Following successful animal experiments (Kawamoto et al. 2004), 
Corautus Genetics ran a clinical phase II trial from August 2004 to August 
2006 which went by the name of GENASIS (genetic angiogenic stimulation 
investigational study). However, no therapeutic effect was achieved com-
pared to the placebo controls. Nevertheless, the company announced that it 
wishes to conduct further preclinical tests of VEGF-2 for other indications 
(diabetic neuropathy, critical ischemia of the legs; www.medicalnewstoday. 
com/articles/53786.php). With regard to the potential of this specific ap-
proach for gene doping purposes, although it may seem irrelevant, the gene-
transfer technique was at least used without dramatic adverse effects, which 
presumably also applies to skeletal muscle. Even in an early announcement 
Corautus Genetics pointed out that the execution of this (in vivo) gene trans-
fer study, the biggest in the world, was in itself a noteworthy success and im-
portant outcome of the clinical trial (www.prnewswire.com/cgi-bin/stories. 
pl?ACCT= 104&STORY=/www/story/03-30-2005/0003291252&EDATE=). 
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MODULATION OF ENERGY SUPPLY 2.3 
The metabolism of glucose (sugar) and fatty acids in skeletal muscle is the pri-
mary mechanism by which energy is supplied for physical activity. Thus, it also 
a factor determining the endurance capacity of athletes. Molecular mechanisms 
that control the efficiency by which muscle cells are supplied with fuel and the 
quality of its metabolism are not only potential targets for genetic and pharma-
cologic manipulations aimed at improving performance. Given their importance 
for the treatment of widespread diseases such as obesity and diabetes, they are 
also a major focus of medical and commercial pharmaceutical research. Among 
the bewildering number of research and development projects in this field, there 
are probably many that could potentially be misused for gene doping purposes. 
FATTY ACID TRANSPORTERS 
All mammals have systems for transporting high-energy substrates through cell 
membranes. The uptake of fatty acids in cells is regulated by (a family of closely 
related) fatty acid transport proteins in the cell membrane (e.g. FATP1, CD36) 
(Hamilton/Kamp 1999; Stahl 2004). Gene transfer experiments with naked 
DNA in animals have shown that the expression of fatty acid transporters in 
skeletal muscle induces an increase in fatty acid uptake in muscle (Clarke et al. 
2004) – theoretically a strategy that could be used for gene doping purposes. 
GLUCOSE TRANSPORTERS 
Transport proteins for glucose can, depending on the cell type, stimulate the 
flow of glucose into cells (e.g. in muscle) or out of cells (e.g. from the liver as the 
central metabolic organ). Like fatty acid transport proteins, glucose transporters 
(GLUTs) also make up a family of six closely related proteins, the products of 
different genes being designated GLUT1-5 and GLUT7 (Kayano et al. 1990). 
GLUTs exhibit tissue-specific distribution and transport glucose (and other sug-
ar molecules) with varying degrees of efficiency (Gould/Holman 1993). GLUT4, 
for example, is the predominant insulin-sensitive glucose transporter in fat and 
muscle tissue in rats and humans (Friedman et al. 1991; Rodnick et al. 1992). 
In the past decade numerous research groups have shown in transgenic mice that 
glucose utilization can be enhanced by overexpression of the gene for GLUT4, 
either specifically in skeletal muscle (Tsao et al. 1996) or in all tissues in which 
GLUT4 is normally expressed (skeletal muscle, cardiac and fat tissue) (Deems et 
al. 1994; Ren et al. 1995; Treadway et al. 1994). Strategies to increase GLUT4 
expression in skeletal muscle or to modulate the efficiency of GLUT4 have 
therefore been proposed for the treatment of type 2 diabetes. In principle, pro-
teins involved in the regulation of GLUT4 are targets for the development of 
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pharmacologic and genetic molecular techniques to modulate glucose uptake in 
skeletal muscle. 
Another target for manipulating glucose availability is the insulin receptor (see 
box for example). 
PROTEIN-TYROSINE-PHOSPHATASE 1B SIRNA (SIRNA THERAPEUTICS, INC., USA) 
The enzyme protein-tyrosine phosphatase 1B (PTP-1B) plays a role in the de-
velopment of insulin resistance and type 2 diabetes by reducing the sensitivity 
of the insulin receptor. Accordingly, inhibition of this enzyme should be asso-
ciated with increased insulin sensitivity and the transport of glucose into 
muscle cells. The company Sirna Therapeutics, which specializes in the devel-
opment of siRNA strategies (si for small interfering) (Section II.1.3), has pro-
duced an siRNA molecule to block the mRNA coding for PTP-1B which re-
duced the expression of PTP-1B in the liver by up to 67% (www.sirna.com/ 
wt/page/metabolic_disease). Because the availability of glucose is a crucial 
factor for the performance of skeletal muscle, this technique could also be 
used for doping. It is not known if clinical trials with these siRNA molecules 
are planned. 
PPAR 
The importance of peroxisome proliferator-activated receptors (PPAR), tran-
scription factors that regulate a whole series of genes involved in energy metabo-
lism, have already been mentioned in the chapter on muscle gene doping. You 
will recall that PPAR-delta influences the composition of muscle cell fibers (Sec-
tion II.2.1). The manipulation of other subtypes (three are known at present: 
PPAR-alpha, beta/delta, and gamma, which are expressed to varying degrees in 
different organs; Gervois et al. 2007), has potential significance for doping inso-
far as these substances promote the supply of glucose to muscle. Thiazolidindi-
ones (also known as glitazones), compounds used as oral antidiabetic drugs, 
bind with high affinity to PPAR-gamma (Levetan 2007). Although the mecha-
nism of action has not yet been elucidated, it is believed that through mediation 
of the PPAR effect either a factor is expressed that reduces insulin resistance, or 
conversely that the expression of a factor is reduced, resulting in insulin re-
sistance (Ishizuka et al. 2007). 
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OVERVIEW OF GENE DOPING METHODS 2.4 
The following tables again summarize the examples of research avenues and de-
velopment projects relevant to gene doping that were identified in the framework 
of the TAB project. It is clear that of the techniques currently undergoing clinical 
testing, there is or was just one (induction of the expression of VEGF-2 in cardi-
ac muscle using naked DNA) that explicitly constitutes a gene therapy tech-
nique. The other methods developed are pharmacologic strategies to modify 
gene activity or to target protein activity. A number of potential gene doping 
methods in the broad sense are in the preclinical (i.e. animal experiment) stage 
(e.g. the well-known substance Repoxygen). 
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proved lipid utili-
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Overexpression of fatty acid 
transport proteins by means 
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mance due to im-
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lin receptor (animal experi-
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Own compilation on the basis of Diel/Friedel 2007 
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Own compilation on the basis of Diel/Friedel 2007 
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Ischemia (lack of 
blood supply) or 
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from heart disease 
Cancer (angiogene-
sis inhibitors can be 





Induction of expression of 
VEGF-2 in heart muscle by 
means of naked DNA (clini-
cal study showed no effect 
in phase II for primary indi-
cation; other indications 
planned.) 
Own compilation on the basis of Diel/Friedel 2007 
To provide further information on potentially relevant scientific developments, 
Section II.2.5 looks at underlying trends in the field of gene therapy that could 
become relevant to gene doping. 
DEVELOPMENT PROJECTS IN THE FIELD  
OF GENE THERAPY 2.5 
The list of gene therapy targets is growing but is not overwhelming. An overview 
of developments in this field can be found on the websites of the Journal of 
Gene Medicine (www.wiley.co.uk/genetherapy/clinical/), which are briefly sum-
marized below (from Diel/Friedel 2007, pp. 98 ff.). According to the source, in 
the period between 1989 and mid-2007 1,309 clinical studies were conducted 
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worldwide in the field of gene therapy (Fig. 5)3, 882 (67.4%) of them in the USA 
and 358 (27.3%) in Europe, with Germany leading in Europe (5.7%) (DFG 
2006). Two thirds of the gene therapy studies focused on the treatment of cancer 
(Fig. 6). However, a trend reversal appears to be taking place. Since 2006, clini-
cal studies have also been conducted for non-life-threatening conditions that 
only impair quality of life (e.g. erectile dysfunction; Melman et al. 2006). 
FIG. 5 CLINICAL GENE THERAPY STUDIES BY COUNTRY (1989–2007) 
 
Source: www.abedia.com/wiley/countries.php 
Approximately two thirds were clinical phase I trials in which the gene therapies 
were tested only in (a small number of) severely ill patients as a last resort (cf 
introduction to Section II.2). Not until clinical phase III is the actual efficacy of a 
new agent demonstrated in comparison to established drugs and/or placebo. 
This stage accounts for just 3.4% of gene therapy studies (43 studies), although 
there is a rising trend. A license application for a gene therapy drug for the 
treatment of an aggressive type of brain tumor was submitted to the European 
Medicines Evaluation Agency in 2005, while in China the first gene therapy 
agent (GendicineTM) for the treatment of specific types of malignant head and 
neck tumors was approved by the country's health authority as early as 2003. 
                                            
3 It is surprising that China is not listed, because it is supposed to be contending with the 
USA for the leading role in this field 
(http://marketplace.publicradio.org/shows/2006/10/12/ PM200610125.html). 
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Other countries 5.7 %
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FIG. 6 INDICATIONS OF CLINICAL GENE THERAPY STUDIES (1989–2007) 
 
Source: www.abedia.com/wiley/indications.php 
With regard to the gene therapy methods employed, protocols using naked DNA 
have increased steadily in recent years and now account for 18% (Fig. 7). This 
situation is highly relevant to gene doping, as nonviral DNA is much easier and 
probably also less risky to use than viral vectors. 




Cardiovascular diseases 9.1 %
Monogenetic diseases 8.3 %
Infections 6.5 %
Neurologic disorders 1.5 %
Eye diseases 0.9 %
Other diseases 1.6 %
Genetic marking 3.8 %
Healthy subjects 1.7 %
Adenoviruses 24.7 %
Retroviruses 22.8 %
Naced plasmid DNA 18 %
Lipofection 7.6 %
Vaccinia viruses 6.8 %
Poxviruses 6.4 %
Adeno-associated viruses 3.5 %
Herpes simplex viruses 3.2 %
RNA transfer 1.3 %
other categories 2.7 %
Unknown 3 %
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The molecular targets of the clinical trials vary considerably. As shown in Fig-
ure 8, a large portion of the gene therapy strategies focused on tissue hormones 
(cytokines and growth factors). This too is relevant to gene doping, because 
these molecules already represent one of the foremost misused drug groups in 
current »conventional« doping practice. 
FIG. 8  GENES TRANSFERRED TO CLINICAL GENE THERAPY TECHNIQUES (1989–2007)  
 
Source: www.abedia.com/wiley/genes.php 
CONTROVERSIAL EVALUATION OF THE SUCCESS OF GENE THERAPY 
Assessments of the results of gene therapy methods are anything but unanimous, 
and the expert reports consulted in the TAB project were no exception. 
Diel/Friedel (2007, p. 17) emphasize that technical implementation remains 
problematic, but they do see some success with gene therapy, especially in the 
treatment of congenital immunodeficiency diseases (such as SCID and septic 
granulomatosis). In addition, there is early evidence that gene therapy is effective 
in a type of leukemia, in skin cancer, and in the blood-clotting disorder hemo-
philia B. 
Kekulé (2007, p. 13), on the other hand, views some of the aforementioned ex-
amples (especially SCID and septic granulomatosis) much more negatively. He 
concludes that that there has so far been no success with gene therapy (in the 
narrow sense) that could be applied to gene doping. 
Diel/Friedel (2007, p. 27) (in agreement with the assessment of the Senate Com-
mittee on Basic Issues of Gene Research; DFG 2006) also believe that ongoing 
trials are unlikely to produce drugs suitable for routine use in the foreseeable 
Antigens 20.3 %
Cytokines 18.9 %
Tumor supressors 12 %
Growth factors 8.2 %
»Suicide« gens 8.2 %
Deficiency elimination 7.9 %
Receptors 5.1 %
Markers 4.1 %
Replication inhibitors 3.7 %
other categories 8.6 %
Unknown 2.9 %
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future, especially since most of the studies are investigating preliminary methods 
for the treatment of very rare diseases, and that mature gene therapy techniques 
are still many years in the future. Nevertheless, they expect licenses to be granted 
for gene therapy agents in Germany within the next ten years – a period that is 
often cited in the international debate. The methods most likely to be approved 
are those that do not involve the integration of extraneous genetic material in 
the patient's DNA. The DFG Senate Committee on Basic Issues of Gene Re-
search sees no fundamental difference between such noninsertional, transient 
active systems and other pharmaceutical agents and predicts their future use in 
non-life-threatening conditions as well (DFG 2006, p. 9). In the present context 
this indicates the early availability and ready accessibility of potential gene dop-
ing methods (in the narrow sense) in the field of easy-to-use vectors (naked 
DNA, plasmids). 
SPECIFIC HEALTH RISKS? 3. 
In all doping approaches the methods and agents used were developed for the 
treatment of diseases and therefore have not been tested for use in enhancing 
performance in healthy individuals. Knowledge about the health risks of drugs 
and other therapeutic methods is gained by observing patients treated with the 
smallest effective dose possible. Misuse for doping purposes, by contrast, always 
involves an entirely different physiologic situation (use by highly trained ath-
letes) and purpose (maximum effect with minimum likelihood of detection). For 
this reason the health risks arising from misuse for doping purposes cannot be 
reliably assessed on the basis of clinical drug trials. This view is confirmed by 
serious and disabling health damage that some athletes have suffered in the past, 
sometimes with a fatal outcome. 
From this perspective gene doping methods could hardly be riskier. Neverthe-
less, from the principle underlying methods for the targeted modification of gene 
activity it is possible to identify some specific risks. However, without an empiri-
cal basis, these remain merely scientifically plausible assumptions. In this context 
a distinction can be drawn between risks arising from the insertion of genetic 
material and risks arising from excessive expression (e.g. production in the 
body) of performance-relevant biomolecules. The following discussion briefly 
summarizes the relevant findings from Diel/Friedel (2007, pp. 110 ff.). 
RISKS ARISING FROM THE INSERTION OF GENETIC MATERIAL 
It is true of every new pharmacologic substance – including gene therapy in its 
current state of development – that initially very little is known or can be known 
about long-term outcomes. 
60 II.  GENE DOPING: SCIENTIFIC BASIS AND PERSPECTIVES OF USE 
 
NONTRANSFERABILITY OF RESULTS FROM ANIMAL MODELS TO HUMANS 
Most of the »successes« of gene therapy have been achieved in mouse, dog, and 
monkey models (in preclinical studies; cf. introduction to Section II.2). It is not 
always possible to transfer these results to humans. A dramatic example is pro-
vided by the trial of TGN1412, an immunomodulating humanized monoclonal 
antibody, in 2006. In phase I of clinical testing all six healthy volunteers devel-
oped multiple organ failure, and at least two of them suffered permanent dam-
age (Mitchell 2007). Because of the assumed unpredictability of the side effects, 
at present only patients with life-threatening conditions who have no alternative 
treatment options receive gene therapy in phase I clinical trials. In the case of 
unapproved gene therapy methods the usual doping practice of self-
experimentation is tantamount to a fatal risk. 
LACK OF TISSUE SPECIFICITY OF THE VECTORS 
With many of the relevant vector systems, tissue-specific gene transfer is not 
possible (Section II.1.3). The unintentional transfer of genes into germ-line cells 
would be particularly dramatic, as the transgene could also be passed on to the 
recipient's offspring – with incalculable consequences. Viral vectors tend to be 
more specific for target cells than nonviral vectors. However, there are major 
differences among viral vectors, ranging from high specificity (e.g. herpes viruses 
for nerve cells) to no specificity at all (adeno-associated viruses). 
UNCONTROLLED SPREAD OF THE FOREIGN GENE IN THE BODY 
Even if tissue-specific gene transfer is accomplished, the foreign gene could sub-
sequently spread uncontrollably through the organ system concerned or even the 
entire body. Some experts see this as one of the major problems of gene therapy 
(A. Amalfitano; www.msu.edu/~folandwa/kathryn_thesis.doc). If, for example, a 
gene transferred to skeletal muscle were to enter all the muscle cells in the body, 
it would also be expressed in cardiac muscle and in smooth intestinal muscle, 
resulting in severe disorders in those systems (e.g. hypertrophy of the heart). In 
the case of growth factor genes, their uncontrolled dissemination would proba-
bly affect cell growth in the entire body – a process closely associated with the 
development of cancer. 
AUTOIMMUNE REACTIONS 
The function of the immune system is to recognize and eliminate foreign mole-
cules in the body. The immune system often also recognizes transferred genes 
and their products as foreign and attacks the cells that contain them. When it is 
exposed to invaders again, the immune system recognizes them immediately and 
launches a rapid, efficient response. This »memory« function of the immune 
system poses a problem for the repetition of gene therapy – a circumstance that 
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could be of major relevance to gene doping, which after all would probably have 
to be repeated several times. For example, in macaque monkeys that received 
gene therapy, the immune system first attacked the slightly modified transgene 
and later the body's natural erythropoietin, leading to multiple organ failure and 
death (Chenuaud et al. 2004). 
INSERTIONAL MUTAGENESIS 
With the insertional vector systems usually employed, it is impossible to control 
the precise site in the genome where the foreign DNA is inserted. If the foreign 
DNA were integrated into another gene, for example a key enzyme of cellular 
metabolism, this would have serious consequences. If the vector were integrated 
into a regulatory DNA element, it could upset a finely tuned balance, and if the 
regulatory element is a tumor suppressor gene, the result could be uncontrolled 
cell growth. 
SIDE EFFECTS OF THE VECTOR: INDUCTION OF IMMUNE REACTIONS 
When nonviral vectors are used (e.g. the direct injection of plasmid DNA into 
muscle tissue; McMahon et al. 1988; Wang et al. 2005) it is mainly local in-
flammatory reactions that are observed. 
By contrast, viral vectors usually trigger systemic reactions that can be severe or 
even life-threatening. These reactions may be due to residual intrinsic toxicity of 
the »defused« virus, but in principle there is also a risk of the viral vectors cross-
replicating with other viruses in the body, thus re-acquiring their original patho-
genicity, i.e. their ability to cause illness. 
CONSEQUENCES OF THE SUPRAPHYSIOLOGIC EXPRESSION OF 
PERFORMANCE-RELEVANT BIOMOLECULES 
A distinction must be made between the health risks arising from a change in the 
concentration of the factor being modulated and the risks generally associated 
with the manipulation of regulatory mechanisms. The risks posed by the su-
praphysiologic expression of performance-relevant biomolecules are not unique 
to gene doping but apply in general to any genetic or pharmacologic manipula-
tion. The following can be differentiated: 
> Side effects that arise solely from the nonphysiologically high expression of 
the factor (A), and 
> Side effects that arise from the factor in supraphysiologic concentrations no 
longer having tissue-specific but rather systemic activity (B). 
A classical example of (A) are the risks resulting from the supraphysiologic ad-
ministration (via recombinant EPO) or the (still hypothetical) amplification of 
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the expression (by gene transfer) of erythropoietin: both lead to the desired in-
crease in hematocrit concentration as well as an undesirable increase in the risk 
of thrombosis. 
An example of (B) is the effect of anabolic steroids (AS) on cardiac muscle and 
spermatogenesis. AS are used for doping due to their boosting effect on skeletal 
muscle. This requires high doses at which the activity of the AS is no longer lim-
ited to skeletal muscle but also affects cardiac muscle, which also enlarges and 
becomes susceptible to disease. In addition, AS have an inhibitory effect on the 
release of follicle-stimulating hormone (FH), which in turn stimulates testos-
terone production in the testicles. The result is a testosterone deficiency that can 
lead to temporary infertility. 
Homeostasis (state of equilibrium) in tissue is generally determined by a balance 
between proliferation (cell growth) and apoptosis (cell death). Any disturbance 
of this balance is thought to be a key precondition for the development of tu-
mors and thus cancer. Growth hormones in particular interfere with these pro-
cesses. Supraphysiologic concentrations can, at least in the long term, promote 
cancerous changes in cells or stimulate pre-existing tumors. A carcinogenic effect 
has been demonstrated, for example, for the doping candidates HGH, IGF-1, 
MGF, EPO, VEGF, Pax7, and PPAR-delta (Section II.2). 
RISKS ARISING FROM THE MANIPULATION OF GENE ACTIVITY 
In view of the complexity of the intracellular regulation of gene activity (Sec-
tion II.1.2), it is understandable why manipulation of these mechanisms can lead 
to a variety of side effects – and potentially cause serious damage to health. 
The substance FG-2216 (see box in Section II.2.2), for example, ultimately pro-
motes EPO production because it prevents the breakdown of an essential tran-
scription factor (HIF). It is assumed that this is not the only effect and that: 
> the stability of other transcription factors is also affected; 
> HIF also affects other genes, possibly in multiple tissues and organs. 
The next level, translation, i.e. the translation of the genetic blueprint (RNA) to 
produce a specific protein, could be disrupted, especially by siRNA methods (see 
box in Section II.2.3) if they not only block the RNA target molecule in a highly 
specific way but also block molecules with a similar structure. Relevant exam-
ples are known (Jackson et al. 2003; Sledz et al. 2003). 
The maturation of (precursor) proteins is often achieved when enzymes remove 
or cut off parts of the molecule or append additional side groups or side chains 
to form a functional hormone. These enzymes are usually not absolutely specific 
in their action, i.e. they are able to process several different proteins. Manipulat-
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ing such enzymes, e.g. to inhibit myostatin (Section II.2.1), could be employed 
but would almost inevitably also have unintended consequences. 
PERSPECTIVES OF USE 4. 
Based on experience with current conventional doping practices, several assump-
tions can be formulated as to whether, how, and to what extent gene doping (in 
the narrow sense and in the broad senses of specifically modulating gene regula-
tion) will be practiced in the future (Diel/Friedel 2007, p. 97). The crucial factors 
determining the use and dissemination of such methods are likely to be – apart 
from their general availability – their presumed achievable effect, i.e. their poten-
tial enhancement of performance, and their detectability or lack thereof (Sec-
tion III). The assessment of potential health risks is of somewhat subsidiary im-
portance. 
ROUTES OF ACCESS 4.1 
Approved methods and agents used in therapy and those in clinical trials are 
probably the most likely candidates for doping. Presumably, experience gained 
in the 1990s with recombinant proteins (e.g. growth hormone and erythropoiet-
in) can be directly transferred. In order to assess which gene doping strategies 
might be relevant in what time window, it is important to keep an eye on cur-
rent research and development trends, especially at pharmaceutical companies. 
This approach to preventive doping research could play a key role as a scientific 
basis for the development of future anti- (gene) doping measures. The molecular 
targets described and the related genetic pharmacologic developments (Section 
II.2) reveal the variety of therapeutic strategies that could be exploited for dop-
ing purposes. In addition, it is assumed that by no means all projects relevant to 
gene doping become known to the public (at least not in their early stages). 
INDIVIDUAL GENE DOPING – EVEN WITHOUT PROOF OF CONCEPT? 
Beside the misuse of approved (or pending) gene-modulating compounds pro-
duced to scientific standards and in compliance with safety regulations and the 
potential use of scientifically based gene therapy methods in the future, 
Diel/Friedel (2007, p. 97) have identified another potentially even more worrying 
possibility: a kind of individual gene doping (in the narrow sense) that circum-
vents all the review mechanisms of drug regulatory procedures. As in the Balco 
affair, in which a small company developed and synthesized designer steroids 
explicitly for doping purposes, including the anabolic hormone tetrahydrogestri-
none (THG), pharmaceutical gene doping agents could also be produced that 
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are specifically tailored to individuals or a small group of athletes. These drugs 
were never approved as medications and therefore were never tested for side 
effects. The existence of THG was not known to the doping control laborato-
ries, let alone to the public at large. 
According to Diel/Friedel (2007), an analogous situation is also conceivable for 
gene doping in the narrow sense. The time and expenditure involved (e.g. for 
constructing expression vectors) would probably be no greater than in the 
aforementioned example involving the chemical synthesis of a low-molecular-
weight steroid compound. The unpredictability of adverse effects, including 
death, would not be a qualitatively new situation, as evidenced by plentiful cases 
in the history of doping. 
Relatively simple conceivable scenarios in which gene doping is used would be, 
for example (Diel/Friedel 2007, p. 108): 
> The construction of viral-based gene carriers 
> The transfection of naked DNA, e.g. in the form of plasmids  
> The synthesis and administration of siRNA 
> The production of gene vaccines to stimulate the production of antibodies 
(e.g. to block receptors). 
The production of the vectors required for such individual gene doping (in the 
narrow sense) or the synthesis of siRNA can be easily accomplished by any 
competent molecular biologist. Appropriate kits are available from many bio-
technology companies. The production of such vectors and molecules is already 
routine practice in normal research establishments. Thus, expression vectors for 
the transfection of cells as well as for experiments on mice and rats are being 
produced and used on a large scale in thousands of laboratories around the 
world. It is theoretically conceivable to construct or modify a vector for individ-
ual gene doping within a few days. As in the case of designer steroids, small la-
boratories could offer their services to individuals for a fee. Many small compa-
nies are already offering expertise in aspects of gene therapy (e.g. transfection or 
the construction of vectors). Taking an example, Diel/Friedel (2007, pp. 127 ff.) 
estimate the likely costs at 10,000 to 15,000 euros – a figure which shows that 
the amounts involved could be well within those already being paid for doping. 
Whether such an expression vector is administered to an experimental animal or 
a human may make a significant difference from an ethical point of view, but 
technically the differences are small (Diel/Friedel 2007, p. 108). An expression 
vector that works in a mouse could in principle also work in humans, though 
with incalculable risks and irresponsible risk-taking on the part of the subjects 
(Section II.3.3). The implementation of individual gene doping according to the 
above scenario would in no way be subject to logic or to the same timescale as 
the serious development of gene therapy methods for medical use in humans. In 
 4.  PERSPECTIVES OF USE 65 
particular, if we can apply experience with current doping practices – and there 
is no plausible reason why we cannot – potential side effects, which form the 
main obstacle (and also the main cost driver) in the development of gene thera-
pies, would play an entirely different (i.e. a wholly subsidiary) role.4 
A common objection to such scenarios of (individual in the sense described) gene 
doping in the narrow sense is that the required methods are not validated and 
specifically that potential performance enhancements have not been demonstrat-
ed in healthy subjects, let alone in highly trained athletes. This objection is wor-
thy of consideration. From the point of view of research into the prevention of 
doping, however, past experience shows us that medical experts have repeatedly 
refuted the efficacy of certain doping strategies (e.g. in the case of growth hor-
mone), yet athletes availed themselves of those methods for doping purposes 
anyway (Diel/Friedel 2007, p. 125). 
As for the future of doping, including all forms of potential gene doping in the 
narrow and broad senses, the following will in all probability continue to apply: 
Athletes who are potential doping candidates and their milieu will not wait until 
a therapeutic strategy has proven effective in clinical trials. Instead, taking 
enormous risks, they will first proceed on a trial-and-error basis – presumably 
with the dramatic consequences sometimes seen in the past (e.g. numerous 
deaths linked to the use of EPO among cyclists in the early 1990s). 
Kekulé (2007, pp. 14 ff.), by contrast, believes it unlikely that the scenario of 
individual gene doping (in the narrow sense) painted by Diel and Friedel will 
come to pass in the next decade. In view of the marginal success of reputable 
gene therapy to date – despite enormous efforts – he thinks illegal doping labor-
atories are very unlikely to achieve better results. The commercially available 
kits that Diel/Friedel (2007) regard as sufficient for developing a new individual 
gene doping method are, he says, unsuitable for the purpose. In particular, so far 
no suitable genes have been identified for the predicted purpose of individual 
gene doping. The likelihood that such a gene will be found by an illegal labora-
tory and not by far better equipped research facilities, he claims, is extremely 
small. Kekulé (2007) therefore predicts that for the next ten years gene doping 
methods will arise solely from misuse of the results of reputable research. 
                                            
4 The basic willingness to experiment with highly risky potential gene doping practices is 
regularly expressed openenly in internet forums for the bodybuilder scene, and scientists 
who have published papers on gene transfer in skeletal muscle of animals frequently re-
port that soon after publishing they received offers from healthy individuals to act as 
test subjects (Diel/Friedel 2007, S. 109). 
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ACCESS POINTS AND DIFFUSION FACTORS 4.2 
The question of when genetic doping strategies can be used for the first time is 
one that has occupied doping researchers as well as international sports associa-
tions and organizations for at least the past ten years, and there is still no clear 
answer. A basic distinction should be drawn between the use of gene therapy-
based methods to modulate gene expression by introducing genetic material 
(gene doping in the narrow sense) and methods for manipulating gene activity 
(gene doping in the broad sense). Overall, gene therapy-based methods must 
overcome much higher misuse barriers, even if, as a whole, the aforementioned 
scenarios of potential individual gene doping appears plausible (Section II.4.1). 
Much more likely is the misuse of the wide variety of methods and pharmaceuti-
cal developments for the targeted manipulation of gene activity as a further de-
velopment of conventional doping with the help of new findings and methods of 
molecular biology. Here – given the current state of development of various pro-
jects in the biotechnology and pharmaceutical industries – it must be assumed 
that such methods can already be employed for doping purposes, because misus-
ers can find access points in clinical trials, as experience in the field of peptide 
hormones (EPO, growth hormone) has shown. Diel/Friedel (2007, p. 124) there-
fore see an acute danger in, for example, methods for manipulating the myo-
statin signal transduction pathway (Section II.2.1) and for modifying the oxy-
gen-binding capacity of the blood (Section II.2.2). As yet, there are no detection 
methods for any of these manipulations (Section III). 
Based on past experience, elite sport is without doubt a possible point of entry, 
presumably including the highly commercial areas that are already at the focus 
of doping control structures (Section IV.2.2) and in which pressure to use unde-
tectable methods is especially great. Here, given the availability of gene doping 
methods, the key factors determining their spread will be their detectability and 
risk of discovery (Section V.1). 
A second point of entry could be highly ambitious or extreme bodybuilding (Sec-
tion V.2). Although this sport normally has fewer financial rewards, there is a 
strong fixation on supernatural physical results and a high motivation for un-
conditional goal achievement. It is plausible that availability and supposed effect 
will play a major role. In internet forums of the bodybuilder scene, for example, 
myostatin inhibitors have long been discussed and requested (Diel/Friedel 2007, 
p. 104). At the same time, for years a growing number of companies that make 
dietary supplements have been advertising and successfully selling products spe-
cifically pitched as myostatin inhibitors (e.g. by names such as Myostat, My-
ozap, Myoblast) (Diel/Friedel 2007, pp. 76 ff.). The active components of all 
these products is an extract from the marine alga Cystoseira canariensis. A sub-
stance in it (CSP-3, a sulfated polysaccharide) is claimed to inactivate myostatin 
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protein, a feat that has never been scientifically demonstrated (it has only been 
shown to bind to circulating myostatin; Ramazanov et al. 2003). The example 
illustrates how keen interest is in new doping substances even without scientific 
proof of efficacy. Clinically tested myostatin inhibitors would certainly be even 
more attractive. 
In the long term, however, a significant diffusion pathway could emerge in the 
field of anti-aging medicine, namely if licensed drugs, e.g. for the treatment of 
excessive muscle loss, become everyday drugs. Then the main factors determin-
ing the rate and extent of their spread will probably be the costs and the health 
risks involved. 
This socially and politically highly pertinent development is being increasingly 
discussed under terms like »lifestyle drugs«, »routine doping«, and »enhance-
ment«, and will doubtlessly become even more important in the future. Trends 
to date relate mainly to the field of psychopharmaceuticals, raising prospects of 
mental performance enhancement and emotional control (TAB 2007 u. Hennen 
et al. 2008). This alone is relevant to physical performance. However, applica-
tions that can be specifically exploited for doping in sport are probably those 
that are at the fringes of treatment for age-related impairments, e.g. treatment 
for excessive muscle loss. Because muscle degeneration often sets in as early as 
middle age, and the question of when it becomes so pronounced that it is re-
garded as pathological (and then termed sarcopenia) cannot be unambiguously 
answered, the number of potential consumers is enormous, as is the potential 
volume of sales. In view of the required development investment of several hun-
dreds of million euros, pharmaceutical and biotechnology companies have an 
interest in marketing their new products as widely as possible. At least since the 
release of Viagra there has also been an unmistakable trend in Europe towards 
drug marketing based on claims of potential performance enhancement. 
Once effective products of this kind are on the market – here we can draw an 
analogy to EPO and HGH – they will be used for doping purposes on a grand 
scale, even if they are only available on prescription. Their spread among ath-
letes, especially in recreational sport, will depend mainly on cost. In principle 
most of the drugs mentioned in Section II.2 will be no more expensive than the 
currently available recombinant growth factors. In the case of low-molecular-
weight compounds, for example HIF stabilizers (Section II.2.2), the costs may 
even be lower. 
A key issue in the fight against and prevention of doping is whether and how 
gene doping can be detected. Past experience would suggest that a reactive de-
velopment of detection methods is extremely unlikely to act as an effective deter-
rent against doping. This calls for the development of new doping control strat-
egies which will entail not only the consistent predictive monitoring of relevant 
scientific developments but probably also whole new forms of athlete monitor-




DETECTABILITY AND TEST DEVELOPMENT III. 
In the public discussion about the peculiarities and new dimensions of gene dop-
ing, the foreseeable difficulties of detection (as a precondition for the imposition 
of sanctions that will stand up in a court of law; cf. Section IV) are identified 
again and again as a major problem – not surprisingly, given that the presently 
available methods and techniques of detection are generally assumed to be inap-
plicable. There can be little doubt that by themselves, individual sports organiza-
tions and anti-doping institutions will not be up to the task of developing valid 
detection and testing methods for the multitude of potential gene doping meth-
ods referred to in the preceding section. 
In 2002 WADA set up a »gene doping panel« to deal specifically with the sub-
ject of gene doping. The task of this panel is to continuously monitor the find-
ings of relevant research in the fields of gene therapy and gene modulation in 
terms of their potential for abuse. The fact that WADA included gene doping in 
its 2003 Prohibited List shows that even at that time it considered gene doping 
to be potentially important, though it did not name any specific methods of gene 
doping or provide any information on the availability or use of such methods. 
Since 2003 WADA has specifically financed projects aimed at detecting gene 
doping. Among other things, this can help scientists who are conducting re-
search into gene therapy or gene modulation techniques that have a potential for 
abuse to take account of this potential for abuse and to develop methods of de-
tection in parallel with their research.5 The forward-looking approach of such 
projects constitutes an enormous advance over the situation that prevailed dur-
ing the development of recombinant peptide hormones6 and is described in more 
detail in Section III.1.2. 
Nevertheless, detection is no more than a first step and is far from being a relia-
ble test yielding results that constitute legally valid evidence of abuse of a sub-
stance or technique for doping purposes. The Chair of WADA's gene doping 
panel describes the present situation with regard to gene doping and its detection 
as follows: »The technology is still in its infancy. We are encouraged by the fact 
that proof can be found that foreign genes have been introduced into a person's 
body. However, the problem is not just that of developing a test; rather, such a 
                                            
5 For example, G. Goldspink (UK) is presently conducting research into gene therapy 
methods of maintaining muscle mass in pathologic conditions and at the same time 
working on methods of detecting possible abuse (www.wada-ama.org/en/dynamic.ch2? 
pageCategory.id=347). 
6 The performance-enhancing potential of recombinant erythropoietin was known even 
before the drug was licensed for use, yet only rarely mentioned by doping analysts and 
scarcely discussed in public during the first few years in which the drug was used. 
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test also has to be validated to the extent that its results can be presented to a 
tribunal or court of law and can be shown to be the only plausible explanation 
for a particular finding. That is very difficult to do and will require a lot more 
work.« (Friedmann, quoted in Diel/Friedel 2007, p. 140) 
The following two sections deal with the fundamental scientific challenges posed 
by, and the concrete research strategies used to detect, gene doping (Section IV.1) 
and the criteria for tests that will stand up in a court of law (Section IV.2). 
DETECTABILITY 1. 
In order for doping manipulations to be successfully demonstrated, three basic 
conditions must be satisfied (Diel/Friedel 2007, p. 131): 
> Information on methods and drugs that may have been used for doping 
purposes must be available. 
> Effective detection methods that are practicable, reliable, and valid must be 
available. 
> A doping control system that applies not only to competitions but also to 
training and that ideally is adapted to available methods of detection must be 
in place. 
At present, no concrete gene doping methods or substances can be named; ra-
ther, only gene doping »candidates« (EPO, VEGF-2, myostatin, etc.) are known 
(Section II.2). Accordingly, no specific detection methods exist as yet. The fol-
lowing discussion therefore provides only a general summary of basic detection 
strategies and draws attention to known problems. In some cases reference is 
made to results obtained using existing doping detection methods, however it 
must always be borne in mind that future methods of manipulation may be far 
more complex and refined than those that have been used to date (Section II). 
The available data do not permit a more detailed exposition than that given 
here. 
Independently of the type of doping, a distinction can be made between direct 
and indirect methods of detection. 
DIRECT METHODS OF DETECTION 1.1 
A direct method of detection demonstrates the presence of a prohibited sub-
stance or its degradation products (metabolites) or specific markers. In the case 
of exogenous substances (or substances that differ to a sufficient extent from 
endogenous substances) (e.g. synthetic anabolic steroids or recombinant protein 
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hormones with definite and easily detectable structural changes), qualitative de-
tection is sufficient in principle. In the case of endogenous substances or sub-
stances that are identical to endogenous substances (e.g. human hormones), on 
the other hand, quantitative determination is required in order to demonstrate 
the presence of nonphysiological concentrations of the substance. More com-
monly, however, the most that can be obtained is indirect evidence of a non-
physiological deviation from the normal state indicative of an (intended) effect 
of the administered substance (e.g. an abnormal hematocrit or hemoglobin level 
in the case of blood doping with EPO). Almost all currently licensed doping tests 
are based on direct evidence, even though many peptide hormones, for example, 
have extremely short biological half-lives (of the order of a few days), whereas 
their effects persist for much longer (Diel/Friedel 2007, p. 130). For this reason 
alone, in-competition testing is inadequate and must be supplemented by out-
of-competition testing (Section IV.2.3). 
In gene therapy and gene modulation, attempts are made either to introduce a 
gene or a gene component into certain cells of the body and there to activate it, 
or else to activate or inhibit an existing gene or gene component. Where the in-
troduced genetic or gene-regulating element is chemically different from endoge-
nous substances, direct demonstration of it is both possible and qualitatively 
sufficient. Where this is not the case, quantitative indirect demonstration of a 
nonphysiological state is required. In relation to gene doping in the narrow sense 
(as compared to conventional doping techniques), demonstration of gene vectors 
likewise constitutes only indirect evidence and is subject to the same problems. 
DIRECT DEMONSTRATION OF GENETIC ELEMENTS 
Given the extremely high sensitivity – and, moreover, the relative technical sim-
plicity – of techniques of DNA and RNA detection as compared to techniques of 
protein detection, doping by means of genetic elements, i.e. gene doping in the 
narrow sense, might be expected to be easily detectable. However, many gene 
doping techniques have characteristics that make detection difficult. 
A precondition for direct demonstration of a gene or gene component is that the 
structure (i.e. in most cases concretely the DNA or RNA sequence) of the intro-
duced material be known. Where a coding gene, e.g. one that codes for a per-
formance-enhancing hormone, is introduced into the cells of a recipient for dop-
ing purposes by means of gene transfer, the sequence is necessarily known, since 
otherwise the gene could not have been synthesized and introduced into the re-
cipient's cells. 
The presence of a transferred DNA sequence that was identical with the corre-
sponding DNA sequence of the recipient's genome would be impossible to 
demonstrate. At least under present circumstances, however, this situation is 
unlikely to arise for at least two reasons: 
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Firstly, the DNA sequences that are transferred are mostly sequences from which 
certain segments (»introns«) that are not required for translation of the genetic 
information into proteins (Section II.1.2) have been omitted. Techniques for de-
tecting gene doping such as are being developed at University Hospital Tübingen 
by P. Simon's working group with the support of WADA are based upon 
demonstration of this difference, e.g. the difference between a possibly trans-
ferred EPO gene and the corresponding endogenous gene (see box in Sec-
tion III.1.2). 
Secondly, promoters and other flanking sequences are generally transferred 
along with the coding region in order to permit integration of the coding region 
into the recipient's nuclear DNA and bring about intensive protein production. 
These sequences too are mostly known, though in many cases not in relation to 
a particular gene. Rather, many such sequences are commercially available 
»standard elements« the detection of which provides evidence only of some form 
of genetic manipulation (and thus may constitute indirect evidence in support of 
an initial suspicion). 
There are two purely hypothetical circumstances in which the actual coding se-
quence might not be known. The first of these would arise with use of a gene 
whose performance-enhancing effect had not been described in the scientific lit-
erature. This is extremely unlikely firstly because of the cost of demonstrating 
an effect on performance, and secondly because this would be a rare scientific 
finding (Section II.1.1). 
The second hypothetical circumstance is deliberate synthesis of (possibly even 
more effective) DNA variants of known performance-influencing gene sequences 
exclusively for doping purposes without publication in a scientific journal or the 
like. This is unlikely because such altered molecules would generally retain such 
structural similarity with the corresponding unaltered molecule that existing 
methods of detection (based either on base pairings or on antibodies) would de-
tect them along with the unaltered molecule. Were they not to do so, the situa-
tion would be similar to that which occurred in the BALCO scandal, in which 
steroids that had been synthesized specifically for doping purposes and whose 
existence (or use) was completely unknown to doping analysts were used 
(Diel/Friedel 2007, p. 129). 
According to many experts, however, the major obstacle to demonstrating the 
presence of introduced genetic elements lies less in the difficulty of demonstrat-
ing structural peculiarities of molecules as in a lack of accessibility or detectabil-
ity. If they are to exert an action, introduced genetic elements almost always 
have to be inserted into body cells and in some cases even into cell nuclei – and 
ideally, only into those of certain organs. They pass into the urine at most only 
in the form of nonspecific degradation products, while their concentration in the 
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blood also tends to be very low, e.g. because naked DNA is very rapidly broken 
down. The temporal window available for their detection is thus likely to be far 
shorter even than that for the detection of peptide hormones – while the alterna-
tive of obtaining tissue samples raises a completely different set of (procedural 
and legal) questions than does the obtaining of urine or blood samples (Sec-
tion IV.2.3). 
DIRECT DEMONSTRATION OF GENE-REGULATING SUBSTANCES 
In some cases the chances of being able to directly demonstrate a modulation of 
gene expression are certainly better if the method or substance concerned is 
known. For example, administration of a blocking antibody is relatively easy to 
demonstrate using immunological methods. In principle, this is true also of 
compounds of low molecular weight (e.g. the HIF stabilizer FG-2216; Sec-
tion II.2.2) (Diel/Friedel 2007, p. 131 ff.). 
Based on the dynamics of the development of gene doping as described in Sec-
tion II.2 and on the diversity and complexity of the field of gene modulation, 
however, it must be assumed that techniques of direct demonstration will gener-
ally become less important for screening purposes, since it would be far too ex-
pensive to test for all possible manipulations. Given, for example, that expres-
sion of the growth factor myostatin can be influenced at at least four different 
levels (transcription, translation, post-translational modification, and intracellu-
lar signal transduction; Section II.2.1) by correspondingly different substances, it 
is far more expedient to demonstrate a nonphysiological change in effect (in this 
case a fall in myostatin concentration) and only if there are concrete grounds for 
suspicion to attempt to identify the specific type of manipulation practiced (this 
is the objective of two projects supported by WADA; see box in Section III.1.2). 
This approach is also supported by the pace of development to date. Whereas in 
the early 1980s the number of methods and substance classes to be considered 
was still manageable, in the 1990s the number increased greatly due to the abuse 
of recombinant growth factors. Even painstakingly developed detection methods 
(such as the test for ingestion of erythropoietin) lost much of their conclusiveness 
within a few years because of the development of new variants of substances or 
procedures. For example, it is believed that the drug Dynepo cannot be detected 
by means of the presently used test for EPO (Diel/Friedel 2007, p. 131 ff.). 
INDIRECT METHODS OF DETECTION 1.2 
For the reasons stated above, most of the projects presently being supported by 
WADA are intended to provide indirect evidence of gene doping – by detecting 
either the gene vectors used or deviations from the normal physiological state of 
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the organism (Diel/Friedel 2007, p. 132). Whereas up to now very basic, easily 
determined parameters such as the concentration of red blood cells or of certain 
steroid hormones have served this purpose, in the future highly differentiated 
profiles of the most varied molecules, i.e. biomarkers, will need to be determined 
in blood and tissue samples taken from athletes if evidence of the wide variety of 
possible manipulations is to be obtained. 
DETECTION OF THE TRANSPORT VECTOR 
As explained in Section II.1.3, there are many different ways in which a gene or 
a gene component can be inserted into a cell or cell nucleus. Like detection of 
the genetic element itself, detection of the vector requires knowledge of its struc-
ture (i.e. in this case also, a typical DNA sequence). 
So far, attempts at gene therapy have mostly used viral vectors, i.e. viruses a part 
of whose genetic information has been replaced by therapeutic genes. In princi-
ple, these viral vectors can be detected in the same way as normal viruses, i.e. on 
the basis of the presence of specific antibodies that the immune system produces 
as a reaction to viral infection and that persist in the immune system for a long 
time (»immunological memory«, »acquired immunity«). Attenuated human vi-
ruses are most commonly used as vectors. However, since organisms are regular-
ly infected with a variety of viruses, the existence of immunological cross reactions 
will in some cases make it difficult to use the presence of antibodies against viral 
vectors as specific evidence of gene doping (Diel/Friedel 2007, p. 132). 
Moreover, as compared to a »normal«, illness-inducing, infection, viral vectors 
introduced for the purpose of gene therapy are used in small amounts precisely 
so that they will not induce an immune reaction. Also, whenever possible they 
are administered locally, i.e. only to a single organ or tissue (e.g. skeletal mus-
cle), so that they will not induce a systemic reaction in the form of an immune 
response. 
Though detection of viral vectors remains conceivable, detection of nonviral vec-
tors (naked DNA, siRNA) is many times more difficult because of the short 
biological half-life of nucleic acids. Though these techniques are to a large ex-
tent still at an early stage of development, they are becoming increasingly im-
portant. Free nucleic acids, especially exogenous nucleic acids, are very rapidly 
destroyed by the immune system (Diel/Friedel 2007, p. 132). 
In the case of techniques in which cells are taken from the body, genetically al-
tered outside of the body (ex vivo), and then returned to the body, it is at pre-
sent entirely unclear whether, and if so how, evidence of such manipulation can 
be obtained. 
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A perusal of the twenty WADA-supported projects on detection of gene doping 
shows that only one of these is aimed at directly detecting vectors (development 
of a test for naked plasmid DNA after intramuscular injection; no. 18 in the box 
in the following section). 
DETERMINATION OF NONPHYSIOLOGICALLY ALTERED 
PARAMETERS 
The importance of this approach for future detection of gene doping in both the 
narrow and the broad sense, and specifically for the development of screening 
tests for doping, is clear from a consideration of the projects that have been sup-
ported by WADA to date (see box). Apart from the project on plasmid detection 
referred to above, only two of these projects (no. 11 and no. 13) deal with the 
possibility of detecting transferred genetic elements or concrete genes for IGF or 
other »candidates«, whereas all the others are aimed at determining whether mo-
lecular patterns in the body show characteristic changes after manipulation. In 
these approaches the entire repertoire of modern biomolecular analysis (DNA 
and protein arrays, imaging techniques, mass spectrometric methods, high-
resolution gel electrophoresis, etc.) is used in order to establish molecular finger-
prints (i.e. highly differentiated and highly specific analytical results for DNA, 
RNA, and protein composition) that occur as a reaction to administration of 
exogenous substances in order to alter gene activity rather than as a physiologi-
cal reaction to ingestion of permitted substances and/or use of training methods. 
Almost all the research projects of this type that have been undertaken to date 
are focused on individual »pathways« of manipulation (e.g. manipulation of the 
synthesis of EPO, growth hormone, or myostatin) and belong in the field of 
basic research (Diel/Friedel 2007, p. 139). They aim to determine whether »mo-
lecular fingerprints« that constitute evidence of manipulation can really be spe-
cifically described and reproduced under realistic conditions. Many projects also 
aim to detect genetic manipulation without thereby providing a specific explana-
tion of a performance-enhancing effect. 
WADA-SUPPORTED RESEARCH PROJECTS ON GENE DOPING 
(STATUS: JANUARY 2008) 
1. Goldspink et al. (UK/I): Manipulation of muscle mass via the growth hormone/insulin-
like growth factor axis (completed) 
2. Gmeiner et al. (A): Application of microarray technology for the detection of changes in 
gene expression after doping with recombinant human growth hormone (completed) 
3. Friedman/Smith (USA): Microarray detection methods for GH and IGF-1 
4. Segura et al. (E): IMAGENE: Non-invasive molecular imaging of gene expression useful 
for doping control: Pilot study in animals after erythropoietin gene transfer (completed) 
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5. Roberts et al. (UK): The application of cellular chemistry and proteomic approaches to 
the detection of gene doping 
6. Rupert/McKenzie (CDN): Development of a prototype blood-based test for exogenous 
erythropoietin activity based on transcriptional profiling 
7. Ho et al. (A/AUS): Detection of growth hormone doping by gene expression profiling of 
peripheral blood cells in humans 
8. Imagawa/Yamamotot (J): Detection of Hypoxia Inducible Gene Manipulation 
9. Diel et al. (D, Sporthochschule Köln): High sensitive detection of genetically and phar-
macological manipulations of the myostatin signal transduction pathway by multiplex 
immuno PCR fingerprint analysis 
10. Thevis et al. (D, Sporthochschule Köln): Analysis of growth hormone isoform profiles in 
human plasma using proteomics strategies 
11. Giacca et al. (I): Molecular signatures of IGF-1 gene doping after AAV-mediated gene 
transfer 
12. Segura et al. (E): IMAGENE: Non-invasive molecular imaging of gene expression useful 
for doping control: Extension study in animals after erythropoietin gene transfer (con-
tinuation of no. 1) 
13. Simon et al. (D, Universitätsklinik Tübingen): Sensitivity and specificity of a gene doping 
test detecting transgenic DNA on a single molecule level in peripheral blood probes 
14. Jorgensen/Kopchick (DK): Proteomic analysis of serum exposed to GH: a future assay 
for detection of GH doping 
15. Khurana/Bogdanovich (USA): Development of tests for detecting myostatin-based dop-
ing to enhance athletic performance 
16. Gmeiner et al. (A): Application of microarray technology for the detection of changes in 
gene expression after doping with recombinant HGH – part 2 (continuation of no. 4) 
17. Schönfelder et al. (D, TU München): Comparative gene expression profiling in human 
buccal epithelium and leukocytes after the abuse of beta-2-agonists and anabolic steroids 
18. Snyder/Moullier (USA/F): A pilot study to develop a reliable blood test for the detection 
of gene doping after intramuscular injection of naked plasmid DNA 
19. Berg et al. (N): Genetic regulation of epitestosterone glucuronidation. Consequences for 
evaluation of urinary T/E ratio 
20. Bhasker (USA): Pilot project for a WADA bioinformatics core facility 
Source: www.wada-ama.org/en/dynamic.ch2?pageCategory.id=347 
Only one of the projects listed above (a standardized test for total myostatin 
activity; no. 15) names the concrete development of a usable test as one of its 
objectives. Two of the projects (on HGH/IGF and EPO respectively) have now 
been completed. In neither case will the results lead to the development of a dop-
ing test within the foreseeable future (Diel/Friedel 2007, p. 139 ff.). 
In a kind of metastudy or cross-sectional evaluation of the individual projects, 
one of the projects (no. 20) addresses the question of which of the enormous 
number of measurement parameters that can be derived from the individual mo-
lecular fingerprints of the various potential manipulation techniques could prove 
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to be especially informative and suitable for use in future routine doping tests. 
An important question about test practice is touched upon in projects no. 9 and 
no. 17, among others: Given the legal and ethical difficulty of obtaining biologi-
cal samples, the question is addressed of whether analysis of easily accessible 
blood cells and oral mucosal cells (for myostatin expression and for RNA pat-
tern after administration of anabolic agents, respectively) is sufficiently reliable 
for test purposes. Behind this lies the question of whether other types of tissue 
sample may be required in the future. 
The answer to this question, and to the fundamental question of whether this 
whole approach will eventually prove successful, is not yet known. From the 
analytical perspective, however, no alternative is apparent at present. 
REQUIREMENTS OF (GENE) DOPING TESTS 2. 
Only if the existence of a prohibited substance or method can be demonstrated 
in principle can a test method for it be developed. The result of such a test is 
generally the only basis on which doping activity can be established. As this evi-
dence must be able to stand up in a court of law (Section IV.2.1), the standard 
of proof in all cases is greater than a mere balance of probability but less than 
proof beyond a reasonable doubt (WADA 2004a, p. 13). According to WADA 
(2004c, p. 19), the criteria for acceptance as a positive test result must be scien-
tifically well founded. Analytical methods for the detection of substances are 
therefore based on WADA-accredited, validated methods. The annex to the 
WADA International Standard for Laboratories (WADA 2004c, p. 57) refers to 
a series of technical documents, however the documents that describe the vali-
dated methods are not freely available. It has not proved possible in the context 
of the present report to specify the concrete requirements that apply to the quali-
ty parameters of tests. Nevertheless, it can be assumed that the following basic 
quality criteria of medical tests must also be satisfied by doping tests: 
> Validity: This provides general information about the applicability of a 
statement. In the present context it means that detection of a certain sub-
stance must unambiguously prove that a certain method, and no other, has 
been used. 
> Reliability: This is a measure of formal accuracy of measurement and indi-
cates the extent to which a test is free from random errors. 
> Sensitivity: This is a measure of the sensitivity of a test (true-positive rate, i.e. 
the proportion of doped people who are correctly identified as such). 
> Specificity: This is a measure of the correctness of a test (true-negative rate, 
i.e. the proportion of doped people who are correctly identified as such). 
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Though the quality criteria that apply to doping tests have yet to be published, 
they are certainly taken into account in the accreditation procedure. Compliance 
with quality criteria, which poses a major challenge even with »conventional« 
doping methods,7 is crucially important for obtaining proof. Carelessness in this 
regard could compromise the value of the evidence obtained, since other se-
quences of events (i.e. other than doping) could then no longer be excluded with 
a satisfactory degree of certainty. One consequence of this would be an in-
creased number of legal disputes aimed at establishing the validity of test results. 
»INTELLIGENT« BIOMONITORING AS A BASIS FOR DETECTING 
GENE DOPING 
Detection strategies employed to date are aimed at providing evidence of the 
presence of a prohibited substance or method that will stand up in a court of 
law. For this purpose the evidence must be direct. If the presence of such a sub-
stance or its metabolites or markers has been directly demonstrated, the purpose 
for which it was used – physiological performance enhancement – is immaterial. 
Even with conventional doping agents and methods, such detection strategies are 
becoming increasingly difficult and expensive.8 A possible alternative would be a 
graduated approach in which standardized analytical measurements of parame-
ters that are relevant to physiological performance would be performed at speci-
fied intervals and followed by specific tests only if any of the standard tests 
yielded abnormal results. 
Regular determination of easily measured parameters to detect doping practices 
is already being discussed and in a few instances even tried. A number of sports 
organizations, especially in the field of cycling, have discussed the possibility of 
establishing individual blood profiles. The International Cycling Union (Union 
Cycliste Internationale, UCI) says that it is working with WADA and the French 
Ministry of Health, Youth Affairs, and Sport to develop a »biological passport« 
that is to be tested in 2008. Similarly, Germany's National Anti-Doping Agency 
(Nationale Anti Doping Agentur, NADA) has announced that as from 2008 elite 
athletes from doping-affected sports will be tested several times a year via urine and 
blood samples (NADA 2007b). In the most favorable case these doping tests can 
directly demonstrate the presence of a prohibited substance, however even if 
they do not, monitoring of this kind can reveal a variety of doping-specific ab-
normalities. Where there are grounds for suspicion, more specific tests can be 
performed. 
                                            
7 Though it is generally assumed that athletes use growth hormone illegally to enhance 
their performance and the structure of this hormone is known, no recognised test for 
detecting it is available as yet. 
8 In Germany the cost of a doping test is already between 350 and 1500 euros, depending 
on what substances are being tested for. 
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At present this »monitoring approach« appears to have potential as a basis or 
preliminary stage for future detection of gene doping by analytically complex 
regular determination of athletes' molecular fingerprints as envisaged by WADA 
research projects (Section III.1.2). Unambiguous evidence of manipulation of 
gene activity obtained in this way would by itself constitute proof of gene dop-
ing. For legal reasons, however, it would probably be necessary to demonstrate 
the specific doping method used in each individual case. 
As this type of monitoring could also provide athletes with a means of counter-
ing the growing phenomenon of »general suspicion«, most athletes are not likely 
to object to it in principle. The TAB project was unable to identify any existing 
»best-practice« examples of, or scientifically validated techniques for, monitor-
ing of this kind (neither the parameters to be measured nor the frequency of 
measurement have been established on a scientific basis). In the development of 
a monitoring technique a number of factual, legal, and organizational consid-
erations have to be taken into account, including responsibilities, financing, 
technical implementation, administration of results, and data protection. In 
these respects many common features are likely to be found between presently 




GENE DOPING: PROHIBITION AND 
CONTROL PROCEDURES IV. 
The struggle against doping has for many years been an area of activity not only 
of sports organizations, but also of political decision makers. Early national ini-
tiatives against doping were followed by international attempts to coordinate 
and unify the actions that were being taken. WADA was established as an inde-
pendent entity in 1999 with the explicit objectives of harmonizing, coordinating, 
and advancing the international fight against doping, promoting the develop-
ment of measures to prevent doping, and thereby protecting athletes' fundamen-
tal right to participate in doping-free sport worldwide. It arose from the anti-
doping commission of the IOC and is funded by international sports organiza-
tions and individual countries. In 2002 WADA formed a »gene doping panel« to 
deal specifically with this subject. In 2003, in view of the rapid advances that 
were being made in terms of new medical therapies, gene doping was included in 
WADA's list of prohibited substances and methods (Prohibited List). This 
brought gene doping within the ambit of WADA's core document, the World 
Anti-Doping Code (WADC), which provides the basis for a coordinated fight 
against doping by sports organizations and public authorities at both interna-
tional and national levels. 
When the WADC and specific standards are incorporated into German law, care 
must be taken to ensure that the individual's right to self-determination is up-
held (Article 2, Paragraph 1, Grundgesetz) (German Basic Law, GG). This 
means that no action may be taken to prevent individuals from jeopardizing 
their own health. Moreover, freedom of association must be preserved (Arti-
cle 9, Paragraph 1, GG) and the right of sport to regulate itself and manage its 
own affairs must be respected unless a criminal offense has been committed. The 
question of criminal offenses related to doping has long been a matter of contro-
versy and formed the impetus for the introduction of the Gesetz zur 
Verbesserung der Bekämpfung des Dopings im Sport (Law to Improve the Fight 
against Doping in Sport), which came into force in November 2007. This appor-
tioned responsibilities in relation to doping between sport and the state. 
The present section deals in particular with the question of to what extent exist-
ing legal norms, testing structures, and sanctions are adequate for dealing with 
gene doping at present and will prove adequate for doing so in the future. In 
Section IV.1 the WADC is introduced as the basic set of rules governing doping. 
Section IV.2 describes the implementation of the WADC in the form of the 
NADA code governing sports organizations in Germany and the application of 
the WADC in doping control procedures. Section IV.3 deals with existing legal 
norms that are applicable to gene doping. The following discussion of legal and 
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procedural foundations concentrates on aspects that are relevant to gene doping. 
Where necessary for a better overall understanding, some of these framework 
conditions are discussed in more detail. 
THE WORLD ANTI-DOPING CODE: THE INTERNATIONAL 
LEGAL BASIS FOR SPORTS ORGANIZATIONS AND 
PUBLIC AUTHORITIES 1. 
As it is included in WADA's Prohibited List, gene doping is in principle covered 
by the World Anti-Doping Code (WADC) (WADA 2004a), which was drawn 
up and adopted in 2003 and came into force in 2004. A revised version is 
planned for 2008. More comprehensively and in more detail than does any oth-
er set of regulations in sport, the WADC defines the prohibition of doping, vio-
lations of this prohibition, and the principles and procedures of testing and sanc-
tions. It points the way to an internationally harmonized set of minimum stand-
ards for combating doping. No sets of rules on gene doping that are not based 
on the WADC and the Prohibited List appear to exist. The WADC with its defi-
nitions and resulting set of rules thus forms the primary reference point for the 
following discussion. 
The WADC defines prohibited doping actions, governs the monitoring of ob-
servance, and provides a framework for the imposition of sanctions. The enu-
merative definition of doping in the form of a list of rule violations is preceded 
by a value judgment of doping that serves as the basis for the prohibition. 
DOPING AS BEING CONTRARY TO THE SPIRIT OF SPORT  
In the introduction to the WADC the purpose of the Code is stated to be »to 
protect the Athletes' fundamental right to participate in doping-free sport and 
thus promote health, fairness and equality for Athletes worldwide« (WADA 
2004a, p. 6 ff.). The fundamental rationale for the WADC is said to be to pre-
serve what is intrinsically valuable about sport (referred to as »the spirit of 
sport«); this value is the essence of the Olympic ideal and accords with WADA's 
understanding of fairness and honesty in sport. The spirit of sport is defined as 
»the celebration of the human spirit, body, and mind« and is said to be character-
ized by the following values: 
> »Ethics, fair play, and honesty 
> Health 
> Excellence in performance 
> Character and education 
> Fun and joy 
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> Teamwork 
> Dedication and commitment 
> Respect for rules and laws 
> Respect for self and other participants 
> Courage 
> Community and solidarity 
Doping is fundamentally contrary to the spirit of sport.« (WADA 2004a, p. 7 ff.) 
In relation to this link between values, the spirit of sport, and violation of the 
spirit of sport in the form of doping, Franke (2007, p. 7) makes the following 
critical comment: »It is unclear whether this additive list of 'sporting values' is 
arbitrary, in need of further additions, or complete, whether the values are inter-
related, whether they form a hierarchy, in what way violating them (e.g. 'fun 
and joy', 'courage', or 'education') inevitably leads to doping, in what way the 
individual values or groups of values can be 'linked' to individual actions, in-
tended actions, or consequences of actions in competitive sport, and finally, in 
what way observance of them in a competitively orientated sports industry that 
receives media attention can be a realistic basis on which to make moral judg-
ments. Even without a detailed critical analysis in terms of sports ethics, it is 
clear that attempts, including that of the WADA Code as it now stands, to es-
tablish a basis for value judgments have no action-determining consequences 
and cannot legitimize such a code.« 
It may well be true that a mere »list of values« of this kind has few »action-
determining consequences« and seems far removed from reality. Precisely in 
view of the competitive nature of the sports industry, however, the establishment 
of such a list at least has the virtue of insisting that rules should be made, and 
violation of rules condemned, on the basis of value judgments. In this way it at 
least answers – in however rudimentary a fashion – the question of the purpose 
of prohibiting doping in the sense that prohibited actions are not merely listed, 
but also related to ethical principles. Even if this relationship is not established 
by argument, the point is made that the rules of competition are more than just 
(external) behavior-influencing precepts and prohibitions; rather, they also pre-
suppose and call for (internal) attitudes (such as fairness and solidarity). 
DOPING AS A VIOLATION OF RULES 
After establishing the ethical rationale for prohibiting doping, the WADC goes 
on in its Articles 1 and 2 to define doping in very precise terms as a violation of 
rules. Prohibited actions and violations of these prohibitions, together with pro-
hibited substances and methods, are gathered together in lists (enumerative defi-
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nition of doping).9 Doping – and thus also gene doping as a prohibited method 
– is defined as the existence of one or more of the listed violations of anti-
doping rules (Table 5). 
All prohibited substances and methods are explicitly listed in a Prohibited List 
that is published separately by WADA as often as is necessary (but at least once 
yearly) (WADA 2008). The primary requirement for inclusion in the Prohibited 
List is the finding by the Medical Committee of WADA that any two of the fol-
lowing three criteria are met: 
> »Medical or other scientific evidence, pharmacological effect, or experience 
that the substance or method has the potential to enhance or enhances sport 
performance; 
> Medical or other scientific evidence, pharmacological effect, or experience 
that the use of the substance or method represents an actual or potential 
health risk to the athlete; or 
> WADA's determination that the use of the substance or method violates the 
spirit of sport described in the Introduction to the Code.« (WADA 2004a, 
p. 16 ff.) 
None of the three criteria (performance enhancement, health risk, violation of 
the spirit of sport) is sufficient by itself, since, for example, all training measures 
also have a potential for performance enhancement and health risks can also be 
associated with other products. On the other hand, a requirement that all three 
criteria be met would be inappropriate, since evidence of a health risk, in partic-
ular, is sometimes difficult or impossible to obtain (WADA 2004a, p. 17). 
The decisions made by WADA on the basis of the three criteria are sometimes 
disputed, but according to the WADC are not negotiable.10 The medical or sci-
entific evidence on which the decisions are supposedly based are not published. 
This process of decision-making by the Medical Committee of WADA can there-
fore not be regarded as transparent or described in sufficient detail as to be 
traceable. 
                                            
9 As compared with an imprecise definition of the nature of doping, this »enumerative« 
definition of doping has the advantage of (legal) precision, however its normative 
weakness must be borne in mind. Its (hidden) message is that no moral convictions are 
required in sport. Rather, all that is required is adherence to legally established rules 
and prohibitions. Moreover, nonprohibited actions and substances – even when they 
serve the same purpose of performance enhancement – are at least not illegal (Bet-
te/Schimank 2006b, p. 171). 
10 Decisions by WADA to prohibit substances and methods are final and cannot be chal-
lenged on the basis that the method concerned does not have the potential to enhance 
performance or does not represent a health risk or violate the spirit of sport (WADA 
2004a, p. 17). 
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TABLE 5 ANTI-DOPING RULE VIOLATIONS AS PER THE WADC 




1 The presence of a prohibited substance or its metabolites or 
markers in specimens of an athlete's bodily tissues or fluids
DT  





3 Refusing, or failing without compelling justification, to submit 
to sample collection after notification as authorized in applica-
ble anti-doping rules or otherwise evading sample collection
O(DT)  
4 Violation of applicable requirements regarding athlete availabil-
ity for out-of-competition testing, including missed tests and 
failure to provide whereabouts information
O(DT)  
5 Tampering, or attempting to tamper, with any part of doping 
control 
O(DT) O(DT) 
6 Possession of prohibited substances and methods O O 
7 Trafficking in any prohibited substance or prohibited method O O 
8 Administration or attempted administration of a prohibited 
substance or prohibited method to any athlete, or assisting, en-
couraging, aiding, abetting, covering up or any other type of 
complicity involving an anti-doping rule violation or any at-
tempted violation 
O O 
DT Doping test 
O(DT) Observation made in connection with doping tests  
O Observation, admission, or other evidence admissible in civil law 
Source: WADA 2004a, p. 10 ff. 
It is immaterial whether use of prohibited methods such as gene doping (Ta-
ble 5, violation no. 2) enhances performance or not. For an anti-doping rule vio-
lation to be committed, it is sufficient that the prohibited method was used or 
that an attempt was made to use it (WADA 2004a, p. 12). 
Table 6 summarizes the substance classes and methods that were classified as 
doping in 2007 and are wholly or partly prohibited until revision of the Prohib-
ited List. 
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TABLE 6 SUMMARY OF FORBIDDEN SUBSTANCE CLASSES AND 
 METHODS OF THE WADA PROHIBITED LIST 
Substances (classes) Methods 
S1 Anabolic agents M1 Enhancement of oxygen transfer 
S2 Hormones and related substances M2 Chemical and physical manipulation 
S3 Beta-2 agonists M3 Gene doping 
The non-therapeutic use of cells, genes, 
genetic elements, or of the modulation of 
gene expression, having the capacity to 
enhance athletic performance, is forbid-
den. 
S4 Substances with anti-estrogenic activ-
ity 
 
S5 Diuretics and other masking agents  
Substances (classes) prohibited 
in-competition 
Substances (classes), 
prohibited in particular sports 
S6 Stimulants P1 Alcohol 
S7 Narcotics P2 Beta-blockers 
S8 Cannabinoids   
S9 Glucocorticosteroids   
Source: WADA 2008 
The wholly or partly prohibited substances within each substance class (Table 6, 
substance classes S1 to S9) are individually named and distinguishable from one 
another. The presence of any of these named substances or their metabolites or 
markers in specimens of an athlete's bodily tissues or fluids is defined as doping. 
In order to keep up with pharmacologic developments, the entire list of prohib-
ited substances is continuously extended and to an increasing extent no longer 
specified in unambiguous terms. This is achieved, for example, by means of the 
formulation »and other substances with a similar chemical structure or similar 
biological effect(s)« (WADA 2008). In this way a larger number of similar sub-
stances are included in the list, however the degree of precision of the list is re-
duced.11 
To date, the detailed descriptions of prohibited methods included in the list have 
been less precise and do not constitute a positive list anywhere near as unambig-
uous as the list of prohibited substances. This is especially true of the description 
of gene doping. This problem of imprecision could be addressed by introducing 
subgroups of category M3 (gene doping) of the Prohibited List (Table 6). 
                                            
11 The possibility therefore cannot be excluded that legal clarification of whether a sub-
stance is similar may be required at a later time. 
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Along with techniques that are classified as gene doping in either the narrow or 
the broad sense, Section II refers to other relevant lines of research based on 
modern molecular biological techniques (e.g. hormone or receptor blockade by 
means of specific antibodies) that can likewise be used to enhance physical per-
formance. In the short term, the risk that such techniques could be abused for 
doping purposes is even greater than that with actual gene doping in the narrow 
or the broad sense. Any extension of the substance classes and/or methods in the 
Prohibited List must also cover these possibilities for abuse. 
The basic descriptions of prohibited doping actions are followed by descrip-
tions of control procedures. These are specified to some extent by means of the 
following separate standards: 
> International Standard for Doping Control (ISDC) and International Stand-
ard for Testing (IST) (WADA 2004b) 
> WADC International Standard for Laboratories (describes the requirements 
for accreditation as a recognized analytical laboratory) (WADA 2004c) 
> International Standard for Therapeutic Use Exemptions (TUE) (WADA 
2004d) 
Adoption and observance of the WADC is basically voluntary for all organiza-
tions. When the WADC was first promulgated, the reactions of international, 
national, and national organizations ranged from cooperativeness through asser-
tions of independence to rivalry. Despite this, WADA is now becoming increas-
ingly accepted both in the world of sport and at the political level as an inde-
pendent anti-doping organization. By the end of 2007 more than 570 sports or-
ganizations worldwide had adopted the WADC. At the same time the Copenha-
gen Declaration, which implements the WADC at the political level, had been 
signed by 191 governments (and ratified by 120 countries). 
THE NADA CODE: THE LEGAL BASIS FOR SPORT 
IN GERMANY 2. 
In 2003 Germany's National Anti-Doping Agency (NADA), an independent 
foundation in civil law, took over responsibility for the fight against doping 
from the joint Anti-Doping Commission (Anti-Doping-Kommission, ADK) of 
the German Sports Confederation (Deutscher Sportbund, DSB) and Germany's 
National Olympic Committee (Nationales Olympisches Komitee, NOK), the 
precursor of the German Olympic Sports Confederation (Deutscher Olym-
pischer Sportbund, DOSB). Though organizationally independent, NADA rec-
ognizes the umbrella role played by WADA and adapts the latter's regulations to 
German circumstances. The form of the WADC that applies to Germany is the 
88 IV.  GENE DOPING: PROHIBITION AND CONTROL PROCEDURES 
 
NADA Code (the set of anti-doping rules that applies to German sport; NADA 
2006b, p. 7), which was drawn up by NADA in conjunction with the DSB and 
the NOK. It adopts both the WADA list of doping violations (Table 5)12 and the 
WADA Prohibited List (Table 6) in its entirety. As a result, the NADA Code 
likewise defines gene doping as a prohibited method and specifies anti-doping 
rule violations. 
The freedom of association referred to above allows sports organizations to de-
termine their internal organizational structure within the framework of civil law 
and to monitor compliance therewith. They are therefore at liberty to incorpo-
rate or not to incorporate the NADA Code into their internal organizational 
statutes. The Federal Government nevertheless makes its support of sport condi-
tional upon incorporation of the NADA Code into valid statutes of association. 
In 2007 the Federal Ministry of the Interior established a »Special Doping Test-
ing« (Sonderprüfung Doping) project group for all grant recipients (31 umbrella 
organizations, 20 Olympic support centers, and four federal performance cen-
ters) and came to the conclusion that in most cases legal incorporation of the 
NADA Code into sports organizations' statutes of association was still causing 
the organizations major problems (BMI 2007b, p. 15).13 Measures were there-
fore agreed to help rectify remaining deficiencies as promptly as possible. 
The situation of sports organizations that are not supported by the Federal Gov-
ernment is even less clear. In principle, even fitness studios could act in accord-
ance with the rules of the NADA Code, however no examples of this could be 
found. 
STATUTES OF ASSOCIATION OF SPORTS ORGANIZATIONS 2.1 
Sports organizations that observe the NADA Code have defined doping, and 
thus also gene doping, as behavior that is contrary to rules and consequently 
forbidden. The corresponding catalog of prohibitions must be incorporated into 
the organization's statutes and rules of association and/or employment con-
tracts, is applicable only within the organization concerned, and within the or-
                                            
12 The NADA Code also prohibits participation or attempted participation in competition 
during a ban imposed by an international or national sports association (NADA 2006b, 
p. 11). 
13 In a report commissioned by NADA, six federal umbrella associations of sports organi-
zations were checked for incorporation of the NADA Code into their statutes: »A provi-
sional finding is that only two associations have adequately incorporated the NADA 
Code into their statutes of association; the reporting experts consider that in the case of 
three associations an intention to incorporate the NADA Code is apparent but the actu-
al incorporation shows deficiencies; and according to the findings of the legal expert re-
port, in the case of one association incorporattion of the NADA Code is inadequate.« 
(BMI 2007b, p. 16) 
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ganization applies primarily to athletes but also to persons in the milieu of ath-
letes. 
(GENE) DOPING – RULE-VIOLATING BEHAVIOR BY AN ATHLETE 
As the doping violations specified in Table 5, along with the associated doping 
controls, impinge upon the individual rights of the athlete, they must be individ-
ually specified (Haas 2002, p. 20, from Simon et al. 2007, p. 18). It is not suffi-
cient to prohibit doping in general. The description of doping behavior associat-
ed with the substances included in the Prohibited List (Table 6, substance classes 
S1 to S9) should satisfy this requirement. Gene doping was included in the Pro-
hibited List as a precaution in the absence of concrete evidence of its use. As 
even among experts there is no consensus as to which techniques and methods 
belong in the category of gene doping (Section II.1), Simon et al. (2007, p. 18) 
question whether the term »gene doping« can be regarded as sufficiently precise. 
In the future gene doping will need to be more precisely defined in order to satis-
fy the principle of clarity and definiteness. However, this will not be possible 
until concrete substances and methods of abuse emerge (Section II.3). 
The principle of »no punishment without guilt« applies also to doping practices 
in sport. This means that the existence of objective and subjective elements of a 
rule violation must be demonstrated (Simon et al. 2007, p. 25). 
OBJECTIVE ELEMENTS OF RULE VIOLATION 
The sports organization bears the burden of proof that a prohibited substance, 
its metabolite, or marker is present in the body of the athlete, that a prohibited 
method has been used, or that some other violation of doping rules has been 
committed. Any form of evidence permitted by the code of civil procedure, in-
cluding an admission, is admissible (NADA 2006b, p. 12). In most instances 
proof is established on the basis of doping tests for which, according to the In-
ternational Standard for Testing (IST) (WADA 2004b), the required standard of 
proof is a sufficient degree of certainty (Section IV.2.2). 
Essentially the same procedure is likely to apply to the demonstration of gene 
doping. Where proof is to be obtained by means of a doping test and a doping 
sample therefore needs to be collected, the right of an association or federation 
to determine its internal organizational structure must generally be weighed 
against the individual rights of the athlete. When these two interests are weighed 
against each other, the proportionateness of an examination must be considered 
(Simon et al. 2007, p. 19 ff.). 
As a noninvasive intervention, collection of urine samples for the purpose of 
doping control is considered in sports law to satisfy the principle of proportion-
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ateness. A control procedure is standardized and fairly well established (Sec-
tion IV.2.3). However, it seems unlikely that gene doping could be detected by 
means of urine samples (Section III.1). As an invasive intervention, collection of 
blood samples is regarded as a substantial infringement of individual rights and 
according to most legal opinion in Germany satisfies the principle of propor-
tionateness only when urine samples are not sufficient for detection. In addition, 
the athlete must have freely consented or contractually obliged himself/herself to 
have blood samples taken. Specific procedures are described in the NADA Code 
(NADA 2006b, p. 59 ff.), but not in the International Standard for Testing 
(WADA 2004b) or the International Standard for Laboratories (WADA 2004c). 
As with urine samples, however, at present it seems rather unlikely that gene 
doping could be detected on the basis of individual blood samples (Section III.1). 
Should it turn out that gene doping can be detected only by means of tissue 
samples, a largely new legal field will arise, since collection of tissue samples is 
regarded as an even more invasive intervention than collection of blood samples. 
The legality of collecting tissue samples would have to be assessed on the basis 
of the same principles, i.e. a legitimate purpose, suitability, need, and propor-
tionateness would all have to be present. In addition, the accredited persons who 
were to collect the samples would have to possess the necessary technical quali-
fications and equipment. The site of sample collection would be subject to en-
tirely different requirements. Existing regional variations in terms of observance 
of standards would tend to become more pronounced, and control of the con-
trollers would become more important (Section IV.2.3). 
Along with the permissibility of sample collection (e.g. blood and tissue sam-
ples), the permissibility of novel specific diagnostic tests for the detection of gene 
doping will need to be considered at the appropriate time. Procedures and ana-
lytical techniques would be permissible if they provided proof that could stand 
up in court (Simon et al. 2007, p. 23). 
SUBJECTIVE ELEMENTS OF RULE VIOLATION 
Each identified violation must give rise to a sanctions procedure in which subjec-
tive guilt influences the severity of the sanction. Responsibility for this is borne 
either by the organizer of the competition or by the national association, which 
in this case refers the matter to an internal disciplinary organ or a court of arbi-
tration (NADA 2006b, p. 31). 
Where, on the basis of a doping test, a sports organization suspects with a 
sufficient degree of certainty that a violation of anti-doping rules has been 
committed, it is not required to provide proof of culpable behavior on the 
part of the athlete concerned. The athlete can rebut this reasonable suspicion 
by demonstrating how the prohibited substance came to be in his/her body 
and that the violation occurred without culpability on his/her part. The re-
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quired standard of proof is a high probability (überwiegende Wahrschein-
lichkeit) (NADA 2006b, pp. 12 and 34).14 
(GENE) DOPING: RULE-BREAKING BEHAVIOR BY PERSONS WHO FORM 
PART OF AN ATHLETE'S MILIEU 
Persons who form part of an athlete's milieu are classified as either athlete sup-
port personnel15 or other association employees. Only athlete support personnel 
are fully subject to the NADA Code, since this was designed exclusively for ques-
tions of sports law. Anti-doping regulations applicable to association employees 
should be agreed at the level of labor law (BMI 2007b, p. 27). 
Tampering or attempted tampering with any part of doping control, possession, 
trafficking, administration or attempted administration of doping agents, and 
any other participation in prohibited acts are prohibited both by the WADC and 
by the NADA Code (Table 5). It is true also of these violations that sports or-
ganizations bear the burden of proof, that evidence permitted by the code of 
civil procedure is admissible, and that the sports organization must demonstrate 
objective elements of a violation as well as subjective guilt. Where a sports or-
ganization succeeds on this basis in demonstrating culpable participation in a 
prohibited act, it can impose sanctions on persons who form part of an athlete's 
milieu in accordance with the law of associations (provided that the person con-
cerned is a member of the sports organization). 
No standardized procedures for demonstrating culpable participation in a pro-
hibited act exist. Some of the offenses specified in the NADA Code are also gov-
erned by public law (Section IV.3). The Federal Government stipulates that 
when a sports organization that it supports becomes aware of a positive analyti-
cal result in an athlete it must check for involvement of any athlete support per-
sonnel and where there is an initial suspicion of criminal behavior must inform 
the responsible public prosecutor's office of this fact (BMI 2007b, p. 78). 
DOPING CONTROL PROCEDURES 2.2 
Doping controls need to demonstrate the presence of a prohibited substance or 
its metabolites or markers in specimens of an athlete's bodily tissues or fluids, or 
the use of a prohibited substance or a prohibited method, with a sufficient de-
                                            
14 The Federal Supreme Court (Bundesgerichtshof) came to a similar decision: In order for 
prima facie evidence of doping to be overturned it is sufficient that there exist a serious 
possibility of an atypical sequence of events (Simon et al. 2007, S. 27). 
15 »Athlete support personnel: any coach, trainer, manager, agent, official, team member, 
or medical or paramedical personnel who works with or treats athletes who participate 
in or are preparing themselves for sports competitions.« (NADA 2006b, p. 46) 
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gree of certainty. They are the most important source of proof of violations of 
the NADA Code. From the perspective of sports law, a rebuttable presumption 
of a violation of anti-doping regulations must be established (objective element). 
This objective is linked to other objectives such as deterring athletes from doping 
and demonstrating to the public that sports organizations are fighting doping. 
According to the NADA Code, the doping control process comprises 
> organization of doping tests, 
> sample collection and handling, 
> laboratory analysis, and 
> hearings, appeals, and imposition of sanctions (NADA 2006b). 
Many parts of the sport-internal doping control process that are specified by the 
NADA Code and the WADA standards could in principle also detect gene dop-
ing – assuming that it is detectable at all (Section III). In some respects, however, 
the existing procedure based upon these codes is already coming up against its 
limits, or else gaps or needs for clarification are becoming apparent. 
Given the crucial role that doping testing and sanctions structures play also and 
particularly in gene doping, they are described in somewhat more detail in the 
following section. 
ORGANIZATION OF DOPING TESTS 
Doping tests were originally performed only during competitions, however from 
the second half of the 1980s out-of-competition testing was gradually added. In 
addition, tests to qualify an athlete to compete are now being performed occa-
sionally. In principle, in-competition testing and the financing thereof are the 
responsibility of competition organizers, whereas out-of-competition testing is 
the responsibility of sports associations. According to the WADC this responsi-
bility can be transferred to national anti-doping agencies. In Germany such a 
transfer of responsibility for out-of-competition testing has largely occurred in 
the case of sports organizations that have adopted the NADA Code. 
OUT-OF-COMPETITION TESTING 
The NADA Code and the WADA International Standard for Testing (IST) speci-
fy the procedure for out-of-competition testing in detail. According to the IST, 
out-of-competition testing should be performed only in a »testing pool« of elite 
athletes. Individual sports associations nominate their national- and internation-
al-level athletes for this testing pool. No criteria for identifying such elite athletes 
on an internationally uniform basis have been established. As a result, there are 
substantial international differences in this regard. 
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Along with a need to increase the number of doping tests performed, other ma-
jor challenges are to eliminate errors in the performance of tests and to increase 
the efficiency of testing. The IST states that in order to be able to test efficiently 
for doping, national anti-doping agencies need to develop a test distribution plan 
that takes into account at least the potential doping risk and possible doping 
patterns in each type of sport based among other things on the physical demands 
of the particular sport, the possible performance-enhancing effects of doping, 
and available research on doping trends (WADA 2004b, p. 13). 
In order to comply with this requirement, NADA has announced its intention of 
introducing »intelligent« doping testing in 2008. To this end athletes are to be 
divided into the following groups and tested more intensively during periods of 
high doping risk as indicated by their competition plans (NADA 2007b): 
> National testing pool (NTP): generally A-squad athletes16, national A teams, 
athletes in the international testing pool, and members of the top team for the 
Olympics. According to NADA this group includes about 1500 athletes, in 
whom a total of 6000 tests are to be performed in 2008. NTP athletes are 
subdivided into three risk groups. Athletes in the highest risk group are each 
to undergo five urine tests and two blood tests, those in the second risk group 
four urine tests and one blood test, and those in the third risk group one urine 
test (BMI 2007b, p. 105 ff.).17 
> General testing pool (Allgemeiner Testpool, ATP): From 2008 this pool is to 
be further subdivided into ATP I (B-squad athletes of Olympic associations 
and A-squad athletes of non-Olympic associations), comprising about 
2000 athletes, who are to undergo a total of 1500 doping tests in 2008, and 
ATP II (C-, D/C-, and D-squad athletes), comprising about 4500 to 
5500 athletes, who are likewise to undergo a total of 1500 doping tests in 2008 
(BMI 2007b, pp. 105 ff.). 
In order to permit out-of-competition testing of athletes with as little notice as 
possible, athletes' whereabouts must be known. The IST states that athletes are 
obliged to file their whereabouts information and keep this information current 
at all times. NTP athletes have a 24-hour deadline for notification of change of 
whereabouts, ATP I athletes a 72-hour deadline, and ATP II athletes no such 
deadline (BMI 2007b, pp. 105 ff.). The imposition of these deadlines for notifi-
cation presupposes a forwarding of personal data by athletes that can be regu-
lated only by means of a voluntary undertaking by the individual concerned. 
Failure to meet these deadlines for notification constitutes a doping violation in 
accordance with the WADC and the NADA Code (Table 5). 
                                            
16 Each sports association assigns athletes to a particular squad on an individual basis and 
exclusively on the basis of performance figures. 
17 The factual bases on which identification of periods of high doping risk and risk groups 
of athletes are based are not specified. 
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At least for the national testing pool, NADA is at present switching from its 
own data collection system (»NADA Xtra.NET«) to the database manage-
ment tool developed by WADA (»ADAMS«). Discussions are being held about 
compliance with nationally applicable requirements for data protection. No 
more precise information about this is available at present. 
NADA's new system of intelligent out-of-competition testing can be expected 
to close a number of loopholes that have existed up to now. As before, how-
ever, participation in this system is basically voluntary, however nomination for 
the 2008 national Olympic team presupposes participation. Federal support for 
sport, which flows via the sports associations, is likewise tied to participation in 
this out-of-competition testing system. Nevertheless, this procedure does not 
extend to all branches of sport. Most sports organizations that are not members 
of the German Olympic Sports Confederation (DOSB) and/or that fall within the 
realm of professional sport do not participate. 
The need for specific control concepts, efficient doping tests, and concepts for 
monitoring will become greater as detection of gene doping drives the cost of 
testing even higher. One major challenge will be how to include special risk 
groups for gene doping in the system (Section V.1). 
IN-COMPETITION TESTING 
Each organizer (mostly national sports associations), on the basis of its individu-
al position, experiences, and financial possibilities, independently determines the 
extent and type of in-competition testing. The extent of testing ranges from 
complete absence of in-competition testing (a few professional sports events, but 
also most regional competitions) to full testing of prizewinners and random test-
ing of other participating athletes. Testing is generally performed immediately 
after competitions and in some cases also before competitions (in which case it 
overlaps with out-of-competition testing). As with out-of-competition testing, 
the general structure of testing and the testing procedure can be specified by ref-
erence to the NADA Code and the IST, however these documents make no rec-
ommendations as to the extent of testing18 or specific substances to be tested for. 
Though the organizer is in principle responsible for the planning and perfor-
mance of testing, WADA and NADA offer assistance internationally and in 
Germany, respectively. The Federal Ministry of the Interior's »Special Doping 
Testing« (Sonderprüfung Doping) project group already recommends that in the 
present situation testing should be entrusted to NADA (BMI 2007b, p. 8). NA-
DA itself states that in the medium term it would be able to take on this respon-
sibility (BMI 2007b, p. 42). Joint development of concepts for in-competition 
                                            
18 As organizers generally allocate funds for in-competition testing on an annual basis, 
increased costs per test generally lead to a reduction in the extent of testing. This has al-
ready had the result that testing can only be performed at the national level. 
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testing by competition organizers and anti-doping organizations would also be 
beneficial in relation to possible gene doping. 
In a few cases, organizers of endurance sports competitions make permission to 
participate conditional upon compliance with norms for certain performance-
relevant parameters – such as the hematocrit or hemoglobin19 level of the blood 
– that can be determined at relatively low cost in all competition entrants. This 
approach is technically and analytically simpler than the use of tests that must 
provide evidence of doping that will stand up in court. It is not intended to de-
tect a multiplicity of possibly used prohibited substances or methods. If the val-
ues obtained are marginally above the specified limit, the athlete is not allowed 
to participate but is not at risk of any other sanctions. Temporary »protective 
bans« of this kind are intended to protect the athlete from possible health 
damage and the competition from a loss of credibility. In conjunction with oth-
er methods, this approach could prove useful for combating new forms of dop-
ing. 
Even today, any doping test that can demonstrate doping violations with a satis-
factory degree of certainty is logistically and analytically complex and therefore 
expensive. The planning of doping controls is rendered more complex by the 
need to take account of each athlete's pre-competition training plans and by 
the limited time frame available for detection of the various substances. In the 
event that individual tests cease to be sufficient by themselves for the detection 
of gene doping, but instead more or less regular measurement of yet-to-be-
determined performance-relevant parameters becomes necessary, the level of 
complexity will increase even further. It is doubtful whether all countries will be 
willing or able to go down this road. If they are not, national differences in 
terms of control of doping violations will become even more pronounced than 
they already are. 
COLLECTION AND HANDLING OF DOPING SAMPLES 
A sample as per the WADC is any biological material that is provided by or col-
lected from athletes for the purposes of doping control. In practice, urine and 
blood samples are virtually the only types of sample used at present. 
According to the WADC, only accredited persons or companies may perform 
doping tests. In Germany the organizers of national competitions often accredit 
these persons or companies themselves. To date very little use has been made of 
the possibility of having the tests performed by NADA (BMI 2007b, p. 40 ff.). 
The WADC stipulates that in the case of out-of-competition testing the planning 
                                            
19 Hematocrit: red blood cells as a proportion of total blood volume; hemoglobin level: 
the amount of the oxygen-carrying molecule hemoglobin as a proportion of total blood 
volume. 
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of random testing must be kept organizationally and legally separate from the 
collection of samples. 
In Germany legally correct sample collection in the world of sport is at present 
offered essentially by only one independent, specialized company. This company 
performs this service both in Germany and abroad and at present employs about 
70 freelance anti-doping testers (PWC 2008). NADA uses this company exclu-
sively. This market segment is similarly uncomplicated worldwide. In each coun-
try there is a more or less large group of testers operating in a variety of corpo-
rate structures. There appears to be some international cooperation. Quality 
assurance can be based upon international certification 9001.2000 of the Inter-
national Organization for Standardization (ISO), however this is not an absolute 
requirement at present. 
Anti-doping testers who have been working for many years assert that the quali-
ty of sample collection has improved greatly over the past 20 years (Steiner 
2007; Teufel 2006). Despite this, not all athletes are tested with the same degree 
of precision either in Germany or abroad, and in many places compliance with 
standards is still inadequate. Were consideration to be given to obtaining blood 
profiles or genetic profiles of individual athletes as part of possible testing for 
gene doping, the demands placed upon testers would most definitely increase. 
They would then need medical training and their equipment would need to be 
adapted to perform an increased number of invasive interventions. 
TRANSPORT OF DOPING SAMPLES 
Following correct sample collection, the biological material is divided into two 
samples of equal size (A- and B-sample), sealed, anonymized, encoded, and la-
beled with the address of the entity commissioning the test. According to the 
NADA Code, details of the transport of urine samples need to be recorded only 
formally at present, and no time or temperature standards are stipulated (NADA 
2006b, p. 52). According to Kindermann/Steinacker (2007), as a result of the pre-
sent transport arrangements »in more than 50 percent of all urine samples no 
hormone at all is detectable, i.e. the samples are unsuitable for their purpose.« 
Even now they require cold transport and storage. In the case of blood samples 
this is stipulated by the NADA Code (NADA 2006b, p. 59). 
The transport and storage requirements depend upon the biological material and 
the substance to be detected. Where a substance is to be detected via RNA or 
DNA components, which are more stable than many substances and their me-
tabolites, no additional transport or storage requirements are expected. Howev-
er, precise statements cannot be made until detection methods have been devel-
oped (Section III). 
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LABORATORY ANALYSIS 
The WADC stipulates that the laboratory analysis must also be kept organiza-
tionally and legally separate from the planning of random testing and the collec-
tion of samples. The result of the laboratory analysis of the bodily tissue or 
bodily fluid sample is the most important, and normally also the only, item of 
evidence that supports the presumption of a violation of a doping prohibition. 
For this reason the requirements that apply to the various laboratories are stipu-
lated by means of a special standard and the analytical procedures are precisely 
defined. 
In order to perform detection procedures, laboratories require a special WADA 
accreditation. The accreditation process is stipulated via the standard for doping 
laboratories (WADA 2004c). Not all of the 34 laboratories that are accredited 
worldwide (Section IV.2.3) are technically equipped to perform all procedures. 
For the detection of gene doping the requirements placed on laboratories will 
become even more demanding. In principle, other, unaccredited laboratories can 
perform specific, legally sound analyses in accordance with the ISO certification 
both neutrally and correctly. Without accreditation, however, they may be 
commissioned to perform tests to detect doping only in countries that have no 
accredited laboratory. The question of whether only WADA-accredited labora-
tories or also specifically ISO-certified laboratories will be allowed to perform 
gene doping tests will need to be decided at the appropriate time. 
Laboratory analyses that can provide evidence of a particular doping violation 
that will stand up in court are based on standardized and scientifically tested 
analytical procedures that have been authorized by WADA (WADA 2004a, 
p. 19). The same will be true of tests for gene doping (Section III). In order not to 
facilitate the development of doping strategies that take account of the detection 
possibilities of tests, the descriptions of the various analytical procedures that are 
used have not been released into the public domain. This policy of secrecy means 
that accredited laboratories enjoy a monopoly of information. Many laborato-
ries that perform standardized doping analyses simultaneously conduct research 
into new methods of detection. The greater the monopoly of information, the 
higher is the value of the information and the greater are the possibilities for, 
and risk of, abuse. Kekulé (2007, p. 25 ff.) expresses the view that restriction of 
access to certain information is unlikely to prevent the spread of specialized 
knowledge. Rather, restriction of access creates possibilities for the development 
of lucrative black markets in which doping networks (e.g. such as that described 
in Donati [2007]) act as buyers and distributors. 
In response to this situation WADA has developed a code of ethics for doping 
control laboratories on the basis of which directors and employees undertake 
not to pass on to outsiders any information that could facilitate doping (WADA 
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2004c, p. 56). The extent to which this code of ethics and monitoring of labora-
tories by WADA can prevent possible abuse of knowledge worldwide is an open 
question. A possible – though also problematic – alternative would be transpar-
ent description of test procedures. This too could remove the basis for the black 
market in information so that individual employees of laboratories would have 
no incentive to pass on their knowledge illegally. In this way the principle of the 
transparent athlete would be extended into a principle of the transparent labora-
tory. 
According to the NADA Code (NADA, 2006b, p. 45), samples of bodily tissues 
or bodily fluids that are collected on instructions from NADA are the property 
of NADA. The sample material may, and all associated documents must, be re-
tained until the limitation time of eight years (even in the case of tests that had a 
negative result). NADA has the right to examine these samples again. The ques-
tion of ownership and rights in relation to samples that were not collected on 
instructions from NADA (in-competition tests) was not considered in the present 
TAB project, however this question will need to be clarified at some time in the 
future. As far as gene doping is concerned, the prospect of analysis at a later 
time could have a deterrent effect, since it would mean that »abusers« could be 
retrospectively exposed and penalized in a few years' time on the basis of pro-
hibitions that are in place today. 
In Germany the analytical laboratory reports any positive test results (results 
that justify a suspicion of doping actions) obtained in out-of-competition testing 
only to NADA, in its capacity as the commissioner of the test. NADA then for-
wards this information to the sports association. In the case of in-competition 
testing the competition organizer and NADA are informed. 
THERAPEUTIC USE EXEMPTIONS 
Before the sports association concerned comes to a decision about sanctions, 
consideration is given to whether a therapeutic use exemption (TUE) is present. 
TUEs permit athletes and their treating physicians to use prohibited agents and 
methods for the treatment of illness. TUEs are an example of the growing com-
plexity of the doping question. This complexity has now reached the point at 
which 
> WADA has developed its own standard containing criteria for assessment, 
forwarding of information, composition of the group of physicians, and the 
recognition procedure, and 
> only accredited persons (TUE Committee) can now make decisions on the 
issue of a TUE. 
The number of athletes in Germany with a TUE is growing. In 2004 a total of 
2462 athletes in Germany had a TUE, in 2005 the number was 2880, and in 
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2006 3513 (NADA 2005, 2006a and 2007a). Without going into the details of 
this complex subject here, it is worth pointing out that TUEs illustrate the fact 
that the increasing number of possibilities offered by modern medicine make it 
increasingly difficult to define the limits of what is permissible, express these 
limits in terms of procedural norms, and implement such norms in a practicable 
way. 
In general, TUEs can be issued only for licensed substances and methods. A sub-
stance or method the abuse of which is classified as gene doping (Section II) 
cannot be the subject of a TUE unless it is licensed for use in the country con-
cerned. Especially in the field of anti-aging therapies, however, problems of dif-
ferentiation may arise in relation to licensing (Sections II.4.2 and V.2.2). 
DECISION-MAKING AND IMPOSITION OF SANCTIONS 
Where a positive analytical result is obtained and there is no TUE, the commis-
sioner of the test checks the correctness of the testing procedure; the athlete is 
then informed and has the opportunity to respond in writing. Where the positive 
analytical result was obtained in an out-of-competition test, the athlete can be 
suspended (temporarily barred from competing). A positive analytical result ob-
tained in an in-competition test leads automatically to disqualification and an-
nulment of competition results. The athlete has the right to have the B-sample 
analyzed in order to rebut the result of the analysis of the A-sample (NADA 
2006b, p. 27 ff.). Where there is no TUE, analysis of the B-sample confirms the 
result of analysis of the A-sample, or the athlete opts not to have the B-sample 
analyzed, a process is initiated. In Germany responsibility for this lies with the 
relevant national sports association or the competition organizer, provided that 
the latter has not assigned this task to NADA (NADA 2006b, p. 26). As from 
2008 it will also be possible to commission the German Sports Arbitration Tri-
bunal (Sportschiedsgericht), operated by the Cologne-based German Institution 
of Arbitration (Deutsche Institution für Schiedsgerichtsbarkeit e.V), to under-
take this result management. 
A hearing is then held by the responsible sports law tribunal of the sports asso-
ciation concerned. At this hearing the affected athlete has the opportunity to use 
other individual means of demonstrating the occurrence of a different sequence 
of events and can explain how the prohibited substance came to enter his/her 
body. If he/she is unable to rebut the presumption that he/she committed the 
violation at least as a result of negligence, a sanction is imposed – in Germany 
on the basis of the NADA Code. A synopsis of the catalog of measures specified 
in the NADA Code, starting with annulment of results and disqualification from 
competing, is shown in Table 7. 
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TABLE 7 VIOLATIONS AND RANGE OF SANCTIONS SPECIFIED IN THE NADA CODE 






















1) Presence of a pro-
hibited substance or 
its metabolites or 
markers in the dop-
ing sample 













































2) Use or attempted 
use of prohibited 
substance(s) or 
method(s) 
culpable two years lifelong   





3) Refusal or failure to 
submit to sample 
collection 
culpable two years lifelong   
5) Tampering or at-
tempted tampering 











































7) Trafficking in pro-
hibited substance(s) 
or method(s) 




8) Administration or 
attempted admin-
istration of prohibit-
ed substance(s) or 
method(s) or other 
complicity 




Ineligibility of an athlete means that he/she is barred for the specified period of time from 
participating in any capacity in any competition or activity (other than preventive or reha-
bilitation measures) of any national or international sports organization.  
Ineligibility of athlete support personnel means that they suffer withdrawal of accredita-
tion, i.e. are prohibited from participating in any (supporting) capacity in any competition 
or performing any official function for the sports association or federation or the athlete. 
Athlete support personnel are referred to in the NADA Code only in connection with traf-
ficking, administration or attempted administration of prohibited substances, or other 
complicity. 
Source: NADA 2006b, p. 35 ff. 
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The catalog applies also to doping violations committed by persons in the athlete's 
milieu. Only a partially regulated procedure is available for detecting doping vio-
lations by persons in the athlete's milieu. This states that whenever an athlete is 
under reasonable suspicion a check must be made for involvement of any persons 
in the athlete's milieu. Where there is sufficient suspicion that an offense against 
public law has been committed, the sports association must inform the public 
prosecutor's office of this fact (NADA 2006b, p. 37). 
Based on the present legal situation, this catalog of measures is fully applicable 
also to gene doping, assuming that it can be detected. As the effect of some gene 
doping techniques is presumed to be very long-lasting, account must be taken 
of the fact that the effect could persist beyond a period of ineligibility. Overall 
it must be expected that with gene doping the entire doping control process 
(both objective elements of a violation and subjective guilt, e.g. of an athlete) 
will impose greater requirements on sports jurisdiction.20 
LIMITS TO THE DOPING CONTROL PROCESS 2.3 
The WADC and the NADA Code contain the rules for doping control processes 
at the international and German levels, respectively. Each sports organization is 
responsible for incorporating these rules into its internal regulations and for im-
plementing these. The extent to which this has occurred varies between and 
within countries. According to the WADC, independent national anti-doping 
organizations (NADOs) should play a leading role in implementing the rules in 
their respective countries. Of the 202 countries that presently participate in the 
Olympic Games, 68 have an NADO that recognizes the WADC and 19 have an 
NADO that does not recognize the WADC. In Germany, NADA states that by 
2008 it will be able to offer an extensive range of services, especially with regard 
to out-of-competition testing as per the IST. 
Testing of doping samples should be performed only in accredited analytical 
laboratories. In 2007 there were 34 accredited laboratories worldwide, of which 
20 were located in Europe, five in Asia, three in North America, three in Central 
and South America, two in Africa, and one in Australia (WADA 2007). 
On the basis of the data published to date it is scarcely possible to draw compar-
isons (in terms of activity and effectiveness) even between countries that have an 
independent NADO and recognize the WADC. Isolated data, e.g. for 1997 (dsj 
                                            
20 Expensive lawsuits could occur. This could become a problem especially for sports as-
sociations with a small budget. WADA already refers to this problem in relation to con-
ventional doping (WADA 2004a, p. 11). 
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2004) and for 2000 (KPMG 2002), have been compared.21 Because of a lack of 
background information, however, such comparisons are of very limited value. 
And because of the different ways in which reports are prepared in different 
countries, even detailed figures on doping are generally not directly comparable. 
Based on Striegel (2007) – and with reservations – all that can be said is that 
testing is performed about three times more frequently in Germany and the 
United Kingdom than in the USA and 2.5 times more frequently in Switzerland 
than in Germany (in relation to the population of these countries). 
Since NADA commenced its work in 2003 it has issued an annual Dopingbilanz 
(doping report). This relates the number of tests performed to the number of 
rebuttable reasonable presumptions of a violation of anti-doping regulations 
(based on doping tests, i.e. A-samples that tested positive and other violations 
such as failure to submit to sample collection).22 In a proportion of the A-
samples that tested positive there was a TUE. In 2004 this was true of 22 cases, 
equivalent to 24% of the reasonable presumptions of a doping violation (out-of-
competition and in-competition testing considered together). The corresponding 
figures for 2005 and 2006 were 40 cases (37%) and 42 cases (42%), respectively 
(NADA 2005, 2006a, and 2007a). 
Table 8 provides a summary of the tests analyzed by the two accredited labora-
tories in Germany in the years 2004 to 2006 and the sanctionable results of 
these tests (positive A-sample and violation of doping control rules) separately 
for out-of-competition and in-competition testing. 
Though it is generally not doubted that doping is started in the out-of-
competition phase in order to achieve a performance-enhancing effect during 
competition, the present control process cannot detect out-of-competition dop-
ing in the same way as it can detect in-competition doping. The proportion of 
positive A-samples found in out-of-competition tests was between 0.25% and 
0.4%, compared to between 1.2% and 1.3% in in-competition tests. If these 
published annual doping reports are complete, four to five times as many posi-
tive A-samples are found in in-competition tests as in out-of-competition tests. 
There are many possible reasons for this that are not apparent from the data. It 
remains to be seen whether and to what extent the NADA concept of intelligent 
out-of-competition testing will alter this situation. 
                                            
21 According to dsj (Deutsche Sportjugend [»German Sports Youth«]) (dsj 2004, p. 15), in 
1997 the number of positive doping samples as a proportion of all samples varied from 
more than 4% (doping laboratories in Montreal, Ghent, and Paris) to 0.5% and less 
(doping laboratories in Oslo, Seoul, Kreischa, and Rome). Data published by the ac-
countancy consultancy KPMG (KPMG 2002, p. 85) lie within the same range (France 
3.7%, United Kingdom 2.5%, Denmark 0.6%). 
22 In accordance with the NADA recommendation, the 2003 doping report is not used as 
a basis for comparison, since it was significantly influenced by changes in the legal 
framework that resulted from introduction of the WADC (NADA 2005) 
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TABLE 8 DOPING TESTS AND SANCTIONABLE RESULTS 
 REPORTED BY NADA FROM 2004 TO 2006 
Ye
ar
 Organization Out-of-competition tests In-competition tests Other* 
Number A-sample 
positive 






NADA 4282 9 (0.2%) 2 (0.05%) – – 
 WADA 64 – – – – 
Assoc.Germany – – – – 53 (1.5%) 
 Abroad 71 – – 898** 5 (0.6%) 




NADA 4482 12 (0.27%) 6 (0.13%) – –  
WADA 197 – – – – 
Assoc. Germany – – – 3839 49 (1.3%) 
 Abroad – – – 153 – 




NADA 4415 10 (0.2%) – – –  
WADA 219 – – – – 
Assoc. Germany 102 2 (2.0%) –
3679 44 (1.2%)  Abroad – – – 
Total 4736 12 (0.3%) – 3679 44 (1.2%) 1 (2%) 
* Reported violations which according to annual doping reports could not be assigned either 
to out-of-competition testing or to in-competition testing. 
** International associations (764) and the International Olympic Committee (134). 
Out-of-competition testing was performed on German athletes both in Germany and abroad; 
in-competition testing was performed in Germany and on German athletes abroad (Olympic 
Games) 
Source: NADA annual doping reports (NADA 2005, 2006a, and 2007a) 
It cannot, however, be concluded on the basis of the apparently small number of 
positive doping tests that doping is only a minor problem overall.23 For one 
thing, only a disappearingly small proportion of competitive athletes are ever 
tested. In Germany each sports association independently determines the scope 
                                            
23 In 2006 the US track-and-field athlete Marion Jones admitted in court that she had 
doped herself, yet 160 doping tests had failed to detect this. According to triathlete Faris 
Al-Sultan, »People only get caught when there's a raid on somewhere. If anybody gets 
caught in a urine test, it's mostly juniors or people from fringe sports who don't have 
enough money to dope themselves professionally.« (reported in Berliner Zeitung, De-
cember 12, 2006) 
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of in-competition testing in its sport. In practice, in-competition testing is largely 
limited to the national championship level. For its part, out-of-competition test-
ing is largely limited to the national testing pool and – because of limited re-
sources – occurs far less at the level of the general testing pool. As a result, up-
and-coming athletes, even those performing at an above-average level, remain 
outside of the existing testing and sanctions structures for a very long time. For 
another thing, like all diagnostic procedures, analytical tests to detect doping do 
not correctly identify all positive (doping) cases as such. As mentioned in Section 
IV.2.2, Kindermann/Steinacker (2007) believe that about half of all doping sam-
ples are unusable because of inadequate cooling during transport to the labora-
tory. By contrast with diagnostic tests used for medical purposes, the sensitivity 
and specificity of the doping tests that are used are not published. It is therefore 
not possible to estimate the frequency of doping on the basis of the presently 
available information. 
The few empirical studies that have been performed (by means of anonymous or 
indirect questioning) on the frequency of doping in competitive sport have 
thrown up sobering figures on the extent of doping in elite sport. In an indirect 
survey24 of more than 1000 Italian competitive athletes and more than 
200 trainers and physicians, Scarpino et al. (1990) found the rate of regular con-
sumption of amphetamines or anabolic steroids to be 10% and that of blood 
doping to be 7%. Rates for occasional doping were two to three times higher, 
i.e. between 20% and 30%. Pitsch et al. (2005), using an anonymous internet 
survey of 448 squad athletes and allowing for the likelihood of false responses, 
estimated a doping rate of 26% (plus 22% probably false responses and an es-
timated 52% of athletes who genuinely had not doped themselves at any time in 
their sports career). There were substantial differences between men and women 
and between different sports. In 2007, using a model it had developed for de-
termining the rate of blood doping, a team from the Swiss Antidoping Laborato-
ry estimated cycling to be 75% doping-free. This, it was concluded, made 2007 
one of the cleanest years for a long time (Geisser 2007). By comparison, accord-
ing to their own estimate 80% of competitive cyclists took EPO in 1996. Revela-
tions about German cyclists in 2007 also suggest that EPO doping is fairly wide-
spread. Doping tests for EPO are shown separately in NADA's annual doping 
reports. A total of 698 tests were performed in 2004, 800 in 2005, and as many 
as 900 in 2006. Despite assumptions about the use of EPO for doping purposes, 
none of these tests detected EPO. 
Moreover, abuse of various new EPO agents which since the expiry of patent 
protection in 2007 have been licensable as medicines, and of other substances 
such as growth hormone, cannot even be detected at present (Donati 2007). 
                                            
24 The question was worded: »How widespread do you consider doping to be in your 
sporting environment?«  
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Bearing in mind the original objective of doping tests (Section IV.2), it must be 
reaffirmed that in practice, doping tests remain the most important, and in many 
cases the only, source of evidence that can justify a rebuttable presumption of an 
anti-doping rule violation. In some cases they are able to prove the existence of 
an anti-doping rule violation and a legally valid sanction can be imposed. On the 
other hand, the converse conclusion, namely that all other athletes are doping-
free, cannot be drawn. In view of the relatively low rate of detection, it must also 
be doubted whether the secondary objectives of testing, namely to deter athletes 
from doping themselves and to show the public that sports organizations are 
fighting doping, are achievable. 
(PARTIAL) LEGALIZATION – AN ALTERNATIVE? 
Given also the assumed, though so far neither proven nor disproven, discrepancy 
between the actual rate of doping and the number of proven (and penalized) 
cases of doping, there are more or less regular calls for (partial) legalization of 
doping. Other arguments put forward in favor of this approach are that, as with 
drug abuse, some health risks may be made greater by criminalization than by 
controlled issue of substances, and arguments based on ethical principles such as 
(re)establishment of a »level playing field«. In relation to gene doping, authors 
such as Miah (2004) and Savulescu et al. (2004) have argued that athletes with 
»better« genes enjoy an unfair advantage in competitive sports. Though this ad-
vantage may not directly ensure victory, there can be little doubt that it increases 
the likelihood of victory. Savulescu et al. (2004) therefore argue that instead of 
performing doping tests in order to detect abuse of a multitude of substances 
and methods, we should look for quantifiable evidence that an athlete is jeop-
ardizing his/her health by ingesting substances. It may prove possible to quantify 
and assess the risk to an athlete's health in very approximate terms on the basis 
of the athlete's hematocrit level, however it remains to be seen how this can be 
achieved with other forms of doping (e.g. those aimed at strengthening skeletal 
muscle). 
Given the existence and broad recognition of the WADC, however, this ap-
proach is decisively rejected on both ethical and political grounds based on dif-
ferent interpretations of similar considerations to those used in favor of legaliza-
tion. According to this view, athletes who reject doping would be disadvantaged, 
as their likelihood of winning would be reduced (Knoeppfler/Albrecht 2007, 
p. 28). As a result, athletes who rejected doping in principle would have no choice 
but to dope themselves in order to give themselves an equal chance, and the prin-
ciple of respecting the health of one's opponents would be rendered obsolete. 
Legalization of doping would deprive athletes of the possibility of »combining 
equality of opportunity in play with health in competitive sport« (Knoeppfler/ 
Albrecht 2007, p. 28). 
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Even assuming it could be confined to elite sport, legalization of doping would 
transform the entire system of sport and rob sport of any value content or social 
function. In the presence of unrestricted doping, the sport-following public 
would, to an even greater extent than it already does, attribute sporting success 
less to athletes and their achievements than to the scientific apparatus that sup-
ports them: »Legalization of doping would largely rob successful athletes of 
their personal aura.« (Bette/Schimank 2006b, p. 366) Furthermore, a broad new 
field of experimentation would be opened up, sport would become an ongoing 
study in which athletes, as the subjects, would be subjected to high risks. Medi-
cal ethics and the physicians who are beholden to it would be unlikely to be able 
to control this development. Eventually the role model function that elite sport 
fulfils for children's sport, youth sport, and recreational sport in general would be 
lost. Since it is certain that if doping were legalized few parents would encourage 
their children to embark upon a career in competitive sport, the basis for re-
cruitment in competitive sport would be lost. Finally, legalization of doping 
would not only undermine the »credibility of real competition as compared to a 
choreographed show« and the possibility of »meaningful identification with the 
athlete«, but also remove the central structural pillars of the system of competi-
tive sport (Franke 2007, p. 16). 
For all the above reasons and notwithstanding the deficiencies of the present 
system, there is no real alternative to the prohibition of doping and a system of 
doping tests and sanctions, and the only viable pathway is that of continuous 
improvement of the effectiveness of testing. In addition to the system of testing 
and sanctions implemented within the world of sport, however, there is a need 
for many other entities to undertake complementary and supportive anti-doping 
measures. A factually and normatively based discussion of the emphasis given to 
ever greater development of control structures and the effectiveness of these 
compared to other anti-doping measures focused not just on individual doping 
actions of athletes needs to be held, and not just within the world of organized 
sport. 
OTHER APPROACHES TO DOPING CONTROL 2.4 
In 2007 the DOSB introduced a declaration/undertaking by physicians, veterinari-
ans, physiotherapists, trainers, and athlete support personnel. By signing this 
the person asserts that he/she has »at no time passed on to, made available to, 
prescribed for, or administered to athletes substances, or used methods, that 
violate currently applicable anti-doping regulations«. A violation can have the 
following consequences: withdrawal of accreditation, demand for reimburse-
ment of dispatch costs, payment of up to 10,000 euros to the NADA-supporting 
association, and reporting of an offense as per the German Drug Law 
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(Arzneimittelgesetz, AMG) (BMI 2007b, p. 79 ff.). This declaration covers gene 
doping. In conjunction with the long retention period for doping samples, it 
opens up the possibility of applying sanctions at some time in the future to dop-
ing violations that are undetectable at present but may become detectable later. 
In principle, a similar, organization-internal declaration could be made by ath-
letes. Were such a declaration to be modeled on the NADA Code, it would 
likewise cover gene doping. Violations would result in imposition of sanctions 
under service law. The German Sports Foundation (Stiftung Deutsche Sporthilfe) 
likewise makes its support conditional upon the making of a declaration where-
by each athlete undertakes never to dope himself/herself (Stiftung Deutsche 
Sporthilfe 2007). In the event of a violation any financial support provided over 
the past two years must be repaid. Individual sports associations such as the In-
ternational Cycling Union (Union Cycliste Internationale, UCI) and the German 
Ski Association (Deutsche Skiverband, DSV) are presently developing similar 
approaches and are making team membership and participation in competitions 
conditional upon the making of such a declaration. Franke (2007, p. 30) is also 
in favor of a voluntary undertaking by competitive athletes that commits them 
in principle not to jeopardize the specialized world of competitive sport and that 
can be developed from a behavioral maxim into a set of guidelines. 
However, the potential effectiveness of such measures remains linked to that of 
the doping control system, since the imposition of sanctions beyond those of the 
World Anti-Doping Code presupposes proof of doping that will stand up in 
court. 
A few anti-doping organizations and sports organizations have announced their 
intention of performing regular doping tests on elite athletes in order to issue 
athletes with »athlete passports« or »biological passports« on the basis of the 
results obtained. Both the technical and the procedural feasibility of such ap-
proaches are currently being investigated.25 The use of »intelligent« biomonitor-
ing as a means of detecting gene doping could be linked to such developments 
(Section III.2). 
(GENE) DOPING IN THE CONTEXT OF PUBLIC LAW 3. 
In Germany doping (and thus gene doping) is not a defined term in public law 
(BMI 2007a). A variety of legal norms deal both with the topic of doping in 
general and – by recognition of international conventions and reference to ap-
propriate lists – with the topic of gene doping as a special form of doping that 
                                            
25 The UCI announced that in 2008 it would introduce a biological passport as a precon-
dition for participation in competitions, but has now put this off until 2009. 
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may arise in the future. In the following, a description of the legal situation in 
Germany is therefore preceded by a summary of relevant international agree-
ments that have been incorporated into German law. 
INTERNATIONAL AGREEMENTS 3.1 
ANTI-DOPING CONVENTION OF THE COUNCIL OF EUROPE 
The parties to this convention dated November 16, 1989 undertook »with a 
view to the reduction and eventual elimination of doping in sport, within the 
limits of their respective constitutional provisions, to take the steps necessary to 
apply the provisions of this Convention.« (Council of Europe 1989). 
In Article 2.1 of the Convention, doping in sport is defined as »the administra-
tion to sportsmen or sportswomen, or the use by them, of pharmacological clas-
ses of doping agents or doping methods«. Article 2.1.c defines sportsmen and 
sportswomen as »those persons who participate regularly in organized sports 
activities«. The Council of Europe thus defines doping as a behavior that occurs 
only in competitive sport. In Article 2.1.b pharmacological classes of doping 
agents or doping methods are defined as »those classes of doping agents or dop-
ing methods banned by the relevant international sports organizations and ap-
pearing in lists that have been approved by the monitoring group under the 
terms of Article 11.1.b« (Council of Europe 1989). This list has now become the 
WADA Prohibited List. The most recent amendment to the Appendix was in-
corporated into German law in June 2007 (Bundesgesetzblatt 2007 Part II 
No. 18, p. 812 ff.). This covers gene doping. 
ADDITIONAL PROTOCOL TO THE ANTI-DOPING CONVENTION OF THE COUN-
CIL OF EUROPE 
The Additional Protocol of September 12, 2002 was incorporated into German 
law in 2007. This protocol forms the legal basis for performing doping controls 
in accordance with the WADC in the territory of other contracting parties. Re-
garding doping definitions, it refers to the Anti-Doping Convention of the 
Council of Europe. 
UNESCO CONVENTION AGAINST DOPING IN SPORT 
The UNESCO Convention of October 19, 2005 was likewise incorporated into 
German law in 2007. This obliges Germany to enshrine the regulations and 
principles of the WADC in corresponding laws. In this way the basis for a uni-
form worldwide approach to doping is meant to be established. The Convention 
is based partly on the WADC. As gene doping is covered by the Prohibited List 
to which the WADC refers, it is also prohibited by the UNESCO Convention. 
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GERMAN LAW 3.2 
Within the framework of constitutional law referred to above, the German Fed-
eral Government can take legal measures to fight doping more effectively. In the 
past the possibilities that exist in this regard have been a matter of controversy.26 
The present outcome of these debates is the Law to Improve the Fight against 
Doping in Sport (Gesetz zur Verbesserung der Bekämpfung des Dopings im 
Sport), which came into effect on November 1, 2007 (Bundesgesetzblatt 2007 
Part I No. 54, p. 2510 ff.). 
LAW TO IMPROVE THE FIGHT AGAINST DOPING IN SPORT 
The law envisages an amendment of the German Drug Law (Arzneimittelgesetz, 
AMG) and the Federal Criminal Office Act (Bundeskriminalamtsgesetz, BKAG). 
In the introduction to the bill it is stated that the Federal Government (Bun-
desregierung) considers itself to be committed to the ethical-moral values of 
sport and to public health and that these are damaged by doping in that partici-
pants in competitive sport, the public, and organizers of sports events are de-
ceived and the health of athletes is jeopardized (Bundesregierung 2007). This 
law too thus relates doping directly to competitive sport. Because of the role-
model function exerted by elite athletes, however, effects on the protection of 
the health of the population at large are also seen. 
GERMAN DRUG LAW (ARZNEIMITTELGESETZ) 
The subpenal German Drug Law (AMG) defines doping actions as falling within 
environmental law and there relates them exclusively to medicinal products 
(Arzneimittel) (§ 2 AMG) and sport. Though reference is made to »doping in 
human beings« and »doping purposes in sport«, doping itself is not defined. 
Since it is stated that the lawmaking body considers itself to be committed to 
public health, a broad understanding of sport must be assumed. 
Potential agents for gene doping are largely substances for the transfer of genes 
or gene components. They are regarded by the lawmaker as medicinal products 
if they are intended for use in humans. In § 4, no. 9 AMG gene transfer medici-
nal products are defined as »medicinal products intended for human use within 
the meaning of § 2, no. 1 which, for the purpose of the genetic modification of 
somatic cells by means of the transfer of genes or gene segments, are or contain 
specific naked nucleic acids, viral or non-viral vectors, genetically modified hu-
man cells, or recombinant microorganisms, without the purpose being, in the 
                                            
26 For example, the suggestion that doping be deemed to constitute anticompetitive behav-
ior according to the criminal code failed to find a parliamentary majority (Bundesre-
gierung 2007; ReSpoDo 2005). 
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case of the latter, to prevent or treat the infectious diseases caused by them«. 
Other potential agents for gene doping in the broad sense, such as antibodies 
and transcription regulators (Section IV.3.2), fall within the substance definition 
given in § 3 AMG. 
Even without special reference to doping, medicinal products may be manufac-
tured for the purpose of dispensing to others in Germany only with the permis-
sion of the responsible authority (§ 13, no. 1 AMG). In the case of gene transfer 
medicinal products this permission is given by agreement with the Higher Feder-
al Authority (§ 13, no. 4 AMG). This norm could be used as a basis for taking 
action against illegal laboratories (Section IV.3.2), provided they are located in 
Germany, and also against trainers, athlete support personnel, or other third 
parties that place gene transfer medicinal products on the market. Infractions 
can be penalized with a period of imprisonment of up to one year or with a fine 
(§ 96 AMG). Use in others and possession of agents cannot, however, be prohib-
ited in accordance with § 13, no. 4 AMG. 
In § 6a (»Prohibition of medicinal products for doping purposes in sport«) the 
AMG also explicitly defines punishable doping actions insofar as the doping 
is to be performed in humans:27 
> »The placing on the market, prescribing, or administering of medicinal prod-
ucts to others for the purpose of doping in sport is prohibited.« (§ 6a, no. 1 
AMG) For the specification of medicinal products, reference is made in § 6a, 
no. 2 AMG to the law of March 2, 1994 on the Anti-Doping Convention of 
the Council of Europe of November 16, 1989. As mentioned above, the 
named list is the WADA Prohibited List, the most recent amendment of 
which was incorporated into German law in June 2007 (Bundesgesetzblatt 
2007 Part II No. 18, p. 812 ff.).28 Section 6a, no. 1 AMG applies only to me-
dicinal products that contain substances that belong to the listed groups of 
prohibited substances or substances that are intended for use with the listed 
prohibited methods. The incorporation of the WADA Prohibited List into 
German law thus makes gene doping a prohibited method in Germany, and 
substances used for this purpose may not be placed on the market, prescribed, 
or used for doping purposes. 
> It is also prohibited »to possess non-small amounts of medicinal products 
that are or that contain substances named in the Appendix to this Law for 
doping purposes in sport insofar as the doping is to be performed in humans« 
(§ 6a, no. 2a AMG). The substances concerned and the »non-small« amounts 
are specified in the Doping Agents Amounts Ordinance (Dopingmittel-
                                            
27 Doping of animals is not covered by the AMG. 
28 The question (referred to in Section IV.1) of the precision and scope of the definition of 
gene doping used in the WADA Prohibited List applies also to the AMG. 
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Mengen-Verordnung, DmMV) of the Federal Ministry of Health (BMG 
2007)29. The substances listed in this appendix to the law largely correspond 
to those of substance classes S1, S2, and S4 of the WADA Prohibited List (Ta-
ble 6). Possession of substances for use in gene doping is thus not prohibited 
in itself.30 
According to the German Drug Law (AMG), substances required for gene dop-
ing that are medicinal products may not be placed on the market, prescribed, or 
used for doping purposes. Even an attempt to perform any of these actions is a 
punishable offense that in accordance with § 95 AMG may result in imprison-
ment for up to three years or a fine. In particularly serious cases31 the punishment 
may be increased to between one and ten years. This norm is directed mostly 
against trainers, physicians, and athlete support personnel rather than against the 
athlete who commits the act on himself/herself. 
FEDERAL CRIMINAL OFFICE ACT 
In accordance with the Law to Improve the Fight against Doping in Sport (Ge-
setz zur Verbesserung der Bekämpfung des Dopings im Sport), the Federal 
Criminal Office (Bundeskriminalamt, BKA) is responsible for launching prosecu-
tions in cases of internationally organized illegal actions involving narcotics or 
medicinal products that call for investigation beyond the borders of Germany and 
of criminal offenses committed in association with such actions. 
OTHER (LEGAL) NORMS 
Where use of doping methods without the consent of the athlete results in dam-
age to health, a criminal assault as per the German penal code (§ 223 ff. Strafge-
setzbuch, StGB) may have been committed. Where, as with gene doping, serious 
damage to health is to be expected, use even with consent could be regarded as 
immoral and would be punishable despite the consent. The severity of the pun-
ishment is determined by the severity of the bodily injury (Simon et al. 2007, 
p. 40). 
                                            
29 Substances included in the WADA Prohibited List formed a starting point. The equiva-
lent of a one-month therapeutic supply was defined as a »small amount«. By compari-
son, the Norwegian anti-doping law prohibits possession only of more than a year's 
supply, such as is issued in sport or bodybuilding (Reinsch 2007). 
30 In order for possession to be prohibited, a »small amount« would also need to be de-
fined.  
31 For example, when the health of a large number of people is jeopardized, when the 
action exposes another person to a risk of death or serious physical injury or damage to 
health, when the action is performed in a professional way or by a gang, or when the 
actions are performed on minors. 
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As well as on the basis of actions prohibited by the German Drug Law, gene 
doping could be punishable under criminal law in cases in which deception or 
falsification of documents occurred because of or in connection with gene dop-
ing. For this to occur, the relevant association- or federation-internal legal 
norms, employment contracts, and/or declarations of principles and obligations 
would need to be suitably formulated. In conjunction with the existing prohibi-
tion of gene doping and the existing rules on retention, later analysis, and limita-
tion periods, this could have a deterrent and consequently a preventive effect 
(Section IV.2.4). 
Where a person who performs gene doping on another person is a physician 
registered in Germany, his/her actions could be punished by the responsible state 
medical association (Landesärztekammer). According to the Federal Ordinance 
for Physicians (Bundesärzteordnung, BÄO), registration as a physician is condi-
tional upon recognition of the ordinance governing the profession and member-
ship of the relevant state medical association. By recognizing the ordinance gov-
erning the profession the physician undertakes »to serve the health of the indi-
vidual human being and of the entire nation« (§ 1, no. 1 BÄO). 
The financial support of sport (as an area of public law) is another area in which 
there is scope for action to combat doping. »Direct financial support by the Fed-
eral Government in the realm of elite sport is provided via federal sports associa-
tions, Olympic support centers, and federal performance centers. In this way 
athletes, physicians, trainers, and other athlete support personnel benefit only 
indirectly from grants of budgetary funds.« (BMI 2007b, p. 8) Recipients of this 
financial support are required to observe the applicable anti-doping regulations 
of WADA and NADA (BMI 2007b, p. 12). In addition, by the end of 2007 all 
elite athletes employed by the Federal Police, the Federal Armed Forces, or Fed-
eral Customs had signed an undertaking never to dope themselves. They accept 
that if they breach this undertaking they will be excluded from financial support 
and will be subject to additional measures under civil service law. In addition, 
they receive documented annual instruction (BMI 2007b, p. 115 ff.). According 
to the WADC and the NADA Code, gene doping is covered by decisions on allo-
cation of grants. A precondition for demands for repayment of grants and in par-
ticular for the taking of measures under civil service law, e.g. dismissal, is comple-
tion of an investigation under sports law and proof of a statutory offense that will 
stand up in court (BMI 2007b, p. 72). 
CRIMINAL PROSECUTION AND IMPOSITION OF SANCTIONS 
Though prosecuting authorities have more extensive investigative powers than 
do sports organizations, they are required to ensure proportionateness of 
measures. They are empowered to have specific investigations performed on a 
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compulsory basis, but may do so only if such investigations are appropriate and 
necessary for establishing the facts of the case. In the absence of a suitable test 
procedure such investigations are not permitted. 
A (gene) doping violation in the sense of self-harming by an athlete is not pun-
ishable under German law. Such an athlete may nevertheless be prosecuted if 
he/she has made a statutory declaration or documented undertaking not to dope 
himself/herself (§ 267 Strafgesetzbuch [German penal code, StGB], Ur-
kundenfälschung [falsification of documents]; § 274 StGB, Urkundenun-
terdrückung [suppression of documents]) (Simon 2007, p. 35). However, in ac-
cordance with the principle of »no punishment without guilt«, sanctions for 
gene doping may be imposed only if proof that will stand up in court can be 
established by means of a suitable method. No such methods are apparent at 
present. 
In order to prove the occurrence of (gene) doping actions in the milieu of the 
athlete (placing on the market, prescribing, and administering), the principle of 
clarity and definiteness must likewise be satisfied and either objective and subjec-
tive elements of a rule violation or the intention »for the purpose of doping« 
must be established. Where bodily harm occurs as a result, proof of intention is 
not required, however objective and subjective elements of a rule violation must 
be demonstrated. Violations fall within the area of medicinal product crime32. 
Up to now, prosecuting authorities have generally regarded violations of the 
German Drug Law as falling within the area of environmental crime and there-
fore not as a priority area of activity (Sürmann 2007). Responsibility lies with 
the German Lands. There have been calls for the establishment of specialized 
public prosecutor's offices, however as far as is known no such offices have been 
established as yet. 
To date, criminal offenses as per the German Drug Law (Arzneimittelgesetz, 
AMG), and thus doping offenses, are not identified as such in police crime statis-
tics. Some retrospective data have been obtained by means of questionnaires, 
however according to Sürmann (2007) the information provided by these is not 
representative. As from 2008 criminal offenses as per § 6a AMG are to be identi-
fied as such and reported to the Federal Criminal Office (Bundeskriminalamt, 
BKA). Along with analysis of crime statistics, surveys of experts have been con-
ducted in order to provide a basis for developing methods of combating the 
growing phenomenon of medicinal product crime. The resulting proposals could 
probably also help to combat gene doping. 
                                            
32 The study »Arzneimittelkriminalität – ein Wachstumsmarkt« (»Medicinal product 
crime – a growth market«), issued by the Federal Criminal Office (Bundeskriminalamt, 
BKA) (Sürmann 2007), is the first attempt to provide information on the state of medic-




DOPING BEHAVIOR IN ITS SOCIAL SETTING V. 
Compared to those of other countries, Germany's doping control and sanctions 
structures are certainly well developed. Despite this, they have not succeeded in 
preventing the use and spread of doping in elite sport. Like other deviant, rule-
breaking behavior in society that cannot be prevented by the threat of punish-
ment, doping may result from individual developmental processes in the course 
of which pro-doping attitudes, mentalities, and behavioral patterns are acquired. 
A situation in which these attitudes prove to be largely resistant to the threat of 
testing and sanctions, and in which athletes often fall into a »biographical trap« 
in which doping is integrated into their life plan as a matter of course, can arise 
only if social structures and people in the athlete's milieu promote and reinforce 
individual doping. 
The following observations are intended to take account of this interconnected-
ness between individual decision-making and the social setting in which it oc-
curs. In the context of the present report this cannot, however, take the form of 
a comprehensive sociological (systems) analysis of the »links between the indi-
vidual and cooperative interests of the protagonists« (Bette/Schimank 2006b, 
p. 26). The objective is more modest than this. The following discussion is in-
tended to demonstrate at least in outline that the subject matter of the present 
report cannot be meaningfully considered purely in biomedical terms. Rather, 
(gene) doping can be understood only if it is analyzed and considered as individual 
behavior in a social setting (rather than as autonomous behavior). 
To this end Section V.1.1 considers how doping behavior can arise during the 
career of a competitive athlete, with particular reference to the role of medical 
support personnel. As important elements in the »support milieu« (Bet-
te/Schimank 2006b), these individuals can contribute substantially to the devel-
opment of a doping mentality among athletes and to reinforcement of the prac-
tice of doping. Other people who form part of the athlete's milieu are referred to 
in Section V.1.2. By reference to sports organizations and individuals and enti-
ties that support sport, it is pointed out that athletes act and make decisions not 
autonomously, but under the influence (even if undetermined) of their social 
milieu. 
Using bodybuilding and sport in the elderly as examples, Section V.2 considers 
the question of how doping behavior typically arises in individual sport. In Sec-
tions V.2.1 and V.2.2, under the heading »Points of entry«, there is a discussion 
of the factors that the athlete is likely to take into account when deciding for or 
against gene doping and that could tend to promote or prevent the spread of 
gene doping. 
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COMPETITIVE SPORT 1. 
Athletes are generally health-conscious and determined people. They are moti-
vated to engage in sporting activity by wishes related to enjoyment of move-
ment, play and competition with others, physical health and/or strength, stami-
na, and a will to achieve. Many of these wishes are linked either consciously or 
unconsciously to athletic bodies as image bearers. Sporting activity can mean 
great subjective success for oneself and a degree of recognition by one's social 
milieu that can act as an impetus to further physical development. In this way 
»shaping of human nature« by training and sporting activity also provides »an 
opportunity for a life plan and the associated endowment of life with meaning« 
(Fuchs et al. 2007, p. 31). 
ATTITUDES AND BEHAVIOR 1.1 
Experience shows that during their sporting development athletes can develop 
attitudes and modes of behavior that lead to doping actions. The decisions that 
an athlete makes in the course of his/her sporting development are not just iso-
lated individual decisions, they are also the result of the individual and com-
bined influence of a variety of people who form part of the athlete's milieu (par-
ents, trainers, sponsors, media, physicians). It seems very likely that use and 
spread of gene doping in competitive sport will be possible only if athletes are 
able to get help of one kind or another from the medical profession. The follow-
ing discussion therefore focuses on the development of the athlete and on the 
role of medical support personnel and physicians. 
INDIVIDUAL DEVELOPMENTAL PHASES 
Most people who achieve success in elite sport nowadays have been playing 
sport since their early childhood. Those who eventually reach the top level start-
ed out simply as talented children who loved sport. In most cases they have no 
realistic idea of where a move into competitive sport might take them and are 
therefore unable to take this question into account when making decisions. To 
sport-loving children, elite athletes are important role models who significantly 
influence their opinion-forming and decision-making processes. 
Children play sport for a variety of reasons, for instance because they enjoy bod-
ily movement or in order to be with friends. Success in their sporting activity 
often puts them on a path that leads towards a career in sport. Those who do 
not drop out, e.g. because they are not prepared to spend the required amount 
of time or are afraid of failing or not reaching the top level, have fallen into a 
»biographical trap« (Bette/Schimank 2006b, p. 126) in that they have found an 
effective means of achieving social status. The subsequent path of their life plan 
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in sport is largely without alternatives, leads in many cases to excessive ambition, 
and can gradually give rise to doping behavior (Singler/Treutlein 2007, p. 16 ff.). 
The final step from being a non-doping to a doping athlete is generally preceded 
by a lengthy process in which barriers are gradually broken down and mental 
acceptance of doping is developed (Laure/Treutlein 2006). In some cases this 
doping mentality develops before any actual doping actions occur, and in some 
cases it becomes more pronounced as further doping actions are committed. 
Referring to people in the athlete's milieu such as physicians, trainers, and sports 
officials, Singler/Treutlein (2007, p. 16 ff.) speak of a »staircase of seduction into 
doping«. This staircase already leads athletes to blood doping and doping with 
growth hormone, for example, and assuming unchanged conditions and avail-
ability it could in the future lead to the decision to practice gene doping. »This 
staircase of seduction into doping is an illustrative model. In reality the path can 
be shorter. It is also possible for someone to take a few steps on this staircase 
but then, fortunately, not reach the stage of doping.« (Singler/Treutlein 2007, 
p. 17) 
Figure 9 shows the gradual development of doping behavior in schematic form. In 
the first phase, namely the discovery of the type of sport to play as a recreational 
activity, the amount of time spent training is still relatively small. Young athletes 
who observe casual and even everyday use of medicines or similar substances 
in their sporting environment can start to develop pro-doping attitudes at an 
early stage. 
The second phase of sporting development generally coincides with the physical 
and mental upheavals that accompany adolescence in the young athlete. If this 
phase is marked by success and social recognition, sport can become the young 
person's principal means of establishing his/her identity. The motive of achieving 
social recognition now increasingly takes over from the earlier motive of finding 
pleasure in play. As the degree of social recognition increases and possible alter-
natives disappear, the athlete is drawn into a vortex from which it is increasingly 
difficult to escape. Increasing demands on the athlete's time and progressive 
marginalization of peer groups other than those associated with sport are ac-
companied by the increasing physical burden imposed by ever more intensive 
training. Exhaustion and over-exertion occur, injuries occur more frequently and 
increasingly are treated with medicines prescribed by specialist physicians. In 
some cases performance-enhancing substances are recommended supposedly as 
preventive measures to maintain health. As a result of all this, even young ath-
letes can become receptive to the idea of taking substances as an »aid« before 
they reach the point at which they have to make decisions both about their 
further development in sport (which can occur only via even longer training 
times) and about their professional future. The decision – if taken – to make a 
career out of sport, the moment of »going professional« (Brissonneau 2004), 
represents a fundamental turning point in the life of the athlete. 
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FIG. 9 DEVELOPMENT OF DOPING BEHAVIOR IN COMPETITIVE SPORT 
 
Figure 9 shows in schematic form the preliminary and developmental phases of doping 
behavior that can occur in parallel with a life in sport. The figures on training times are 
intended only to give a general idea of how sport takes up more and more of the athlete's 
time. 
Own illustration, from Brissonneau 2004 
In the third phase, the development of sporting prowess largely determines daily 
routine and displaces other activities. Increasingly, the athlete trains to the limit 
of his/her physical capacity in accordance with methods optimized by perfor-
mance physiology for 25 or more hours per week, depending on the type of 
sport, in order to be able to participate successfully in the large number of com-
petitions that finance the ever-growing competitive sport industry. The milieu in 
which the athlete moves is progressively reduced to a narrow, success-oriented 
world of sport in which expectations, incentives, and rewards are determined by 
sporting achievement. This development is characterized by a continuous »max-
imization of economic income and career opportunities« (Bette/Schimank 
2006b, p. 129). The athlete has to measure himself/herself against other athletes 
who may or may not be doping themselves. He is now caught in the doping 
trap, and in the absence of alternatives he joins the doping community. He is 
now subject to the doping control system. The risk of being caught is greatest at 
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After joining the doping community an athlete becomes even more result-
oriented and single-minded. From there it is a relatively small step to the fourth 
phase, in which »all that matters is winning« and increasingly subtle doping 
agents that must be undetectable (or that are not detected) are used because the 
athlete's whole career depends on their use. 
EMPIRICAL STUDIES ON DOPING AT DIFFERENT PHASES OF SPORTING 
DEVELOPMENT 
A small number of quantitative studies have been performed on the extent 
and types of doping practiced in the early stages of sporting development. 
Laure/Treutlein (2006) analyzed the results of 39 empirical studies on doping 
in adolescents in North America and ten studies from Europe that also at-
tempted to quantify doping behavior during the early phases of sporting de-
velopment. The North American studies from the 1990s found that doping 
often started before the age of 14 years and that adolescent competitive ath-
letes made use of doping agents far more commonly than did noncompetitive 
athletes. Doping with anabolic steroids formed the focus of the studies. Only 
Rickert et al. (1992) studied doping with growth hormone. In that study 5% 
of male interviewees from two schools in Chicago (mean age 15 years) stated 
that they had used growth hormone for doping purposes. 
Two empirical studies on doping in competitive sport were performed in 
France in 1991 and 1998. The 1991 survey of 2425 children aged between 12 
and 20 years likewise found that age and involvement in competitive sport in-
fluence doping behavior. Overall, 2.9% of the boys and 1.4% of the girls 
admitted to having used doping agents. Of the boys who played sport, 2.4%, 
2.5%, and 7.7% took part in sports competitions at the local, regional, and 
national level, respectively. The 1998 study was based on a survey of 2000 
amateur athletes from all types of sport in Lorraine. »9.5% had taken doping 
agents at some time during the preceding 12 months. Most affected were the 
20–29 and 35–39 year age groups. 10.8% of competitive athletes, but only 
4.9% of recreational athletes, had taken doping agents. Most at risk were 
athletes performing at a high level (17.5% compared to 10.3% of athletes 
performing at a lower level).« (Laure/Treutlein 2006, p. 53)33 
In a direct survey of 480 squad athletes performed using a randomized re-
sponse technique, Striegel (2007, p. 51) found an overall doping rate of 
6.8%. There was no breakdown by type of sport, age, or gender, nor was 
any information provided on probably incorrect answers. 
                                            
33 Similarly, the German Federal Government's health report for 2006 included a sum-
mary of published studies on doping in recreational and mass sports (Müller-Platz et al. 
2006), however the state of organized sport was scarcely referred to and no quantitative 
information on it was provided. 
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In an internet survey of 448 squad athletes that likewise used a randomized 
response technique, Pietsch et al. (2005) found a doping rate of 26% (plus an 
estimated 22% probably incorrect answers) (Section IV.2.3). 
RISK-BENEFIT CONSIDERATIONS AND JUSTIFICATION STRATEGIES 
On the basis of the available scientific literature on the life courses of perfor-
mance-oriented athletes, it is possible to identify certain common behavioral 
patterns and also certain time-points or phases in an athlete's career when the 
risk of doping is particularly high. These include: 
> transitions between one level of sporting performance and the next (often asso-
ciated with changes of trainer, support personnel, and sports team or associa-
tion; phase transitions in Fig. 9); 
> times at which the limits of training possibilities are being approached (when 
intensification of training at an already high level results in progressively 
smaller increases in performance); 
> times of crisis (which become more frequent because of the increasing physi-
cal, mental, social, and financial risks that can result from accidents, chronic 
injuries, and long-term damage); 
> the twilight of the athlete's career (when the athlete's physical performance 
has passed its peak and younger athletes are posing an increasing threat). 
Nevertheless, competitive athletes are not a homogeneous group. Differences 
related to type of sport and to gender, for example, have yet to be studied to any 
great extent either qualitatively or quantitatively. 
It is reasonable to assume that all groups of athletes consider both the benefits 
and the risks of doping (Fig. 10). Various criteria are included, weighted, and 
balanced against each other so as to come to an overall assessment of the risk-
benefit relationship. This balancing of risks against benefits doesn't necessarily 
occur before the decision to dope or not to dope is made, but can just as easily 
occur later. From the point of view of the doping athlete (and of his/her support 
personnel), this process of balancing risks against benefits can lead to a rational 
decision. This can be illustrated by imagining a simple thought process of this 
kind (Knoepffler/Albrecht 2007, p. 20): If from the point of view of a perfor-
mance-oriented athlete the expected improvement in performance is great and 
the health risk is low, doping is a rational strategy, whereas if doping is likely to 
bring only a minor improvement in performance but its health risk is high, it is 
an irrational strategy. This process in which the athlete weighs benefits against 
risks will be discussed again later in relation to potential points of entry for gene 
doping. 
 1.  COMPETITIVE SPORT 121 
However, as well as basing their decision-making behavior on the utility princi-
ple, athletes often have to consider rules and regulations if their doping actions 
are to be stable and consistent. Bette/Schimank (2006b, p. 226 ff.) coined the 
term »neutralization rhetorics« to refer to typical arguments used by athletes to 
render deviation from rules plausible to themselves and others. 
FIG. 10 FACTORS IN THE SUBJECTIVE RISK-BENEFIT ANALYSIS IN (GENE) DOPING 
 
Own illustration 
Justification strategies include the argument that since other athletes dope them-
selves, one must do the same in order to avoid disadvantages. Also used as justi-
fications are inconsistencies in doping testing (»testing deficit«) and the assertion 
that the fight against doping is pointless in any case. Another line of argument is 
that doping can be an aid to overcoming the risks, in some cases to one's very 
existence, associated with a career in sport. Finally, reference is made to the 
massive pressure exerted by the sports industry, which supposedly leaves athletes 
with no option but to dope themselves (Fig. 11). 
FIG. 11 ARGUMENTS USED BY DOPING ATHLETES TO JUSTIFY THEIR ACTIONS 
 
Source: adapted from Bette/Schimank 2006b, p. 226 ff. 
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Arguments such as these also have effects that extend beyond the individual ath-
lete to doping athletes as a group. Taken together, the various justifications con-
stitute a sort of »counter-morality« that attempts to justify doping and refute con-
trary norms and precepts (Bette/Schimank 2006b, p. 244). 
MEDICAL SUPPORT 
The notion of health that is accepted in the world of elite sport is not the same 
as that which prevails in the early stages of a sports career or outside of the 
world of competitive sport (Brissonneau 2004). This is because the health of 
someone who plays sport five hours per week is not comparable with that of 
athletes who train at the limit of their physical capacity for 25 or more hours per 
week (Fig. 9). A workload of this kind results in certain physical deficits that call 
for rest periods to permit recovery from physical exhaustion. Rapid succession 
or long duration of competitive sporting events often leaves no time for such rest 
periods during the competition season. The logic of elite sport »systematically 
brings its principal protagonists, i.e. athletes, to the brink of injury and illness« 
(Bette/ Schimank 2006b, p. 55). The athlete comes to experience the limits of 
his/her physical capacity. This creates a need for a network of professionals who, 
for example, advise their athletes to apply for Therapeutic Use Exemptions 
(TUEs, Section IV.1.3) so that they can use specific drugs to mitigate the ef-
fects of overexertion and exhaustion. The increasing intensity of drug therapy 
reduces athletes' »pharmacologic barrier«. 
As athletes move in the direction of elite sport they come into increasingly close 
contact and work ever more closely with the medical profession. Producing an 
optimal performance at precisely the right time now calls for precise medical 
planning. As a result of the commercialization of elite sport, some sports physi-
cians now specialize in this area. According to the German Society for Sports 
Medicine and Prevention (Deutsche Gesellschaft für Sportmedizin und Präven-
tion e.V., DGSP) there are now about 11,000 sports physicians practicing in 
Germany and between 150 and 200 of these specialize in elite sport. 
According to Brissonneau (2004), when the question of the relationship between 
doping and sports physicians is considered a distinction needs to be drawn be-
tween clinicians, who are in very close contact with athletes and provide them 
with medical care, and researchers, to whom athletes are essentially objects of 
investigation. Specific to clinicians is the fact that many of them are former ath-
letes who share their passion for sport with their patients. They are fascinated by 
these people and want to help them. Health is an important consideration for 
them. They care for elite athletes whose training volume and methods are in-
creasingly risky and harmful to health and who as a result are often exhausted 
and sometimes injured. Prescription of pharmacologic products rises accordingly 
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and is justified with the argument that the products concerned are intended to 
help keep the athlete's body healthy despite the extreme demands that are being 
placed on it. 
Those sports physicians who care mostly for elite athletes who train for up to 
30 hours per week have to some extent become performance physiologists and 
tend towards research. The medical care that they provide serves the purpose of 
enhancing athletes' performance and optimizing their performance-to-risk ratio. 
Using training methods in which individual physiology and the monitoring 
thereof occupy an increasingly important role and using improved techniques for 
recuperation, they help athletes to get ever closer to the limits of their potential. 
Actions are increasingly determined by the credo of elite sport, namely to win at 
any cost. Aids developed in the fields of sports medicine, biomechanics, and 
pharmacology help to make the athlete's overtaxed body fit to withstand the 
demands of elite sport in which the only thing that matters is winning. An »un-
well body« is undesirable (Bette/Schimank 2006b, p. 54). 
Like many other people who are directly or indirectly involved in doping, physi-
cians and medical support personnel reflect upon their behavior, want it to have 
a purpose, and try to justify it. They develop their own ideas about what is right 
and wrong because they are troubled by the fact that they are using illegal sub-
stances to help athletes achieve certain physiological objectives. By either tolerat-
ing or actively assisting in the practice of doping, physicians are exceeding their 
traditional role of curing, alleviating, or preventing illnesses on the basis of med-
ical indications. They also know that they may be harming the athlete's health 
(Fuchs et al. 2007, p. 35). The ethical principles of the medical profession are 
especially relevant to any physician who participates in the doping of an athlete: 
In order to avoid inconsistencies in their actions, those who are sworn to the 
dictum »first, do no harm« must be able to justify their behavior on the basis of 
the intention to preserve health or minimize harm (Singler/Treutlein 2007, 
p. 18). Doping is therefore portrayed either as a means – where no other means 
are available – of improving the constitution, or promoting the recuperation, of 
an athlete more rapidly and intensively than would otherwise be possible or as a 
means of preventing the athlete, in his/her own interest, from using doping 
agents at his/her own initiative (Fig. 12). 
Given the likely effectiveness of such arguments, which are directed also at ath-
letes and to some extent at the public, Singler and Treutlein (2007, p. 20) cor-
rectly point out that the success of preventive strategies is crucially dependent on 
awareness of such arguments: »Such lines of argument must be denounced as 
unacceptable at the outset in prevention processes ranging from athlete educa-
tion and the training of sports trainers and sports teachers through to medical 
school curricula. Athletes need an 'early warning system' for this purpose so that 
on the basis of the common euphemisms they can identify possible pro-doping 
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attitudes in persons in their milieu. For there's no doubt that such euphemisms 
will continue to play an important role.« 
FIG. 12 ARGUMENTS USED BY DOPING PHYSICIANS TO JUSTIFY THEIR ACTIONS 
 
Source: Singler/Treutlein 2007, p. 19 
ELITE SPORT AS A POINT OF ENTRY FOR GENE DOPING 
Elite sport seems the most likely point of entry of gene doping into competitive 
sport. Even if gene doping turns out to be no more effective than conventional 
doping methods, in its case 
> the pharmacologic barrier is especially low, 
> the pressure to use undetectable doping methods is greatest34, 
> the willingness to run risks is greatest, 
> because of the high degree of commercialization, relatively large amounts of 
money are available, and 
> international structures (laboratories, personnel, transport)35 are already in 
place to some extent. 
As is already the case with conventional doping, the types of sport most likely to 
be affected by gene doping are firstly those in which success is associated with 
clearly defined physiological performances (»cgs« sports: centimeter, gram, sec-
ond; Emrich et al. 2004) and with great intangible and tangible benefits, and 
                                            
34 Though doping with growth hormone is assumed to be less effective than doping with 
anabolic steroids, doping with growth hormone could spread because abuse of anabolic 
agents has now become relatively easy to detect. 
35 Specialized laboratories already supply the existing doping networks in elite sport. De-
pending on cost and availability (Section II), the range of doping products could be kept 
within certain limits or further expanded by means of even more specialized laborato-
ries. Because of the high degree of specialization in biotechnology, individual substances 
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secondly sports in which doping behavior is not much discussed and not very 
efficiently combated. The rate at which gene doping spreads will depend on a 
number of factors that can be seen by the athlete as either obstacles or incen-
tives. 
At present, the biggest and most effective obstacle to gene doping is nonavaila-
bility or nonaccessibility. As far as abuse of gene therapy methods (gene doping 
in the narrow sense, Section II.1.) is concerned, this obstacle will probably per-
sist for some time yet because of the early state of development of such methods. 
The obstacles to abuse of specific gene regulatory methods (gene doping in the 
broad sense, Section II.1.) are rather less, since some therapeutic methods of this 
kind have already reached the stage of clinical development (Section II.2). Non-
availability can also mean that an agent or method exists – e.g. has reached or 
completed the clinical trials stage – but has not yet been licensed. Spinoffs from 
clinical trials would be illegal, but possible. This illegality would not be a real 
obstacle to all potential abusers. Current doping practice is not limited to sub-
stances that are licensed only for use in animals (e.g. clenbuterol, an agent used 
in calf feed) (Striegel 2007) or even to untested substances that were developed 
specifically for doping purposes and have never been licensed (e.g. the synthetic 
steroid hormone THG manufactured by the American company Balco). 
Another obstacle to gene doping is unknown health risks (Section II.3). Here 
again, the perception of this risk on the part of potential users and their advisers 
and support personnel differs considerably according to the willingness of those 
concerned to take risks. Information on possible health consequences is imparted 
mostly in milieus that support or approve of doping. These milieus are largely 
closed circles that filter out alternative, critical information. This is one reason 
why elite athletes are so willing to take risks and so impervious to contrary ar-
guments. Thus, in a survey conducted by Bamberger/Yeager (1997), 50% of the 
elite athletes who were surveyed stated that they would take undetectable per-
formance-enhancing substances if this meant that they would win all the compe-
titions in which they participated over the next five years and then die. Though 
this result should perhaps not be given too much importance, it certainly sug-
gests the existence of a heavily skewed cost-benefit calculation. In competitive 
sport top performances are achieved by division of labor. This means that re-
sponsibility for the athlete's health, including health risks and side effects, is del-
egated.36 In this respect the behavior of elite athletes does not differ from that of 
the overwhelming majority of the population: they have faith in the competence 
and the sense of responsibility of those who provide them with medical care. 
                                            
36 Little empirical knowledge is available as yet on the willingness of athletes, and even 
less on the willingness of physicians, to take risks in these contexts. Information of this 
kind could be useful for the development of target-group-specific measures against gene 
doping. 
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The third obstacle to gene doping relates to the way in which it is used. For as 
long as gene therapy continues to call for very specialized knowledge, specific 
skills, and special aids, abuse of it for gene doping purposes and the spread of 
gene doping are likely to face substantial obstacles. In medicinal product devel-
opment great efforts are made to ensure that use is as simple as possible, since – 
along with efficacy and side effects – simplicity of use is a central determinant of 
whether a new product is granted a product license and thus acquires market 
potential. Before a dosage form can be simplified, however, the method that un-
derlies it must be shown to work safely. One reason why experts consider the 
risk potential of gene doping in the broad sense to be much greater than that of 
gene doping in the narrow sense is that administration of agents of the former 
kind is simpler than that of agents of the latter kind (Section II.2) 
Finally, an athlete's views and decisions about doping are influenced by his/her 
perception of the effectiveness of the control system and the severity of the sanc-
tions system. As previously stated (Section IV), gene doping is prohibited both to 
athletes and to athlete support personnel in competitive sport and is punishable 
by periods of ineligibility and loss of accreditation, respectively. Since the sub-
stances that are emerging as possible candidates for gene doping are covered by 
the German Drug Law, all manufacture for the purpose of issue to others with-
out permission is prohibited. Placing on the market, prescription, and use in 
others for the purpose of doping are also punishable by law. However, as long 
as violation of these prohibitions cannot be detected,37 the risk of discovery is 
low and this obstacle is probably of little value. 
THE ATHLETE'S MILIEU 1.2 
From a sociological perspective, doping is far more than just an action by indi-
viduals (Bette/Schimank 2006a and 2006b; Franke 2007; Knoepffler/Albrecht 
2007). Consequently, the phenomenon of doping cannot be properly understood 
purely on the basis of an analysis of individual deviant behavior. Instead, social 
structures and the athlete's milieu must also be considered, since via specific mo-
tivating structures, supporting measures, and omitted actions, these have con-
tributed to the rise of doping. Singler/ Treutlein (2007, p. 10 ff.) make the fol-
lowing statement in this regard: »Doping on its present scale would be incon-
ceivable as a phenomenon that goes beyond individually deviant behavior if it 
did not receive some kind of support from many quarters. This support does not 
                                            
37 As odd as it may sound, the non-detectability of present doping agents and methods is 
an important obstacle to the use of gene doping. As long as presently practiced doping 
methods cannot be detected, the pressure to switch to new undetectable methods of un-
known risk is relatively low. Even conventional blood doping underwent a renaissance 
when doping with EPO stopped being »safe« because the risk of detection increased. 
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need to be active in the sense of direct participation in doping. Support is also 
given precisely via the omission of actions.« The present Section of this report 
therefore deals with institutional motivating structures insofar as these could be-
come relevant to gene doping. 
COMMERCIALIZATION 
It is a commonplace, but nonetheless true, that sport, which was originally play, 
has long since become a business. Its economic potential in a globalized, media-
driven world is based on its entertainment value, its image value, and its ability 
to act as a vehicle for product information. Sport as a business provides elite 
athletes with the possibility of participating in the value creation of this econom-
ic sector. The more important is winning, the more tangible are the economic 
consequences of success or failure (KPMG 2002, p. 9). Almost universal adher-
ence to the principle that only winning counts leads to a »winner-take-all rat 
race« (KPMG 2002, p. 13) that by its nature is open to any means that help to 
improve performance. 
The imperative to perform has thus become a defining characteristic of sport, 
however it applies also to society as a whole, in which »in association with sim-
ultaneous economization of resource conditions« performance and competition 
are the dominant principles of action. Competitive sport has thus become »a 
reflection of the achievement-oriented society« in which »everyday life and 
competitive life« have become structurally linked (Franke 2007, p. 2). 
Over the past few decades many involved parties (e.g. sports organizations, 
media, industry) both in Germany and abroad have gradually developed sport, 
especially elite sport, into a kind of trademark. The particular feature of the 
brand sport is that it can function as an image bearer to represent a large variety 
of quite different things, e.g. performance, team spirit, stamina, and health, in all 
cases closely linked to success and as far as possible not linked to unfair or de-
ceitful behavior. The public projects authenticity of performance onto the system 
of competitive sport as a wish and a demand. 
One of the pillars that finance elite sport – sponsorship – is based on this con-
struct of sport as an image bearer. Sport itself is also an almost universal medi-
um through which an enormous international target group can be reached, the 
»ultimate communication vehicle for sponsors and the core business for many 
media companies« (KPMG 2002, p. I). On this is based another pillar of sports 
financing – advertising revenue. The resulting mutually reinforcing exploitability 
of only the results of competitive sporting efforts has led to a situation in which 
the rewards, both material and non-material, for these results are in some cases 
extravagant. This also puts athletes under greater economic pressure (KPMG 
2002, p. 9 ff.). The prospect of high earnings at the top of the performance lad-
der influences all of competitive sport and has the result that even in the early 
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stages of their career many athletes are strongly motivated to work their way to 
the top so as to reap some of these rewards. 
Global commercialization of sport has led to an increasingly specialization-based 
optimization process in which a variety of participants help the individual ath-
lete to produce outstanding performances in order to maintain and develop the 
trademark. As a result, the various participants and beneficiaries, including 
sports associations and federations, media, and the public at large, each have 
specific expectations with regard to the performance of the athlete. They are 
focused on outstanding performances, records, and victories along with an ex-
pectation of »naturalness of achievement« (Franke 2007). These demands can 
be quite contradictory, as illustrated by the attitude of society: »On the one 
hand, society shows a growing willingness to use powders and pills for health 
and good looks. On the other hand, we continue to condemn athletes taking 
substances to cope with the physical pressures of top sports.« (KPMG 2002, 
p. II) 
SPORTS ORGANIZATIONS 
Sports organizations can be regarded as mediators between the athletes whom 
they support and on whom they place demands on the one hand, and the de-
mands imposed by the athlete's environment – politics, sponsors, the media, the 
public – on the other hand. As guardians and developers of the trademark 
»sport«, they help athletes to develop and improve their physical performance 
and they organize competitions. Their position and their influence, both in abso-
lute terms and in relation to other sports organizations, therefore depend upon 
the achievements of athletes and the fascination with competition generated by 
these achievements (Bette/Schimank 2006b, p. 432). 
Sports organizations finance both individual people (talent scouts, trainers, ther-
apists, psychologists – i.e. athlete support personnel as per the NADA Code 
[NADA 2006b, p. 46]) and infrastructures (sports academies, performance cen-
ters, Olympic support centers) in order to help athletes optimize their perfor-
mance. The individual developmental phases on the path to a career in sport 
(Fig. 9), to which the would-be athlete increasingly has to make a commitment 
in early childhood in order to have any chance of rising to international level, 
are accompanied and shaped by specialized athlete support personnel working in 
special facilities. The transition from one developmental phase to the next is al-
most exclusively result-oriented, i.e. dependent on the achievement of certain 
performance figures. Athlete support personnel are likewise dependent on the 
sporting achievements of athletes, since – depending on their contract – their 
entire income is directly or indirectly linked to the sporting achievements of ath-
letes. As a result of this interdependency, the incentives to perform that are set 
by sports organizations and their athlete support personnel are accompanied by 
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heavily result-oriented expectations in terms of athletes' sporting development 
and achievements. 
By organizing tournaments, sports organizations drive the development and 
spread of the trademark »sport«. Over the past few years there has been a no-
ticeable trend towards more and more tournaments, closer links between indi-
vidual competitions, increasing performance requirements, and expansion to 
include ever larger numbers of athletes.38 This means that athletes are required 
to produce top performances that subject them to extreme physical strain at an 
ever younger age and at ever closer intervals (Section V.1.1). Substantial sources 
of income that finance large parts of the entire system are therefore available in 
elite sport, which consequently functions largely independently of public subsi-
dies. 
At the same time, however, competitions have to have a degree of credibility, 
which is a component of the trademark »sport«. Both in its self-perception and 
in the perception of others (the media and the public), competitive sport is a 
»particularly ethical system of conduct« (Franke 2007, p. 10) – though as such, 
also a fragile construct. This fragility is evident in the form of a certain tension 
between the »precept of outdoing«, i.e. absolute striving for victory, and the 
»precept of equality«, i.e. the principle of fairness and equality of opportunity. 
Whereas the latter precept calls for cooperativeness, the »precept of outdoing« 
calls for »authentic« achievement39, i.e. rule-compliant achievement not based 
on deceit (Franke 2007, p. 11). It is therefore only natural that sports associa-
tions and competition organizers should attempt to portray doping as a periph-
eral issue. In order to sustain the belief that competitions are fair, the problem of 
doping is played down and at the same time critical observers and athletes who 
report the existence of doping practices in the environment of competitions or 
teams are marginalized via accusations of »letting the team down« or »general 
suspicion« (Singer/Treutlein 2007, p. 13). 
However, it is by no means just by smoothing things over and by marginalizing 
whistleblowers that sports organizations react to the risk that doping could 
                                            
38 This is illustrated by the continuous increase in the number of world cups that require 
participation in a number of competitions, e.g. the Tour de Ski (eight cross-country ski-
ing races over ten days), the ProTour (27 cycling road races per season), and the Youth 
Olympic Games (for athletes 14 to 18 years of age), the creation of which was approved 
by the IOC in 2007 and which are to be held for the first time in the summer of 2010 
and the winter of 2012 with the participation of 3000 and 1000 young athletes, respec-
tively. 
39 Widespread use of gene doping would make the expectation of authentic achievement 
even lower than it has already become due to the increasing medicalization of sport. 
»Gene doping would spark a competition between biotechnologists ... Competition 
would no longer be between athletes, but between biotechnologists; the athlete would 
be reduced to a biotechnological agent.« (Fuchs et al. 2007, p. 6) 
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eventually make the whole world of sport seem dishonest and unattractive – 
especially in the eyes of the mass media, the public, and private and public spon-
sors. In response to growing disillusionment, especially on the part of the sport-
loving public, with the »special world« of sport (Franke 2007) with its supposed 
attributes of honesty and fairness, they are forced to take a position on the ques-
tion of doping, since otherwise sponsors could terminate their contracts and pol-
iticians could cut their funding. Since their very existence depends on this sup-
port (Bette/Schimank 2006b, p. 313), sports associations become active in the 
fight against doping. Their repertoire of anti-doping measures includes pedagog-
ic strategies and informational campaigns that provide relevant information, e.g. 
on the health damage that can result from doping. Another important area of 
action is that of control and sanctions structures. It is here, however, that the 
ambivalent situation in which sports associations find themselves is especially 
clear: controls and sanctions could indeed make elite sport somewhat »cleaner«, 
however this could jeopardize its very success. Like athletes, sports associations 
are thus caught in a »doping trap«. Again as with athletes, the situation is exac-
erbated by the risk that other associations, either domestic or international, are 
unable or unwilling to cooperate by imposing systematic controls. 
This constellation of elements that form part of, and result from, the »systems 
logic« of competitive sport largely explains the much-criticized tardiness and 
inconsistency of sports organizations that fail to combat doping in systematic 
fashion, but instead merely »simulate« a commitment (Bette/Schimank 2006b, 
pp. 380 and 395). 
STATE SUPPORT – RECREATIONAL SPORT, TALENT DEVELOPMENT, 
ELITE SPORT 
Support of sport by the German Lands is directed at recreational sport and tal-
ent development right up to the elite level. This support is intended to contribute 
to, among other things, preventive health, prevention of antisocial behavior, and 
a reduction in violent behavior (Bundesregierung 2006). The responsibility of 
the Lands is limited to the developmental phases of sport in which doping men-
talities arise but punishable doping actions have generally not yet occurred 
(Fig. 9, phases I and II). Because of Germany's federal structure, the individual 
Lands are able to fashion their sport support programs autonomously. Ap-
proaches vary with regard to both support of sporting achievements and actions 
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to influence doping behavior.40 The Sports Ministers Conference (Sportminister-
konferenz, SMK) of the German Lands has so far been restrained in its state-
ments about doping. In 2006 it called for harsher penalties for doping violators, 
and in 2007 it expressed the view that those entrusted with the task of combat-
ing doping should be provided with all necessary means to do so (www.sport 
ministerkonferenz.de/dateien/PM%20300707.pdf). So far, however, anti-doping 
measures have scarcely been discernible as a topic. Doping is seen mostly as a 
problem of elite sport. To date, the attitude of the Lands scarcely suggests that 
they see themselves as having any specific responsibilities in the fight against 
doping. 
The German Federal Government continues what the Lands have started. Its 
support of sport is intended to reinforce positive signals both inside and outside 
of competitive sport. Its support is explicitly directed at elite sport and tied to 
performance figures such as squad membership and medal chances at interna-
tional tournaments. This applies both to direct support of individual athletes 
and to support of sports organizations. When providing support the Federal 
Government respects the sense of responsibility and the autonomy of sport and 
places its trust in sport's »self-cleaning« capacity, however it demands ob-
servance of the World Anti-Doping Code (WADC). 
As well as supporting sport, the German Federal Government still largely fi-
nances the anti-doping activities of NADA and other preventive anti-doping re-
search up to the level of WADA. Up to now this financial support has gone al-
most exclusively to the system of doping controls and sanctions. In 2007 legal 
measures relating to the fight against doping were strengthened. These are di-
rected mostly at persons in the athlete's milieu (Section IV.3.2). Doping control 
remains a responsibility of the Lands. The powerful incentives to strive to reach 
the top level in sport are still present. 
The finding that the world of athletes and sports organizations is structurally 
linked to the world of doping is true also of the world of politics. The state sup-
ports sport because it is interested in success. However, since this success is sup-
posed to be achieved in conformity with rules, the state also supports doping con-
                                            
40 In Baden-Württemberg, for example, the Ministry for Culture, Youth, and Sport does 
not deal with doping as a topic in itself. However, in 2005 a general survey of state 
support of sport was conducted and the current situation, state of development, and 
outlook were assessed. The Land Sports Association (Landessportverband, LSV) per-
formed a stocktaking and review of its anti-doping activities (LSV 2007). Similarly in 
Berlin, the subject of doping is not referred to in direct connection with the support of 
sport. Neither on the web pages of, or in any other informational material on the sup-
port of sport in Berlin provided by, the Berlin Senate Administration for the Interior 
and Sport (Senatsverwaltung für Inneres und Sport) nor on the web pages of the Berlin 
Sports Federation (Landessportbund Berlin) do the terms »doping« or »anti-doping« 
appear. 
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trol and sanctions systems in sport and establishes its own rules in the form of 
laws. Success in the fight against doping could, however, mean failure on the part 
of national athletes, especially as the doping practices of competitors from other 
countries may be opaque and the doping control and sanctions systems of some 
countries may be largely symbolic and ineffective. 
PRIVATE SPONSORS 
As a result of the marketing of sport and the development of sport into an image 
bearer and trademark, sporting performances and competitions in various types 
of sport have become exploitable for financial gain and of increasing interest to 
private sponsors. Over the past few years the resulting opportunities for major 
commercialization of some types of sport have led the German Federal Govern-
ment to limit its support to a single rung of the sports career ladder and leave 
other levels to private sponsors. 
Private sponsors get involved in order to use sport to draw attention to them-
selves and their products. Sports competitions and individual elite athletes per-
mit a transfer of image to companies' products and companies themselves. They 
hope that characteristics associated with competitive sport such as youthfulness, 
dynamism, and motivation will be projected onto the company. Within certain 
limits, public discussion of doping in the type of sport concerned does not jeop-
ardize this objective41 provided that doping cannot be linked directly to the 
sponsor. When these limits have been exceeded in the past, the resulting threats by 
industry to withdraw from sports sponsorship have at least led to an intensifica-
tion of efforts to fight doping. As yet, however, there has been little evidence of 
the adoption of any coordinated anti-doping policy by involved companies or of 
any concerted action against doping, e.g. involving cooperation between private 
companies and anti-doping organizations or public authorities. 
CONCLUSION: DOPING AS A STRUCTURAL EFFECT 
Elite sport is part of a global market phenomenon in which athletes and the 
people in their milieu have, by their actions and omissions, created a system of 
which doping behavior is an integral part. Bette/Schimank (2006b, p. 149 ff.), 
for example, regard doping as a structural effect. Knoepffler/Albrecht (2007) 
conclude that in the presence of the existing motivating structures in sport only a 
very strong and determined personality can resist the temptation to engage in 
doping. It would therefore be a mistake to attempt to change the present situa-
                                            
41 In 2006 the Gerolsteiner racing team conducted a survey of people who watched cycling 
races. Only 7% of those surveyed stated that they had stopped watching cycling on tel-
evision because of the problem of doping in cycling. The rest were unconcerned. This 
phenomenon is apparent not just from survey results and viewing figures, but also from 
spectator behavior at sporting events. 
 1.  COMPETITIVE SPORT 133 
tion by working only with athletes using methods such as provision of infor-
mation, explanation, and education. Rather, the whole situation that has led to 
doping needs to be examined and consideration given to the responsibility of 
those who have contributed to the development of the institutional motivating 
structures: »Only as a result of the failure of many people to take action against 
doping has the spread of doping firstly to elite sport, and over the past few dec-
ades also far beyond this into the realm of fitness and recreational sport, been 
able to assume such wildfire-like proportions. ... Germany's federal system has 
facilitated this failure to act by a variety of people and institutions both inside 
and outside of sport. When asked to take the initiative in the fight against dop-
ing, decision-makers at all levels have been able to deny responsibility and pass 
the buck to other institutions. These likewise did not consider themselves to bear 
responsibility for dealing with the problem. This led to a system of organized 
lack of responsibility. A particular feature of this system of institutional encour-
agement of doping is that it was able to come into being with only a minimum 
of conspiratorial communication. As a result, there are scarcely any people or 
institutions who can be held concretely responsible for the wrong turns that 
were taken. Such a system develops and becomes established as if by itself.« 
(Singer/Treutlein 2007, p. 7 ff.) 
According to Singer/Treutlein (2007, p. 13), the making of changes to the entire 
system of sport and a breaking down of the tangled network of benefits involv-
ing athletes, sports associations, industry, and the media will require immense 
efforts and a »Copernican change« in the sense of responsibility of office-holders 
at all levels of public and political life both inside and outside of sport. Doping is 
a »collectively created« problem and as such (like global environmental prob-
lems) can be solved only by joint activities at multiple levels (Bette 2006, p. 87). 
As another turn in the vortex of doping, gene doping could signify both a real 
risk to sport and an opportunity to break down the system of »institutional en-
couragement of doping«. Gene doping could act as a warning sign. Public de-
bate about gene doping could make clearer what is to a large extent already 
known, namely that doping undermines the public's interest in and willingness 
to identify with athletes, »dupes politicians whose task it is to allocate public 
funds, prevents the image transfer that is the objective of sponsoring arrange-
ments, and disillusions sport's recruitment base in schools and families« (Bet-
te/Schimank 2006b, p. 308). As a new wave of doping could further devalue not 
only the intangible values of sport but also the concrete material interests of all 
those involved at all levels of sport, gene doping could prove to be a signal for a 
change of course. 
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INDIVIDUAL SPORT 2. 
For most people the motivation to engage in individual sport arises mainly from 
a desire to maintain health and physical performance. Because in many cultural 
milieus these aims imply an athletic physique, which is also associated with sev-
eral other stereotypes such as success and recognition, the desire for an athletic 
body or increased strength is deeply rooted. As in competitive sport, many peo-
ple who strive to achieve an athletic body are health-conscious and remain so 
throughout their active athletic phase. 
Sport at the individual level is based on the rejection of organized settings and 
the association of athletic activity with certain norms and rules. Fitness studios 
see themselves as unbiased, neutral providers of services tailored to the wishes 
of athletically active people. The rules in fitness studios do not define self-
doping as a violation. Hence, controls and sanctions under civil law cannot be 
applied. Everyone is free to indulge in self-harming behavior if they so desire: in 
some cases it is overlooked, in other cases it is actively supported.42 Consequent-
ly, fitness studios or their milieus can become marketplaces at which profession-
al, well organized doping drug traffickers and consumers meet. Analogies to the 
»system of organized irresponsibility« described by Singler/Treutlein (2007) 
should therefore not be dismissed out of hand. 
BODYBUILDING 2.1 
As long as the basic motivation for athletic activity is to maintain physical 
health, the obstacles to the emergence of doping behavior among individual ath-
letes are probably relatively high, especially if the athletes are able to obtain in-
formation from independent sources. However, if the underlying motivation 
becomes the »building« of an athletic body with associations of energy, strength, 
and success (image projection), doping behavior can quickly develop. Such be-
havior is bolstered by social trends such as the increasing medicalization of eve-
ryday life, the declining importance of traditional virtues (e.g. diligence, disci-
pline, abstinence), and the rising importance of hedonistic values of self-
realization (happiness, communication, pleasure).  
                                            
42 It is not known whether fitness studios pass anti-doping conduct rules in agreement 
with their users. In Germany they are not subject to any specific civil sports jurispru-
dence but only the laws of the state. In some cases it is therefore argued that behavior in 
fitness studios should not be referred to as doping but rather as drug abuse. 
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The emergence of a doping mentality and doping practice depends on numerous 
factors43 but is not necessarily a drawn-out process. The initial encounter with 
doping substances can occur in the early phase of discovery of the athletic body. 
Many adolescents embark on the problematic use of drugs relatively early, as 
studies in the USA have shown: before the age of 17 or 15 (Giebing 2002, p. 24) 
or even earlier (Feigenbaum et al. 1998). At this age the potential for harm is 
especially great, and the side effects are often more severe than for example in 
male adults. On the bodybuilding scene the development of doping behavior is 
ushered in by the misuse of muscle-growth-enhancing drugs in adolescents (Bätz-
ing 2007; Laure/Treutlein 2006, p. 54 ff.) (Figure 13, phases I and II). 
FIG. 13 DEVELOPMENT OF DOPING BEHAVIOR IN THE BODYBUILDING SCENE 
 
Own illustration 
Giebing (2002, p. 24) points out that according to some US studies »nearly one in 
ten male adolescents has already used anabolics«. A noteworthy finding is that 
adolescents who do not use anabolics do not by any means reject them and in fact 
evince a willingness to take them. This is compounded by poor knowledge of the 
side effects (Giebing 2002, p. 24) and the ready availability of anabolic drugs (via 
the internet, professional structures that also serve the general drug market, pliant 
physicians, or counterfeit prescriptions coupled with inattentiveness of pharma-
cies) (Boos et al. 1998; Donati 2006 and 2007). 
                                            
43 An international literature review conducted for WADA showed that doping behavior 
tends to be influenced by gender, age, training frequency, type of sport, consumption of 
other drugs, and familiarlization with other doping athletes as well as by the individu-
al's body perception and self-image (Backhouse et al. 2007, pp. 10 ff.). 
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If the desire for an athletic body and its exhibition grows stronger (Fig. 13, Phase 
II), the internet with its communication possibilities provides an ideal setting for 
finding like-minded people and exchanging information on, for example, sales 
channels – even without fixed organizational structures. In many cases the motiva-
tion to engage in doping stems from a lack of training success and/or time. Ac-
cording to Boos et al. (1998), 12% of individual athletes who indulge in doping 
have less than two years' training experience, and another 16% only train two 
to three years before resorting to doping agents. If the athlete then wants to ex-
hibit his/her physical fitness thus achieved, national and international amateur 
competitions provide a stage for this. However, it is reasonable to assume that 
the use of performance-enhancing drugs is motivated only in small part by a 
desire to participate in competitive events (Giebing 2002, p. 25). 
If the body is developed to an extreme degree, practitioners can become profes-
sional – even in the body building arena. This is phase III (Fig. 13). Performance 
pressure and economic dependencies mount, giving rise to motivating structures 
for doping. Giebing (2002, p. 23) reports that in the performance-oriented sport 
of bodybuilding, doping is used on an extensive scale. 
EMPIRICAL KNOWLEDGE OF DOPING IN FITNESS STUDIOS 
It has now been relatively well documented by numerous studies that the 
use of doping substances has developed into an »epidemiologically signifi-
cant phenomenon« in Western industrialized countries (Striegel/Simon 2006, 
p. 63). Increasingly, not only elite sport but also recreational and fitness sport 
are affected. EU studies from 2002 indicate that at least 6% of the 16 million 
members of approximately 23,000 fitness studies use doping substances 
(Donati 2006, p. 22). 
The 2006 health report by the German federal government summarized sur-
veys on doping in recreational and popular sport (Müller-Platz et al. 2006). 
In one of the documented studies in which members of 58 fitness studios 
were surveyed (454 evaluated questionnaires; return rate 35%), 22% of the 
men and 8% of the women admitted misusing drugs. The following points 
were clear: 
> Misuse commenced well after the individuals started training. 
> Those who admitted to drug misuse for doping purposes were less well ed-
ucated on average than those who denied misusing drugs. 
> The misuse of anabolic drugs was associated relatively frequently with the 
use of other stimulants and drugs (Boos/Wulff 2001, from Müller-Platz et 
al. 2006, p. 16). 
A 2001 study conducted among 113 fitness studios in southern Germany 
produced the following results based on 1,802 anonymized questionnaires 
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(return rate 34.5%) (Striegel/Simon 2006): 13.5% of the respondents (19% 
of the men and 4% of the women) had already taken doping substances 
(Striegel 2007, p. 111). 98.5% of these cases involved the use of anabolic 
drugs. Unlike the study by Boos/Wulff (2001), this investigation found a neg-
ative correlation between the use of doping substances and alcohol consump-
tion. Moreover, the group of doping-substance users tended to be health-
conscious and socially well integrated, i.e. they were not a »group of socially 
deprived individuals with a tendency towards generalized drug use« (Strie-
gel/Simon 2006, p. 65). 
According to Müller-Platz et al. (2006, p. 17) doping substances were detect-
ed in 39% of urine samples at bodybuilding events in Germany in the period 
from 1995 to 2000. Control tests detected not just anabolic substances but in 
most cases all the usual doping agents.  
BODYBUILDING AS A POINT OF ENTRY FOR GENE DOPING 
Ambitious bodybuilding is likely to be the main point of entry for gene doping 
in individual sport. In this context gene doping – like conventional doping in 
individual sport – focuses mainly on the formation of skeletal muscle. The 
stronger the personal fixation on the development of a muscular physique, the 
greater is the individual's willingness to accept risks and experiment, including 
offering him/herself as a test subject – and this does not apply only to the rela-
tively small group of professionals. Thus gene doping could be used in ambitious 
bodybuilding at the same time or even earlier than in competitive sport (unlike 
in the past where doping drugs were first used in competitive sport and only lat-
er in the fitness arena). The scope, speed, and form of diffusion will probably 
depend on a number of restrictive and promotional factors, as in organized 
competitive sport. 
In individual sport too the greatest barrier to the use of gene doping is currently 
its unavailability or inaccessibility. As in the case of elite athletes, this barrier is 
probably greater for gene therapy methods than for specific gene-regulating 
methods. However, unavailability as such is a relative quantity whose effective-
ness depends on the willingness to take risks by procuring and using untested 
drugs and methods. As soon as these drugs are available (in the sense that they 
exist), misuse is likely to occur. All the forms of drug crime that currently exist 
(illegal imitation products; impure, unknown, and uncontrolled substances; ille-
gal trafficking) can occur, as described in the report of the German Federal Bu-
reau of Investigation on drug crime (Sürmann 2007). Criminal infrastructures 
and distribution networks (Donati 2006) are able to supply new untested sub-
stances, especially if they do not involve increased demands with regard to their 
use and handling compared to previous drugs. With the help of the internet, 
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criminal supply structures meet organized demand structures (specific forums, 
blogs, chatrooms). However, these distribution structures probably do not yet 
include special laboratories at which individual athletes willing to engage in dop-
ing can be »treated«. 
Bodybuilders as a group already seem to have poorer health-risk perception than 
other population groups. Knowledge about potential side effects of doping drugs 
is often generated from milieus that favor doping (Striegel 2007, pp. 115 ff.). 
Overall, this results in the supposed effectiveness being overstated and the risks 
understated. Because the risks are glossed over, side effects do not have much of 
a deterrent effect. Relevant internet pages show that a willingness to experiment 
is present. 
In addition, the gene doping barrier in the ambitious bodybuilding scene will be 
determined by the efficacy, dosage forms, and costs. The relevant frame of refer-
ence are the anabolic steroids. For new drugs to prevail in this »marketplace«, 
the balance between muscle-building effects, complexity of use, and costs must 
be better than that of anabolic steroids. Hence, techniques that can only be ex-
ploited with the help of specialists may find use in professional bodybuilding, 
but the danger of them spreading further is less likely. Based on the current state 
of knowledge, gene doping in the broad sense, especially in relation to the 
blockade of myostatin, must be seen as an immediate danger (Section II.4). 
EXCURSUS: OLDER ATHLETES 2.2 
In individual as well as in organized sport, supply and demand among older peo-
ple are growing apace. This trend is expected to continue unabated due to the 
increasingly prevalent view that preventive health maintenance brings about a 
gain in quality of life particularly for older people and is probably also more cost-
effective than the curative approach. This trend is being driven by a demographic 
shift with the »aging of society«. Sport is a keystone of the preventive health 
maintenance approach. Many sports associations, sports clubs, and fitness studios 
cater separately to older people with a growing number of events and competi-
tions, especially in the endurance area.44 The motivation for older people to en-
gage in sport is usually intimately linked to the aim of maintaining health, coupled 
with a desire to slow the progression of age-related physical changes. But age is no 
guarantee against excessive athletic ambition. Many older athletes wish to achieve 
top athletic performance and tend to deny physical aging processes.  
                                            
44 Take marathon running as a recreational sport, for example: In 1979 there were 50 
events with approximately 10,000 runners. In 2005 there were 153 marathon events 
with an estimated hard core of approximately 100,000 active runners, whose mean age is 
steadily rising (http://de.wikipedia.org/wiki/Marathonlauf).  
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The growing importance of sport for older people is coupled with a changing 
understanding of medical science, which increasingly pursues not only curative 
but also preventative goals. Thus, it is becoming more and more an aim of medi-
cal science to offer interventions in functional body processes. A growing and to 
a large extent wealthy segment of the population is becoming an interesting tar-
get group for commercial medicine. Analysts regularly predict a huge market 
potential for pharmaceutical products for preventive health maintenance. The 
licensing of a drug, which is granted on the basis of proof of efficacy in a specific 
indication, opens up possibilities for other uses. The principle of freedom of 
treatment in Germany grants physicians broad discretionary powers in the 
choice of treatment. Physicians may not traffic in, prescribe, or use drugs for 
doping purposes (§ 6a no. 1 AMG, Section IV.3.2). However, in order to coun-
ter the age-related loss of skeletal muscle, for example, physians can suggest cer-
tain measures to their patients based on their medical competence (age, indica-
tion, form of treatment [preventative or curative treatment, training, a healthy 
diet, and/or »anti-aging« or »lifestyle« therapies]). On the basis of age or a con-
dition-related indication, it could then also be possible to treat deficiencies that 
have no pathogenic value in order to improve the individual's well-being (compa-
rable in some respects to the marketing strategy for the PDE-5 inhibitor Viag-
ra  or the use of the amphetamine derivative Ritalin ). This development will be 
favored by an overall high level of social acceptance of efforts to slow the rate of 
physical aging processes by pharmacologic means. 
Even if such use does not constitute doping as defined by association and crimi-
nal law because it does not explicitly aim to enhance performance in sport, this 
form of application of new therapeutic options will influence and shape sport. 
The trends described above also show that doping in older or unhealthy individ-
uals is becoming increasingly difficult to define and delineate and has led to a 




NEED FOR INFORMATION AND ACTION VI. 
Gene doping means entering a political sphere characterized by incomplete and 
uncertain knowledge about future developments coupled with an urgent need 
for action due to its considerable potential for misuse. The possible timeframe for 
doping in sport (and beyond) is likely to be extended by gene doping. This could 
lead to another turn of the doping spiral or it could negate successes already 
achieved. The following examples of options for action take this situation into 
account. Together, these options can form the backbone of a specific anti-gene 
doping strategy. 
OBSERVING DEVELOPMENT PROJECTS WITH REGARD TO THEIR RELEVANCE 
TO GENE DOPING 
Gene doping misuses knowledge from basic and/or applied research in the life 
sciences that was intended to lead to new therapeutic strategies. Continuous 
predictive monitoring of biomedical and pharmaceutical development projects 
and of the potential demand side could provide strategically important infor-
mation about trends relevant to doping. Screening need not cover the entire 
range but could concentrate on those areas of development expected to be highly 
relevant to gene doping. This report points out some developments along these 
lines (Section II). Continuous monitoring could become a kind of early warning 
system, providing guidance for those involved in the fight against doping and 
insights into preventive doping research. Close cooperation between preventive 
doping research, existing control and monitoring institutions and drug research 
would be required. 
RESEARCHING DETECTABILITY, DEVELOPING TESTS, DESIGNING INTELLIGENT 
MONITORING 
There is a great need for research and development work to devise gene doping 
detection methods and suitable validated tests. A two-step approach within the 
control system currently appears to be the most promising. It covers intelligent 
monitoring and, where there are grounds for suspicion, specific tests for verifica-
tion. This kind of monitoring must aim to measure specific performance-relevant 
physiologic parameters of athletes that could provide evidence of manipulation. 
It calls for specialized knowledge, i.e. what parameters measured at what inter-
vals can provide evidence of doping-induced developments and abnormalities? 
In addition, numerous details of so-called results management must be consid-
ered (e.g. storage periods). At the same time, there is a need for legal clarification 
with regard not only to proportionality and suitability but also data protection 
and personal protection. If this approach can be refined into a practicable con-
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cept with suitable validated tests, the prospects for countering the expected rise 
in new doping practices, including gene doping, are good. 
DEVELOPING CONCEPTS AND ACTIVITIES FOR PUBLIC INFORMATION 
CAMPAIGNS SPECIFIC TO GENE DOPING (BEHAVIOR PREVENTION) 
In parallel with the further development of testing and sanctioning structures, 
independent public information campaigns focusing on gene doping must be 
devised. Given the current early stage of development, these could certainly have 
a preventative and behavior-modifying effect. For them to work, however, a 
broad design is needed which covers the whole process of individual sports de-
velopment during which mentalities and behavioral patterns favorable to doping 
can gradually arise. Such an approach should take into consideration both the 
athlete's immediate milieu (trainer, manager, physician) and the role of sponsors 
and the media. 
A key topic could be the unknown health risks involved. The potential and in 
some cases probable consequences should be presented in relation to the athlete 
type and the relevant circumstances. Where health is a strong motivator in sport, 
an attitude critical of doping could be fostered or developed. However, such ed-
ucation campaigns meet their limits where attitudes favoring extreme perfor-
mance prevail. Here one must be realistic with regard to the target group of top-
level athletes who have already embarked on their athletic careers. The practical 
application of concepts would have to be accompanied by interdisciplinary re-
search that provides a stimulus for refining the concepts on the basis of critical 
evaluation. However, public awareness of the fact that gene doping is a real 
danger must be awakened and heightened. The political debate can highlight the 
fact that gene doping could be a trend intensifier for doping practice in competi-
tive sport and beyond. 
ADAPTING FUNDING POLICIES 
Sport in general and elite sport in particular is shaped by a large number of ac-
tors. In the context of the public funding of sport, those receiving financial sup-
port are now required to adhere to the rules set down by WADA and NADA. In 
this respect, gene doping is covered. Repayment of financial support in the event 
of violations, however, requires proof that will stand up in court. Here again 
detection proves to be the Achilles heel. Nevertheless, the demand for compli-
ance with anti-doping rules should be upheld in any case and, indeed, applied 
even more stringently to gene doping. To this extent, the state could serve as a 
role model for private sector sponsorship in its funding activities. 
 VI.  NEED FOR INFORMATION AND ACTION 143 
GERMAN DRUG LAW: CHECKING ITS APPLICABILITY AND FURTHER 
STATUTORY OFFENCES  
The German Gesetz zur Verbesserung der Bekämpfung des Dopings im Sport 
(Law to Improve the Fight against Doping in Sport) has created better condi-
tions for the prosecution of doping, particularly in the athlete's own milieu. It is 
a jurisprudential and legislative challenge to review and if necessary refine suita-
ble legislative norms in the light of further development. For example, gene dop-
ing could be more clearly defined as a prohibited act in order to satisfy the prin-
ciple of clarity and definiteness. Given the recent extension of the definition of 
doping to include any substance intended for use in conjunction with prohibited 
methods, it should be possible to include substances relevant to gene doping. To 
this end reference could be made in § 6a, nos. 2 and 2a AMG to § 4, no. 9a, 
AMG. In this way, the use of gene transfer agents for the purpose of gene dop-
ing could be prohibited.  
In the light of further development, it should also be considered whether the 
constituent element »nicht geringe Menge« (= more than a small amount) is even 
valid for gene doping or whether instead any medically unindicated use of gene 
transfer agents in humans should be made a punishable offence. Given a specific 
risk potential, in due time it could be examined whether gene doping substances 
reasonably suspected of carrying a risk should be equated with narcotic drugs. 
This would afford an opportunity to make possession a punishable offence un-
der the Betäubungsmittelgesetz (Narcotics Law). 
The state has the capacity to assist organized sport in the pursuit of cases of gene 
doping. The setting up and training of special police units and specialized public 
prosecutor's offices for the effective criminal prosecution of offenders, clearly 
defined contact routes and contact persons, and closer cooperation between 
prosecuting authorities and other relevant entities and individuals (science, 
sport, pharmaceutical manufacturers) are already important means for combat-
ing conventional doping and will be indispensable in the fight against gene dop-
ing. 
PARLIAMENTARY TECHNOLOGY IMPACT ASSESSMENT, PUBLIC DEBATE 
The relevance of gene doping stems not only from its significance as a factor that 
will probably intensify the problem of doping in sport. Rather, the potential dif-
fusion of gene doping options reflects another highly relevant problem: a grow-
ing social trend towards the use of pharmaceutical agents or (neuro-) technical 
methods to manipulate physical and psychological performance beyond sports. 
»Routine doping« or »enhancement« is a topical subject that will continue to be 
relevant to technology impact evaluation and the select committees of the Ger-
man Bundestag in the future. 
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Like a lens, gene doping focuses the overarching aspects of doping in sport. The 
field of gene doping will allow the German Bundestag and its select committees 
to take a pioneering role in the political and social debate. Proactive positioning 
that is visible to the public could also include an initiative to establish further 
impact and prevention research as a basis for political and legal measures. The 
problems that gene doping might pose in the future for sport in general and 
competitive sport in particular are a strong argument for the responsible actors, 
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Just like a phantom, the topic of »gene doping« keeps haunting the debates regarding the 
future of competitive sports for years. Very often, corresponding fantasies and visions 
culminate in the imagination of super athletes who are permanently manipulated with 
regard to their genetic disposition. However, the application scenarios to be expected will 
be far more unspectacular, but more probable and more obvious at the same time. Very 
soon, we will have to expect the use of new substances as well as of methods in gene and 
cell therapy for targeted manipulation of gene activity. Their use promises a highly effici-
ent performance enhancement and will be difficult to prove, if at all. This book provides 
comprehensive answers to the key questions of the further development: Which scientific 
results could cater to the needs of potential gene doping? Where are the future gateways 
in top-level and popular sports? And how can prohibitions and monitoring be used in 
responding to this?  Another question will be which individual behavioural patterns of 
athletes and which social contexts will play a role with regard to the potential »career« of 
gene doping.
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